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Abstract
Vanadium lias emerged as an extremely potent agent witli insulin-like properties.
These insulin-like properties have been demonstrated in isolated celis, tissues, different
animal models of type I and type 2 diabetes as well as in a limited number of human
subjects. Vanadium treatment lias been found to improve abnormalities of carbohydrate
and lipid metabolism and of gene expression in rodent moUds ofdiabetes. In isolated ceils,
it enhances glucose transport, glycogen and lipid synthesis. and inhibits gluconeogenesis
and lipolysis. The molecular mechanisms responsible for the insulin-like effects of
vanadium compounds have been shown to involve the activation ofseveral key components
of insulin signaling pathways, which include the rnitogen-activated protein kinases
(MAPKs). extracellular signal-regulated kinasel/2 (ERKT/2) and phosphatidylinositol 3-
kinase (P13-K) / protein kinase B (PKB). It is interesting that the vanadium effect is
associated with enhanced tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1)
whule the requirernent for insulin receptor (IR) protein tyrosine kinase (PTK) activity in
vanadium-rnediated effects is stili controversial. Since the MAPK and P13-K’PKB
pathways are implicated in mediating the mitogenic and metabolic effects of insulin
respectively, it is plausible that vanadium-induced activation of these pathways serves as a
mechanism for its insulin-like responses. The work presented in this thesis has been
designed to explore the cellular mechanisms of action of vanadium compounds as insulin
enhancing and -mimicking agents.
In the first pari of our studies. we have investigated the molecular mechanism by
which vanadyl sulfate (VS) prolongs and enhances insulin action. We demonstrated that
VS enhances the magnitude and duration of insulin-induced ERKI/2 and P13-K activities,
which is associated with prolonged interaction between IRS-1 and the p8 subunit of P13-
K. Since ERKI/2 and P13-K are key components of the insulin signaling patliway. these
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studies have suggested that prolonged activation of these two kinases contribute to the
molecular mechanisrns ofthe insulin-enhancing effect of VS.
In the second part, we have investigated the mechanism responsible for a stronger
insulinomimetic effect of organo-vanadium compounds (OVC) over inorganic vanadium
saits. Our studies have demonstrated that OVC are stronger inhibitors of protein tyrosine
phosphatases (PiPases) and this effect is associated with robust tyrosine phophorylation of
several cellular proteins, including 1R13-subunit and IRS-l. In addition, the OVC are
superior to VS in augmenting the association between IRS-1 and p. leading to a potent
activation of PKB/glycogen synthase kinase- 313 (GSK-313) phosphorylation. Taken
together, these studies indicate that the high PTPase inhibitory potential of OVC translates
into greater phosphorylation of PKB and GSK-313, which may in turn contribute to greater
effectiveness of OVC in ameliorating glucose horneostasis and insulin sensitivity in rodent
models of diabetes mellitus.
In the third part of our studies, we have attempted to identify the putative protein
tyrosine kinase (PTK) as an upstream modulator of vanadium (IV) oxo bis (maltolato)
(BMOV) (an OVC which has been shown to be a more potent insulino
mimetic/antidiabetic agent than inorgani e vanadium salts)-induced PKB phosphorylation.
These studies have revealed that among several receptor PTKs, the activation of insulin
like growth factor receptor type 1 (IGF-1R)-PTK plays an important role in provoking
BMOV-induced PKB phosphorylation. We have also dernonstrated an involvement of
PKC6 as a mediator in BMOV-induced PKB phosphorylation by using pharmacological
isozyme-specific inhibitors ofPKC.
Hydrogen peroxide (H202), a reactive oxygen species (ROS). has been shown to mimic
insulin action, and many sttidies have indicated that vanadium treatment of celis resuits in
the generation of ROS such as H202. Vanadium-induced production of ROS has been
rcported to mediate its cellular effects in many cells. Therefore, in the las, part of these
studies, we have examined if the phosphorylation of PKB and ERK1/2 induced by H202
shares some common features with vanadium with regard to a role for IR-PTK as an
Vupstream modulator of this effect. These studies have demonstrated that in contrast to
vanadium compounds, H202-induced activation of ERK1/2 and PKB requires both tyrosine
kinase activity of IR as well as c-Src. but the role of c-Src-PTK is more dominant in this
process.
In conclusion. the studies presented in this thesis have identified that vanadium
induced prolonged interaction of IRS-Y/p85, resulting in sustained activation of
ERK1/2/P13-K is important in enhancing insulin action. We have also demonstrated that,
compared to inorganic vanadium saits the OVC are more potent inhibitors of PTPases and
stronger activators of P13-KJPKB. This observation may form the basis for the high
efficacy of OVC in regulating glucose homeostasis in diabetic rodents. An important role
for IGF-1 R activation as an upstream PTK to evoke 3MOV-induced PKB phosphorylation
was also identifled in these studies. Finally, we have established that H202, another
insulin-mimetic agent, utilizes the IR and c-Src-PTK to initiate P13-KJPKB and ERK1/2
activation.
Keywords: Diabetes; Vanadium; Insulin Signaling; Insulin Receptor; Protein Tyrosine
Kinase; Protein Kinase B; Extracellular Signal-Regulated Kinasel/2; Protein Tyrosine
Phosphatase
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Résumé
Le vanadium se comporte comme un agent extrêmement efficace ayant des
propriétés comparables à celles de 1insuline. Ces propriétés comparables à celles de
l’insuline ont été démontrées dans des cellules isolées, des tissus, chez différents types
d’animaux ayant un diabète de type I et de type 2. aussi bien que chez un nombre limité de
personnes humaines. Le traitement au vanadium améliore les anomalies du métabolisme
des glucides et des Lipides et de l’expression des gènes chez les modèles animaux
diabétiques. Dans les cellules isolées, il rehausse le transport du glucose, la synthèse du
glycogène et des lipides, et empêche la gluconéogenèse et la lipolyse. Il a été démontré que
les mécanismes moléculaires responsables des effets des composés de vanadium
comparables à ceux induits par l’insuline impliquent l’activation de plusieurs composantes
clés de la voie de signalisation de l’insuline. Celles-ci incluent les protéines mitogen
activated-protein kinases (MAPKs). les extracellular signal-regulated kinasel/2 (ERK1/2)
et le phosphatidylinositol 3-kinase (P13-K) / la protéine kinase B (PKB). Il est intéressant
de constater que l’effet du vanadium est associé à la phosphorylation de la tyrosine du
substrat du récepteur d’insuline de type Ï (IRS-l) tandis que le recours à l’activité de la
protéine kinase de la tyrosine (PTK) du récepteur de l’insuline (IR) pour les effets du
vanadium est sujet de controverse. Puisque les voies de la MAPK et de la P13-K / PKB sont
impliquées dans la médiation des effets mitogènes et métaboliques de l’insuline
respectivement, il est plausible que l’activation de ces voies par le vanadium serve de
mécanisme pour ces réponses. Le travail présenté dans cette thèse a été conçu pour explorer
les mécanisme cellulaires de l’action des composés du vanadium comme agents de
rehaussement et d’imitation de l’insuline.
Dans la première partie de notre étude, nous avons étudié le mécanisme
moléculaire par lequel le sulfate de vanadyl (VS) prolonge et rehausse l’action de l’insuline.
Nous avons démontré que le VS rehausse l’ampleur et la durée des ERKI/2 et l’activité de
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la P13-K induites par l’insuline, associées à l’interaction prolongée entre l’IRS-l et la
sous-unité p8 de la P13-K. Puisque les ERK1I2 et la P13-K sont des composantes clés de
la voie de signalisation de l’insuline, ces études ont suggéré qu’une activation prolongée de
ces deux kinases contribue au mécanismes moléculaires de l’effet de rehaussement de
I’ insuline par le VS.
Dans la deuxième partie, nous avons étudié le mécanisme responsable d’un effet
insulino-mimétique plus fort des composés organiques de vanadium (COV) versus les sels
inorganiques de vanadium. Nos études ont démontré que les COV sont des inhibiteurs plus
puissants des protéines phosphatases de la tyrosine (PiPase) et que cet effet est associé à
une phosphorylation plus robuste de la tyrosine de plusieurs protéines cellulaires, y compris
la sous-unité 1R13 et l’IRS-l. En outre, les COV sont supérieurs au VS pour augmenter
l’association entre l’IRS-l et la p85 menant à une activation plus efficace de la
phosphorylation de la PKB et de la glycogen synthase kinase 33 (GSK-3j3). Dans son
ensemble, cette étude a indiqué que l’inhibition plus marquée de la PTPase par les CVO se
traduit par une plus grande phosphorylation de la PK3 et de la GSK-3t3. qui. à tour de rôle.
peuvent contribuer à une plus grande efficacité des COV en améliorant l’homéostasie du
glucose et la sensibilité à l’insuline chez les animaux diabétiques.
Dans la troisième partie de notre étude, nous avons essayé d’identifier la protéine
kinase de la tyrosine (PTK) putative comme modulateur de la phosphorylation de la PKB
induite par le vanadium (IV) oxo bis maïtolato (BMOV) (un COV qui s’est avéré un agent
insulino-mimétique / antidiabétique plus efficace en comparaison avec les sels inorganiques
de vanadium) en induisant la. Ces études ont indiqué que. parmi plusieurs récepteurs PTKs.
l’activation du récepteur de Ï’insuÏin-like growlh factor type I (IGf- Ï R) joue un rôle
important en provoquant la phosphorylation de la PKB induite par le BMOV. Nous avons
également observé une participation de la PKC comme médiateur dans la phosphorylation
de la PKB induite par le BMOV en utilisant des inhibiteurs pharmacologiques spécifiques
d’isozymes de la PKC.
Le peroxyde d’hydogène (F1202), une espèce réactive oxygénée (ROS). a démontré une
action imitatrice de l’insuline, et plusieurs d’études ont indiqué que le traitement des cellules
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au vanadium entraîne la génération de ROS . telle que le H202. Il a été démontré que la
production de ROS par le vanadium est impliquée dans la médiation de ses effets
cellulaires. Par conséquent, dans la dernière partie de cette étude, nous avons examiné si la
phosphorylation de la PKB et des ERK1/2 induites par le 11202 partage quelques
caractéristiques communes avec le vanadium quant au rôle du récepteur de l’insuline (IR)
PTK comme modulateur de cet effet. Ces études ont démontré que. contrairement au
vanadium, l’activation des ERK1/2 et de la PKB par le 11202 requiert l’activité de la kinase
de la tyrosine du IR. et celle du c-Src, mais la PTK du c-Src joue un rôle plus dominant
dans ce processus.
En conclusion, les études présentées dans cette thèse ont identifié que le vanadium
potentialise l’action de l’insuline via une interaction prolongée entre l’IRS-l et le p85 ayant
pour résultat une activation soutenue des ERK1/2/ P13-K. Nous avons également démontré
que, par rapport aux sels inorganiques de vanadium, les COV sont des inhibiteurs plus
efficaces des PTPases et des activateurs forts de la P13-K / PKB. Cette observation peut
servir de base pour interpréter l’efficacité plus marquée des COV pour maintenir
l’homéostasie du glucose chez les animaux diabétiques. Un rôle important de l’activation de
l’IGF-lR agissant comme PTK pour évoquer la phosphorylation de la PKB induite par le
BMOV a également été identifié dans ces études. Nous avons également établi que le 11202,
un autre agent insulino-mimétique, utilise la PTK du récepteur de l’insuline et du c-Src
pour induire l’activation de la P13-K’ PKB et des ERK1/2.
Mots-clés : diabète, vanadium, signalisation de l’insuline, récepteur de l’insuline, protéine
kinase de la tyrosine. protéine kinase B. extracellular signal-regulated kinasel/2, protéine
phosphatase de la tyrosine
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1CHAPTER 1
Introduction
1.1-HISTORICAL ASPECT 0F VANADIUM
Vanadium. a group V trace elernent that belongs to the first transition series of elements. is
ubiquitously distributed in the biosphere as well as in mammals and represents the 21 st
most abundant element (about 0.02%) in the earths crust (1). Pure vanadium is a bright
silver-white, soft, ductile metal. Andreas Manuel Del Rio was the flrst chemist to postulate
the existence of this new element in 1801, but Nus Gabriel Sefstrom, a Swedish chernist,
lias been credited for its discovery in 183 1 (2). It was named after Vanadis, the Norse
goddess of beauty. youth and lustre, because its saits possess beautiful colours (2).
Vanadium lias become the subject of interest arnong nutritionists since the discovery of this
metal as an essentiaÏ eÏement in various species (3;4). WhiÏe the vanadium requirement in
lower organisms has been established, its essential value in humans remains to be proven
(5;6). Although most foods contain low arnounts of vanadium (<1 ng/g). they are a major
source of exposure to vanadium for the general population (7). Many cereals, fisli, fresli
fruits and vegetables contain the element: more than 40 mg per g. Daily vanadium intake
has been estimated to be 10-160 tg. and its main food sources are black pepper. dill seeds.
mushrooms, parsley, shellfish and spinaci, which contain between 0.05 to 1.8 tg vanadium
per g (7;8). Analysis of body fluids, organs and tissues has estimated that the total body
pool of vanadium in liumans is between 100 and 200 tg (6;7), and it ranges from 0.014 to
7.2 jiM in mammalian cells (1 ;8).
2J.2-CHEMISTRY 0F VANADIUM
1.2.1-Vanadium saits: Inorganic compounds
ihe vanadium element can exist in four valency states, 2, 3, 4 and 5. and, thus, its
chemistry is complex (2;9). Vanadium occurs as vanadyl (VO2) below pH 3.5 and in basic
solutions, its predominant forrn is orthovanadate (V043), which is chemically sirnilar to the
phosphates (P043) (2;9). Vanadium presents as H2V04 in neutral solutions (7).
Metavanadate (V03). the predominant species in body fluids (e.g. plasma). enters cells by
an anion transport system and is reduced by glutathione (GSH) to the vanadyl state (V02+
forrn. Exogenously-adrninistered vanadyl suiphate (VS) and ammonium vanadate have
been found to tightly bind serum transferrin, indicating that this protein may serve as a
vanadium transporter (10). As vanadyl. it can interact potently with the phosphatases, and
inhibition is attributed to a five-coordinate vanadate complex which mirnics the transition
state of the phosphate ester hydrolysis reaction. Chemical structures of these vanadium
saits are shown in Fig. 1.
1.2.2-Vanadium complexes: Pervanadate and organovanadium compounds
In an atternpt to improve potential therapeutic efflcacy, several vanadium complexes were
synthesized by many laboratories. Such complexes include peroxovanadate generated upon
mixing of vanadate with hydrogen peroxide (H202) (Il). These compounds. similar to
vanadate, also have structural resemblance to the phosphate. Jnterestingly, adding peroxo
group(s) sequentially causes an increase in their potency to inhibit protein tyrosine
phosphatases (PTPases). ihis may be due to their enhanced ability to irreversibly oxidize
the bound thiol groups on PiPase.
3o O
liv liv
VN HOY\
Q - HO
Metavanadate Orthovanadate
H2O%O H2
v.vl
H2O I NDH2
o
s03-
Vanadyt Sulfate
Figure 1: Chemical structure of inorganic vanadium compounds
4Peroxovanadate exerts redox activities (oxidation-reduction) which arise due to the
formation of a complex upon reaction with II2O2. It has been reported that in the acidic,
basic and neutral pH ranges, vanadate forms mono-, tri- and diperoxo-vanadium
complexes, respectively. In this regard, vanadate can act as an antioxidant because it
rernoves F1202 from the surrounding upon chemical reaction. Diperoxovanadate. at
physiological pH, is stable for several hours and degraded at a siower rate by catalase
compared to free H202.
Other types of vanadium complexes. named organovanadium compounds (OVC), are
synthesized by complexing vanadyl to organic ligands. These include vanadium (1V) oxo
bi s(maltolato) (BMOV), vanadium (IV) oxo bis (acetylacetonate) (VO(acac)2/VAC),
vanadium (IV) oxo bis (3-ethylacetylacetone) (VET). vanadium (IV) oxo bis
(ethylmaltolato) (BEOV). vanadium (IV) oxo bis (6-methylpicolinato). and L-glutarnic acid
-monohydroxarnate-NaOV complex (12-1$). The chernical structures of some of these
OVC are shown in Fig. 2. These OVC have been shown to be more absorbed and Iess toxic
than inorganic salts (12:19-21). Subsequently. they were found to exhibit significantly
enhanced insulin-mimetic activity in diabetic laboratory animais compared to inorganic
VO2 introduced as VS.
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Figure 2: Chemical structure of some organovanadium compounds
67.3-DIABETES AND INSULIN-MIMETIC EFFECTS 0F VANADIUM COMPOUNDS
Diabetes has been known to afflict human populations since prehistoric times. Susruta, an
Indian physician, described the diabetic syndrome in 400 B.C., calling it Madhumeh” or
“honeyed urine” (22:23). Our modem era lias witnessed a surge in the incidence of
diabetes. and it is estimated that at present approximately 150 million people world wide
have the disease (24:25). According to the World Health Organisation (WHO). this
number might double by 2025 (25).
Diabetes is caused by an absolute or relative lack of insulin secretion or action, and lias
been classified into two major forms: type I. forrnerly known as insulin-dependent diabetes
mellitus. and type II, that is. non-insulin-dependent diabetes mellitus. In type I diabetes.
the absolute lack of insulin secretion is due primarily to the destruction of 13-cells by
autoimmune mechanisms. On the other hand, in type 2 diabetes, f3-cells are able to produce
insulin, but their insulin secretory response and insulin action on target tissues are
defective, which results in hyperinsulinemia and insulin resistance (26). About 90% of the
total diabetic population fails into the type II category. whule the remaining 10% are type I.
Type II diabetes may be treated by diet control or by oral hypoglycernic agents. such as
sulfonylurea, biguanides and thiazolidinediones (27-30). However, type I diabetics require
regular daily injections of insulin to treat their diabetes, and some type II diabetics in the
advanced stage of the disease also need insulin. Although the availability of highly
purified insulin and the use of oral hypoglycaemic drugs as monotherapy or in combination
with other agents (27:28) have greatly improved the management of diabetes. it still
rernains a major health concem for humans with its prevalence increasing out of control
(31). Thus. new therapeutic approaches are needed to more efficiently treat and hopefully
cure diabetes.
7In this regard, several studies performed in the Iast 2 decade have suggested that
compounds of the trace element vanadium exert various insulin-mimetic and anti-diabetic
effects in vitro and in vivo (32). The eariiest documented evidence of the insulin-like
effects of the inorganic vanadium sait, sodium orthovanadate (Na3VO4), was published by
Lyonnet et al. (33) in 1899, 22 years before the discovery of insulin. This group observed
that oral Na3VO4 administration decreased glucosuria in 2 out of 3 diabetic patients (33).
Their smdy went uimoticed for a long time. but the demonstration of an in vitro insuiin
mimetic effect of vanadium salis by Tolman et al. (34) in 1979 sparked further interest.
The latter group (34) showed that several inorganic vanadium compounds. simiiarly to
insulin, stimulated glucose transport and oxidation in adipocytes, increased glycogen
synthesis in the rat diaphragrn and hepatocytes. and inhibited gluconeogenesis in liver ceils.
Since then. nurnerous studies have revealed various insulin-mimetic effects of vanadium
compounds in vitro and in vivo. including the stimulation of glucose transport and glucose
oxidation (34-3$), glycogen synthesis (3439-41), and lipogenesis (42;43) as well as the
inhibition of lipolysis (37;43) and gluconeogenesis (34).
Among the in vivo actions of vanadium, the discovery that attracted the attention of
diabetologists and endocrinologists was the serninal work of Heyliger et al. (19) which
showed that Na3VO4 normalized hyperglycemia in an animaL model of diabetes mellitus.
Since then, these findings were followed by those of several groups who confirmed and
extended them to animal models of type 1 and type 2 diabetes mellitus as well as humans.
Both inorganic salts. such as sodium orthovanadate (Na3VO4, NaOV). Vanadyl sulfate
(VOSO4 3H20 / 4W0. VS). sodium metavanadate (NaVO3. NaMV) as weil as OVC such
as BMOV, VAC, VET, or bis (6-methylpicoiinato) oxo vanadium were tested in most of
these studies. Following section will summarizes some ofthese studies.
$1.3.1-Effect on animal models of type I diabetes mellitus
1.3.1. 1-Effect of inorganic va,tadittn, saits
The studies of Heyliger et al. (19) were performed in female rats rendered diabetic by
injection of streptozotocin (STZ), a compound that specifically destroys insulin-producing
13 ceils of the pancreas (44). STZ-diabetic rats are generally considered a mode! of type 1
diabetes mellitus (45). Orally-administered NaOV in drinking water (0.8 mg/ml). over a
period of 42 days, was shown to decrease plasma glucose from 20 mM to 8.7 mM (19).
Interestingly, in these studies, vanadium was not associated with an increase in plasma
insulin. In fact, NaOV treatrnent lowered insulin levels even in normal rats without
significantly altering plasma glucose (19). It was, therefore. suggested that the vanadium
induced reduction of glycemia was independent of its effect on insulin secretion. These
investigators also noted severe diarrhoea in some STZ-diahetic rats. This condition.
however, was corrected by administering NaOV in 0.5% NaC1 solution (19).
The studies of Heyliger et al. (19) were confirrned and expanded by Meyerovitch et al. (20)
who demonstrated that NaMV (0.8 rng/ml in drinking water) decreased plasma glucose in
STZ-diabetic male Wistar rats to almost normoglycemic (in some cases. hypoglycaemic)
levels within 2 to 4 days of treatment (20). Subsequently, the giucose-lowering effects of
vanadium compounds were validated by several other investigators. In ail these studies.
hyperglycaemia was significantly reduced and. in many cases, virtually normalised by oral
administration of vanadium compounds to diabetic rodents. The dose of vanadium salts
required for exerting a maximum glucose-lowering effect varied between studies, but a
median concentration of 0.5 mg/ml in drinking water appeared to be sufficient. The
glucose-lowering action was rnaintained during the course of therapy, but the animals
became hyperglycaemic within 2-4 days afler its cessation (20). In 1 experiment. however,
where STZ-diabetic rats were given VS for 3 weeks, normoglycaemia was sustained for 13
weeks afier withdrawal oftreatment (46).
9A comparative study of NaOV, VS and NaMV showed that regardless of the type of
vanadium saits used, the decrease in plasma glucose levels, glucosuria and urinary volume
and the improvement in oral glucose tolerance were similar in ail cases (47). These
investigators also observed that although plasma glucose levels increased rapidly after
treatment withdrawal, they remained significantly lower than those found in non-treated
STZ-diabetics for at least an additional 4 weeks (47).
1.3. 1.2-Effect oforgaiiic vanadium coinpottnds
To overcome the gastrointestinal side-effects of vanadium and to enhance its absorption
through the gut, McNeill et al. (12) pioneered the use of OVC in rat models of diabetes.
Administration of a VS-maltol complex (BMOV, 1.5$ mM) to STZ-diabetic rats in
drinking water for 4 weeks reduced plasma glucose from 13.9 to 7.0 mM and corrected the
polydypsia associated with diabetes (12). BMOV elicited the glucose-lowering response
within 1 day oftreatment. decreasing plasma glucose from 20 to 8 mM (21). in contrast to
the use of inorganic vanadium salts, which required about 4-7 days for a similar glucose
Iowering outcorne (19;20). Intraperitoneal injection of BMOV was even more effective
than BMOV administration in drinking water because it decreased blood glucose to tess
than 9 mM within 8 hours (21). The ED50 of BMOV was found to be 3 times lower than
that of VS (0.08 versus 0.22 mmol/kg) and thus, it was 3 times more potent (21). In
addition. BMOV was beffer tolerated. as evidenced by a lack of gastrointestinal toxicity
(diarrhoea). and no mortality (48).
Subsequently, several new OVC were synthesised to test their antidiabetic potential (14-
17). Among these complexes, the anti-diabetic potential of BMOV has been investigated
most extensively (12;19-21).
Reul et al. (13) recently compared the effects of 3 different OVC, BMOV, VAC, and VET
to inorganic VS on glucose metabolism in STZ-diabetic rats. Their studies showed that ah
3 OVC were more potent than VS in eliciting the hypoglycaemic response, and VAC
appeared to be superior to VET and BMOV (13). The superior effect of VAC may be due
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to its better intestinal absorption since a higher plasma vanadium level was achieved at 1
and 3 weeks in comparison to either BMOV or VET (13). Moreover, vanadium therapy of
diabetic rats with OVC did flot evoke any marked toxicity on hepatic and renal functions
(13). Thus. it appears that these complexes have an advantage over the inorganic saits as
potential anti-diabetic agents.
In addition to inorganic and organic vanadium compounds. peroxovanadium compounds
have been tested as insulin-mimetic agents (11 ;49). Intraperitoneal or intrajugular injection
of bis-peroxovanadium into STZ-diabetic and biobreeder rats markedly reduces
hyperglycaemia within 30 min (49;50). However, unlike other vanadium compounds, flot
many studies have been performed with peroxovanadium compounds.
1.3.2-Effect on animal models of type II diabetes mellitus
The anti-diabetic potential of various vanadium compounds bas also been examined in
animal models of type 2 diabetes mellitus. Three well-characterised models, genetically
obese, fatty (falfa) Zucker rats, genetically-diabetic C57 BL/KsJ-db/db (db/db) mice, and
genetically-diabetic ob/ob mice (45), have been investigated. Administration to falfa rats of
NaOV 0.5 mg/mI in drinking water and up to 0.25 rng/g in food for 3 rnonths considerably
irnproved their glucose homeostasis as well as oral glucose tolerance (51). In addition.
during an intravenous glucose tolerance test, the glucose disappearance rate, an index of
glucose utilisation. was 50% higher in treated rats cornpared to the controls. whereas
plasma insulin levels were reduced by 50% (51). In db/db mice, 12-week therapy with
NaOV 0.6 mg/ml decreased plasma glucose from 24 to 7 mM (52), and only 0.25 mg/ml
was sufficient to lower blood glucose from 15 to 8 mM (52). A similar response was
exhibited in ob/ob mice where the glucose-lowering effect was evident within a week,
reaching a maximum after 16 days oftreatment (53).
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The impact of a diet mixed with NaOV (1 .5 rng/g) (rather than in drinking water) was
also investigated, in a high-sucrose diet-induced hyperinsulinemic insulin-resistant rat
mode!. and it was found that hyperglycaemia as well as hyperinsulinernia (54) were
signiflcantly irnproved. In addition to NaOV. the organo-vanadium compound BMOV was
found to reduce hyperinsulinemia. insulin resistance and glucose intolerance in falfa Zucker
rats (55-57). On the other hand. the effect of peroxovanadium cornpounds on the above
rodent modeis of type 2 diabetes mellitus bas flot yet been examined.
VS bas been investigated in Psammomys obesus. a gerbi! (nicknamed the ‘sand rat”) that
represents a nutritiona!!y-induced mode! of diabetes and insulin resistance (58).
Psammomys obesus receiving a high-energy diet become hyperglycaernic and
hyperinsulinemic (59). VS at a dose of 5 rng/kg body weigbt for 5 days resulted in
proionged restoration of normogiycaemia and normoinsulinemia in this model (5$). In
addition. these changes were associated with a normal glucose toierance test and a
decreased level of the hepatic gluconeogenic enzyme phosphoenol pyruvate carboxykinase
(PEPCK) (5$). Interesting!y, vs was ineffective when administered to sand rats that had
complete!y iost their insulin secretory capacity. indicating a requirement of !ow-!evel
insulin for vanadium to work in these animais. Thus. vanadium appeared to be an insulin
potentiator/enhancer rather than mirnicker in improving insulin resistance in sand rats (5$).
1.3.3-Clinical studies in human diabetes mellitus
The demonstration of a beneficiai action of vanadium compounds in both type I and type 2
anima! modeis of diabetes mellitus encouraged severa! investigators to embark on research
in hurnan diabetics. In earlier studies, srnall doses (50-125 mg/day) ofNaMV or VS were
administered orally to a iimited number of type 1 or type 2 diabetic subjects for periods
ranging from 2 to 4 weeks (60-62). In type I diabetics. NaMV (125 mg/day) for 2 weeks
had no effect on fasting plasma glucose ievels. but caused a small yet significant deciine in
daily insulin requirements and improved glucose utilisation in 2 out of 5 patients (60). In
type 2 diabetics, NaMv resu!ted in increased insuiin sensitivity due to enhanced non-
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oxidative glucose disposai (60). Similarly. VS improved insulin resistance in type 2
diabetics accompanied by a slight decrease in fasting plasma glucose and glycosylated
haemoglobin (HbA1), enhanced insulin-mediated glucose uptake and suppressed hepatic
glucose production (HGP) (61;62).
Since only a limited number of subjects were treated with low doses of vanadium for a
short duration in these eariy studies. 2 independent groups recently investigated the effect
of long-term treatment with higher VS doses in a larger type 2 diabetic population (63:64).
Goldfine et al. (63) treated 16 patients with VS doses varying from 75 to 300 rng/day for 6
weeks and observed that fasting glucose declined significantly only in the 300-mg VS
group whereas HbA1 decreased in both the 150- and 300-mg groups. Interestingly, these
treatments had no effect on either basal HGP or on the suppression of HGP in response to
insulin. A sirnilar study conducted by Cusi et aI. (64). who treated 11 type 2 diabetics with
VS at a dose level of 150 mg/day for 6 weeks, found that both HbA1 and fasting plasma
glucose were significantly decreased. In these investigations, VS reduced endogenous
glucose production and increased insulin-mediated glucose disposal. However, none of the
clinical research undertaken so far demonstrated complete normalisation of
hyperglycaemia, as has been the case in animal models of diabetes mellitus. The difference
may be attributed to a much lower blood vanadium level reached in patients (1-10 iIM) than
in animais as well as the duration oftherapy (63).
1.4-MECHANISM 0F THE HYPOGLYCAEMIC EFFECT 0F VANADIUM
The precise mechanism by which vanadium compounds improve hyperglycaemia and
glucose homeostasis in diabetes remains unclear. Vanadium therapy in a type 1 model of
diabetes mellitus slightiy but insigniflcantly increased plasma insulin (I 9;20). whereas a
significant, up to 50% decrease in plasma insulin was observed in type 2 models (51-
53;65;66). Clearly, this alteration in insulin levels can not be attributed to the anti-diabetic
effects of vanadium compounds in type 1 diabetics, but may be beneficial for type 2
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diabetics. The hypophagic influence of vanadium compounds miglit contribute to their
hypoglycaemic outcome (67). but studies showing that organic or peroxovanadium
compounds exert acute glucose-Iowering actions within a few minutes to hours after their
administration (not sufficient to suppress feeding) (11;12;21;4$-50) do not support this
hypothesis. Furthermore, both in vitro and in vivo, vanadium compounds modify glucose
and Hpid metabolism in adipose tissue, muscle. liver and several cultured ceil unes (32:68),
which may serve as a more plausible mechanism for the glucose regulatory effects of
vanadium.
1.4.1-Effect on glucose transport
The stimulatory effect of NaOV on glucose transport lias been observed in rat adipocytes
(36:3$;69), rat skeletal muscle (40:70). human skeletal muscle (71:72), 313-Li
adipocytes (73), and L-6 myotubes (74:75). In most of these studies. a high (mM)
vanadium concentration was required to enhance glucose transport. However, Dubyak and
Kleinzeller (36) reported that long-terrn (3-hour) treatrnent with 300 1.iM NaOV stimulated
glucose transport. which was 80% the value achieved with 17 nM insulin. Thus. longer
incubation with low vanadium concentrations may be sufficient to evoke a physiologically
relevant increase in glucose transport.
Since insulin-stimulated glucose transport is mediated by an insulin-sensitive glucose
transporter protein type 4, GLUT-4 (76;77), the effect ofNaOV, VS or BMOV on GLUT-4
was investigated in diabetic rodent models (5$;7$-$2). In the basal state, GLUT-4 is
localised in intracellular sites, and upon insulin stimulation. it is translocated to the celi
surface to facilitate glucose uptake by target cells (76). Vanadium exposure of STZ
diabetic rats lias been shown to restore the expression and/or cdl surface translocation of
GLUT-4 in skeletal muscle (7$;79). and heart (80;81). In addition. VS treatment of a
nutritionally-induced, insulin-resistant model of Psammomys obesus. lias been found to
restore membrane-associated as well as total protein and mRNA content of GLUT-4 in the
gastrocnemius muscle (52). On the other hand, in contrast to STZ-diabetic or sand rats,
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NaOV in insulin-resistant falfa rats increased insulin-mediated glucose utilisation in
muscle without any effect on either GLUT-4 protein or rnRNA (22). The discrepancy
between the vanadium effect in STZ-diabetic or sand rat and insulin-resistant fa1fa rodents
may be attributed to the fact that GLUI-4 content remains unaltered in insulin-resistant
models (83;84) whereas SIZ-diabetic rats exhibit decreased GLUT-4 expression
(78;$5;$6). Thus. it is difficult to establish a simple correlation between GLUT-4 content
and glucose uptake and utilisation in vivo ($2). However, an increase in the intrinsic
activity or enhanced targeting of GLUT-4 to the ccli surface might contribute to improved
glucose uptake by vanadium (22). In isolated rat adipocytes ($7) and in cultured L-6
myotubes (75), NaOV bas been shown to stirnulate GLUT-4 transiocation to the cell
surface. Ibus, vanadium compounds are capable of stirnulating glucose transport through
an effect on GLUI-4.
1.4.2-Effect on glycogen metabolism
Another physiological response modulated by vanadium is mediated by its action on
glycogen synthesis. NaOV and VS have been found to stimulate glycogen synthesis in in
vitro systems. including the mouse diaphragm (41). rat hepatocytes and diaphragm (34;88),
rat adipocytes (39;89). Chinese hamster ovary ceils over-expressing insulin receptor (CR0-
HIR) (90) and 313-LI adipocytes (73). These cornpounds also improve depressed
glycogen levels in the liver of SIZ-diabetic (91 ;92) as well as in other insulin-resistant
rodent models (52;93). In addition, NaOV bas been demonstrated to restore the glycogen
synthetic rate in 90% pancreatectomized, diabetic rats (94). On the other hand, treatment of
7-week STZ-diabetic rats to BMOV failed to improve insulin-stirnulated glycogen synthase
activation in skeletal muscle (95) wbereas similar treatment enhanced it in fa!fa Zucker rats
(96). Ihe reason for these discrepancies is not clear, but it is possible that the basal level of
glycogen synthase activity is moduÏated differentiaÏÏy in a tissue-specific manner in various
models ofdiabetes (93).
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Since vanadate treatment normalises the decreased activity of the active glycogen
synthase form in the liver of STZ-diabetic rats (91), and activates glycogen synthase in rat
adipocytes (89), it has been suggested that this may be one of the mechanisms by which
vanadium compounds enhance glycogen synthesis ($9;91). Vanadate has also been found
to increase glucose-6-phosphate (G6P) by inhibiting glucose-6-phosphatase (G6Pase)
activity in rat adipocytes (97;9$). Moreover, vanadate restores the depressed levels of G6P
in the adipose tissue, liver and muscle of STZ-diabetic rats (97). Since G6P is an allosteric
modulator of glycogen synthase activity (99), alteration of its levels may rnodify the
activation status of glycogen synthase and, eventually, glycogen synthesis. Similarly to the
effects in animal models of diabetes, 3-week VS therapy (100 mg/day) in type 2 diabetic
patients has been associated with an increase in insulin-stimulated glycogen synthesis (61).
However, in a more recent study, VS treatment (150 mg/day) for 6 weeks in humans,
although it caused a 1 .5-fold enhancement of glycogen synthase fractional velocity (an
indicator ofheightened glycogen synthase activation), failed to elicit any significant change
in either basal or insulin-stimulated glycogen synthase activity (63). Thus, the impact of VS
therapy on glycogen synthase activity in hurnans rernains controversial, and needs to be
examined in detail.
1.4.3-Effect on gluconeogenesis
In addition to the stimulatory action on glucose uptake and utilisation, vanadium-induced
suppression of hepatic glucose output can also contribute to improved glucose homeostasis.
In fact, decreased hepatic glucose production has been noted in diabetic animals
(94;100;101) and humans afier vanadium therapy (61;62;64;101), but some studies have
failed to obtain this result (60;63). The reason for these discrepant findings is not clear at
present, but the study model, duration of therapy, and vanadium dose rnight have been
determining factors. An inhibitory action ofNaMV on glucose output bas been documented
in the isolated, perfused rat liver (102), and VO(acac)2 bas been shown to suppress
gluconeogenesis in isolated hepatocytes and kidney cortex tubules from control and
diabetic rabbits (103). Consistent with these data on gluconeogenesis, vanadium treatment
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decreased the heightened expression of the gluconeogenic enzymes PEPCK and G6Pase
(13:98:104-109).
1.4.4-Effect on lipogenesis and lipolysis
In addition to their action on glucose metabolism. vanadium compounds have been reported
to modulate Iipid metabolisrn both in vivo and in vitro. NaOV treatrnent of insulin
resistant, sucrose-fed diabetic rats and fa!fa Zucker rats significantly lowered plasma
triglycerols (93). Furthermore, NaMV and VS decreased plasma cholesterol levels in
hurnans (63:64:110), and this effect was associated with a decline of low- as well as high
density lipoproteins (64); however, no change in either plasma free fatty acid or triglyceride
fractions was noted (62;63). Vanadate has also been shown to reduce total and free
cholesterol levels in normal subjects (111), which may be due to inhibition of the steps
involved in cholesterol biosynthesis (1 12:113). In isolated hepatocytes (114) and
adipocytes (37). NaOV modulated lipid metabolism by’ stimulating lipogenesis and
suppressing lipolytic activity.
1.5-VANADIUM TOXICITY
Despite their impressive anti-diabetic properties, vanadium compounds have been
associated with several toxic effects (115:116). The most common toxic effects are
diarrhoea, decreased fluid and food uptake, dehydration and reduced body weight gain
(20:67:78:91:94:106:117) which can, however, be corrected by adding NaC1 to the drinking
water, adjusting the pH of the solution to neutrality, and by gradually increasing the dose of
vanadium (20:41). Organic vanadium compounds are much safer as anti-diabetic agents
than inorganic vanadium salts. and diabetic rats receiving organic compounds did not show
any gastrointestinal side-effects and did flot develop diarrhoea (13). Administration of the
chelater tiron was also found to minimise vanadate toxicity without altering its anti-diabetic
actions (115).
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In addition to gastrointestinal discomfort, other toxic effects of vanadium saits have been
documented in the literature, whicli include hepatotoxicity, nephrotoxicity and
teratogenicity as we!! as deve!opmenta!/reproductive toxicity (115; 116). Tliey stimulate
mitogenesis and ce!! proliferation in cu!tured ce!!s (112) and, thus, have tlie potentia! to
exert tumorigenic/carcinogenic activity. In contrast, recent work lias demonstrated that
vanadium compounds inhibited serum- and growth factor-stimulated mitogenesis (119;120)
and possess anti-tumor activity (121;122). Many other studies have, however, fai!ed to
detect any change in the levels of urea, creatinine, g!utamic oxaloacetic transaminase, and
g!utamic pyruvic transarninase (123), indices of kidney and !iver functions. Moreover, no
significant changes in the histopatho!ogy of severa! tissues, inc!uding the liver, sp!een,
stomach, heart and lung, have been observed among contro! and VS-treated anima!s (124).
E!ectron microscopic examination of ob/ob mice treated with NaOV for 47 days did not
reveal any sign of hepatotoxicity (20). Some reports have indicated that vanadium
compounds cause behavioural changes in rats exposed to NaMV (125). In patients treated
with vanadium saits, gastrointestinal discomfort was the most common toxic effect, which
could be corrected by decreasing the dose !evel (60;61). Moreover, c!inica! studies have
been of short duration (up to 6 weeks) and have uti!ised muci lower doses than those
administered in animal experiments; thus, the !ong-term toxicity of vanadium in humans
rernains to be explored. Clear!y, at present, there is no consensus on the toxic effects of
vanadium compounds, and detailed and systernatic investigations are needed to evaluate the
toxicity of various vanadium cornpounds before undertaking long-tenu c!inica! tria!s in
humans.
1.6-MOLECULAR MECHANISM 0F VANADIUM ACTION
At the mo!ecu!ar !eve!, the precise mechanism by which vanadium e!icits insu!in-!ike and
anti-diabetic effects remains poor!y characterised. Since vanadate is a potent PTPases
inhibitor, and insu!in receptor (IR) activation requires increased tyrosine phosphorylation of
its f3 subunit (126; 127), it was be!ieved that vanadium caused an activation of IR by
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preventing dephosphorylation of the IR-t3-subunit. The insulin like effects of vanadium
salts were therefore attributed to be secondary to PTPase inhibition. In this manner one or
more tyrosine kinases that participate in the insulin signaling cascade may be indirectly
inftuenced. Thus, it is primordial to dissect the signal transduction pathways stimulated by
insulin for better understanding of the mechanism of vanadium action at the cellular level.
1.6.1- The insulin signaling cascade
Insulin, the primary hormone implicated in blood glucose control, acts by stimulating
glucose influx and metabolism in adipocytes and muscle and by inhibiting gluconeogenesis
by the liver. The insulin action in target cells is propagated by binding to its receptor on
celi membranes (Fig. 3). The IR consists of a heterodirneric Œ2, 132 structure. Insulin
binding to the IR-Œ-subunit results in conformational changes, leading to enhanced intrinsic
protein tyrosine kinase (PTK) activities of the 13-subunit by multi-site tyrosine
phosphorylation. Once activated, IR-PTK can phosphorylate several cytosolic IR
substrates, including insulin receptor subtrates (IRSs), Src hornology collagen (Shc) and
adaptor protein with pleckstrin homology (PH) and Src homology 2 (SH2) domains (APS).
The phosphorylated proteins dock downstream effector molecules that contain the SH2
domain (12$), which are then able to activate two key signaling pathways. In one pathway,
the association of IRS type 1 (IRS- 1) with growth factor receptor binder-2 (Grb-2)
complexed with mammalian son of seven less (mSOS) results in subsequent activation of
the Ras, Raf, MEK and extracellular signal-regulated kinase (ERK) pathway. Activated
ERK1/2 phosphorylates and activates a downstream ribosomal protein kinase, p9O. Both
ERKI/2 and 90rsk can be translocated to the nucleus where they phosphorylate
transcription factors, and contribute to the mitogenic and growth-promoting effects of
insulin (12$;129).
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Figure 3: Schematic model showing key elements of the insulin-signaling cascade
Insulin (Ins) -induced tyrosine pliosphorylation and activation of insulin receptor substrates
(IRSs) by the protein tyrosine kinase (PTK) of -subunits lead to recruitment of Src
homology (SH-2) dornain-containing signaling proteins, such as Grb-2-SOS, the p85
regulatory subunit of P13-K, a lipid and protein kinase. The IRS-associated complex
initiates 2 signaling pathways. One pathway. known as the MAPK pathway, consists of
Ras/Raf/MEK!ERKI/2 and p9Orsk. Both ERKI/2 and p9Orsk can be translocated to the
nucleus where they can activate transcription subsequent to the phosphorylation of several
transcription factors. Another pathway involves P13-K activation, which resuits in the
generation of PIP3. PIP3 activates a variety of downstrearn signaling components,
including PDKs, PK3, mTOR, p7Os6k, PKC, GSK-3 and fKHR. PKB and PKC are
involved in a glucose transport system. mTOR regulates protein synthesis via p7Os6k.
Glycogen synthesis is regulated by PKC directly and by PKB via GSK-3. PKB-rnediated
phosphorylation of FKHR inhibits its effect on transcriptional activity. (Abbreviations are
defined in the list of abbreviations).
* Adapted/Modffied from (12$;129;301).
1F
IRafi
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I Ccli growthGene transcription
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The second pathway that radiates from the IRS complex upon insulin stimulation
involves phosphatidylinositol 3-kinase (P13-K) activation (127;129) (fig. 3). P13-K
phosphorylates phosphatidylinositol (PI) lipids at position 3 of the inositol ring, and
generates 3-phosphorylated forms of PI, such as phosphatidylinositol 3, 4, 5 triphosphate
(PIP3) (130). which is implicated in the activation of phosphoinositide-dependent kinase
(PDK) and related serine/threonine protein kinases responsible for the phosphorylation and
stimulation of several downstrearn signaling protein kinases. such as protein kinase B
(PKB) (also known as Akt), p70 ribosomal S6 kinase (p70’6”)(l3l) and protein kinase C
(PKC)-zeta (132). Activation of these protein serine/threonine kinases bas been
hypothesized to mediate the metabolic effects of insulin at the level of glucose transport,
GLUT-4 translocation, glycogen and protein synthesis (129). In addition to the P13-K-
dependent pathway of insulin-induced glucose transport. recent studies have suggested a
potential role of an alternate P13-K-independent mechanisrn of glucose transport (133).
Ibis mechanism involves insulin-induced tyrosine phosphorylation of the protooncogene
Cbl (133). Cbl associated protein (CAP) and APS are important components of this
mechanisrn and contribute in the membrane targeting of tyrosine phosphorylated Cbl to
lipid rafts which eventually activates a small 9 guanosine triphosphate (GIP) binding
protein, TC 10 (134). Ihe activation of IC 10 has been suggested to be a crucial step in
mediating insulin-induced GLUT-4 translocation (134:135).
The following sections provide a full description of sorne of the key components of the
insulin signaling cascade.
1.6.1.1- The insiilln receptor
Ihe IR is present in all vertebrate tissues with varying degrees of expression. Its
concentration ranges from 40 receptors on circulating erythrocytes to more than 200,000
receptors on myocytes. adipocytes and hepatocytes (128). The IR gene is present on the
short ami of hurnan chromosome 19, is more than 150 kilobases, and contains 22 exons,
which encode 4.2-kb cDNA (4). The IR is composed of two extracellular Œ-subunits and
two transmembrane 3-subunits linked to each other by disulfide bonds (128) (fig. 4). Both
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the c- and f3- subunits are derived from a single proreceptor by proteolytic processing at
a cleavage site consisting of four basic amino acids. Alternative splicing sunounding exon
11 resuits in two receptor isoforms differing by 12 arnino acids close to the COOl-1
terminus of the a-subunits. The a-subunit and f3 subunits weigh 135 and 95 kilodalton
(kDa) respectively. The Œ-subunit is located entirely outside of the ce!! and contains the
insu!in-binding site with stoichiometry between J and 2 insulin molecules/receptor,
whereas the intracellular section of the f3-subunit possesses intrinsic insulin-regulated
tyrosine kinase activity. Different biochernical approaches have found that the distinct
regions of the first 500 amino acids of the Œ-subunits contain ligand-binding determinants
(136). Therefore, insulin-binding affinity is increased by replacing amino acids 64-137 of
the insulin-like growth factor type 1 receptor (IGf-IR) Œ-subunits by corresponding
residues from the IR. In addition. replacing amino acids ofresidues 325-524 from the IR in
this chimera enhances insulin-binding (136137). The a-subunit of IR can also act as a
regu!atory subunit of the tetrameric receptor because the unoccupied IR c&-subunits inhibit
the tyrosine kinase activity of the f3-subunits. Depletion of the u-subunits by deletion
mutagenesis or proteolytic cleavage or certain point mutations in the Œ-subunits (Arg$6 —
Pro) abrogate this inhibition (138). The carboxy-terrninal of the Œ-subunits has four Cys
residues, 647, 682, 683 and 684, which are involved in subunit disulfide linkage. Cys 647
to Ser 647 mutation did not cause any change in insulin binding, but these mutants were
defective in insulin-stimulated kinase activity. Therefore. insulin-stimulated signa!
transmission from ligand binding to kinase activation requires proper covalent interaction
between the Œ- and f3- subunits for normal subunit communication (139; 140).
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Figure 4: Structure of the insulin receptor
The insulin receptor is cornposed of two o-subunits and two J3-subunits linked by disulfide
bonds. The Œ-subunits are entirely extracellular and contain the insulin binding domains.
while the 13-subunits penetrate through the plasma membrane into the cytoplasm. The 13-
subunit has several tyrosine autophosphorylation sites. ATP binding dornain and regulatory
region necessary for the activation of its intrinsic protein tyrosine kinase activity.
* AdaptedlModified from (127).
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The IR-f3 subunits consist of short extraceilular sites for glycosylation, a transmembrane
dornain of 23 amino acids and an intracellular region which bas protein tyrosine kinase
activity required for insulin action (Fig. 4). The IR-f3-subunits possesses different
functional regions. inc luding the adenosine triphosphate (ATP)-binding domain and
autophosphorylation sites in the intraceilular juxtamembrane region (Tyr 960, and possibÏy
Tyr 953 and Tyr 972), a regulatory region (Tyr 1146. Tyr 1150 and Tyr 1151). and the C
terminus (Tyr 13 16 and Tyr 1322). In vitro mutagenesis experiments have provided
evidence that a key lysine residue at position 1030 (LyslO3O), which is an ATP-binding
site, when replaced by other amino acids, causes complete loss of kinase activity of the f3
subunit aÏthough insulin-binding is unaffected (141;142). A similar function for a lysine
residue at position 1012 bas been found (143;144). The discrepancy in the position of
lysine between these two studies is due to differences in the approacb used in numbering
these residues.
Tyrosine phosphorylation occurs through a transmechansim in which insulin binds to the x
subunit of one Œf3-dimer and thus stimulates phosphorylation of the adjacent covalently
linked f3-subunit (145). Autophosphorylation of ail tbree tyrosine residues ofthe regulatory
region increases tyrosine kinase activity of the IR. Deletion of 1 or ail tyrosine residues in
this region by mutation reduces insuiin-stimuiated kinase activity (146;147).
Thejuxtarnembrane region oftbe IR-f3-subunit containing Tyr 960 within NPXY (Asn-Pro
any amino acid-Tyr) motifs plays a role in signal propagation. Repiacement of Tyr 960 by
phenylalanine or alanine inhibits signai transmission without affecting autophosphorylation
in the other regions and kinase activity in vitro (142:149). Anaiysis of Tyr960 point
mutation shows a type of receptor that is impaired in internaiization in response to insulin
(150). In addition, Tyr960 to Phe point mutation is unable to phosphoryiate IRS-1, a
crucial IR substrate, which resuits in decreased P13-K activation and blocks glycogen and
DNA synthesis (151). Thus, the juxtamembrane region is a criticai dornain required for
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both insulin-stimulated signaling via IRS-1 phosphorylation as weil as receptor
internalization.
The C terminus of the IR contains two autophosphorylation sites. Tyr 1316 and Tyr 1322,
which may not be essentiai for kinase activation (152). In contrast, the C terminus lias
serine and threonine residues phosphorylated in response to phorbol esters, cyclic
adenosine monophosphate (cAMP) analogues. and insulin itself. thus Ïeading to decreased
insulin-stimulated tyrosine kinase activity (153-155). Thus. the C terminus plays a
reguÏatory role that is essential for signaling.
1.6.1.2- The insulln receptor siibstrates
As stated earÏier. activated IR-PTK mediates the insulin response through tyrosine
phosphorylation of IRS proteins which serve as docking sites for effector molecuies
responsibie for propagating the insuiin signal (156). At least four IRS proteins have been
identified in mammais. Whiie IRS-1 and IRS-2 are wideiy expressed in ail tissues, IRS-4 is
only expressed in the brain, thymus, kidney and f3-cells and IRS-3 is present in rodents and
highly restricted to adipose tissue (157). Iwo other srnali proteins caiied. Gab and p62d
have been shown to be substrates ofthe IR and are considered to be IRS proteins (156).
IRS proteins have severai common features and are composed of a NI-12-terminal PH
and/or phosphotyrosine binding (PTB) domain foliowed by a COOH-terminal tail
comprised of multiple tyrosine and serine/threonine phosphorylation site residues. The
generai structure ofIRS-l is presented in Fig. 5.
The roie of the PH dornain in IRS is flot known because physiologicaliy-relevant binding
partners are undefined; however, phospholipids, acidic peptides, or specific proteins such as
PH domain interacting protein (PHIP) are defined as PH domain-binding partners (15$),
but the mechanism of this coupiing is unknown.
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IRS- 1 serves as a type of docking protein for recruitrnent and activation of other enzymes
that ultirnately mediate insulin effects. The relative positions of the pleckstrin homology
(PH) and phosphotyrosine binding (P13) domains are indicated. Potential tyrosine
phosphorylation sites are indicated by Y while known phosphorylation motifs are enclosed
in boxes below potential binding partners, including P13-K, Grb-2 and SHP-2.
(Abbreviations are deflned in the list of abbreviations)
* Adapted/Modifled from (156).
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Figure 5: Structure of the Insulin Receptor Substrates-1 (IRS-1)
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The PTB domain was found to mediate interactions of IRSs with the IR, insulin-like growth
factor type 1 receptor (IGF-1R) and interleukin-4 (IL-4) receptors through phosphorylated
NPXY motifs located in these receptors.
The tyrosine phosphorylated residues in the COOH-terrninal serve as docking sites for SH2
domain-containing signal transducers. including p8, a regulatory subunit of P13-K. SH2
domain-containing tyrosine phosphatase (SHP2). Src-like kinase fyn or adapter rnolecules.
such as Grb-2, nck, Crk, SHB and others that mediate downstream signais (129).
Moreover, other partners including SV4O large T antigen. Œvt33 and 1 4-3-3 bind to IRS
proteins through an unknown tryosine phosphorylation-independent mechanism (129).
The role of serine/threonine phosphorylation sites bas not been fully unraveÏled. but severai
studies have shown that factors. known to induce insulin resistance. such as free fatty acids
(159), turnor necrosis factor-a (TNF-a) (160), angiotensin II (Ang TI) (161), endothelin-l
(162) and chronic insulin treatrnent (163), lead to increased serine/threonine
phosphorylation of IRS-1 and consequently to impainuent of insulin signai transduction.
Many Ser/Thr-kinases which phosphorylate IRS-1 are identifled including Raf. MEK.
mitogen-activated protein kinase (MAPK). p90ts, Rho kinase-Œ (R0K-), and PKC
isoforms and kinases downstream ofthe P13-K cascade such as PDK-1, PKB. mammalian
target of raparnycin (mTOR), 7056K and glycogen synthase kinase-313 (GSK-3f3) (164).
Specific Ser/Thr phosphorylation sites in IRS-1 identified in vitro include Ser-302, Ser-307,
$er-612, Ser-636, Ser-639, Ser-731 and Ser-789. 0f these, Ser-307 phosphorylation has
been studied most intensiveÏy as a rnechanism for disrupting IR/ÏRS- I interactions (164).
Importantly, a high level of phosphoryiated Ser-307 has been detected in vivo in human
skeletal muscles (165) and in insulin-resistant rodent models (166). Serine phosphorylation
of IRS-1 by some of these kinases has been shown to impair the ability of insulin to
enhance IRS- 1 tyrosine phosphorylation (167) and lead to proteasome-mediated
degradation (168). Taken together, Ser/Thr phosphorylation ofIRS-1 could represent one
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of the molecular mechanisms by which diabetogenic factors rnight induce insulin
resistance.
1.6.1.3-Pliosphatidylinositol 3-Kinase (P13-K,)
As discussed earlier, IRS proteins serve to couple IR-PTK to the P13-K cascade. P13-Ks
are a family of lipid kinases that phosphorylate the D3 hydroxyl group (3 ‘-OH) of the
inositol ring in phosphatidyl inositol (PI). Products of the P13-K reaction include PI3P.
P13, 4P2 and P13. 4.5P3.
P13-Ks have been divided into three classes (I, II and III) based on sequence homology and
substrate preference. Class I P13-Ks are heterodimers cornposed of a catalytic subunit with
molecular mass 110 (pi 10) and an adapter/regulatory subunit. This class is further divided
into classes lA and lB. While class lA is activated by receptor PTK (RPTK) and Ras. class
lB is activated by heterotrimeric G protein-coupled receptor (GPCR) and Ras. The
preferred in vivo substrate of this class I enzyme is PI(4,5)P2. Nonetheless, in vitro this
class can also phosphorylate PI, PI4P, and P15P.
Class lA bas three isoforms, a. f3 and & of the catalytic p110 subunit and several forms of
regulatory subunits (p8. p’, p8 and p) generated by the expression and
alternative splicing of three genes, p$5Œ, p8 and p5’. Activation of class TA occurs since
the catalytic p110 subunit associates with a p85 regulatory subunit which contains two SH2
domains that specifically recognize phosphorylated tyrosine in pYMXM (Tyr-Met-any
amino acid-Met) motifs present on activated growth factor receptors or their substrates.
The principal role played by this class seems to be the regulation of ceÏÏ growth and
proliferation (169; 170).
On the other hand, Class lB has only one member of the catalytic subunit called pI 1 Oy and
one form of the regulatory subunit p101. The pli Oy/pl0l complex is translocated to the
membrane and activated by the f3-subunits of trimeric G proteins at the membrane
(169;170). Since pi lOy is expressed at a low level in cardiornyocytes, endothelial and
2$
vascular smooth muscle, it could be the isoforrn that plays a role by controlling vascular
tone and heart contractility (171). In addition, pi lOy is highly expressed in white blood
celis throughout the hematopoietic system that controls processes in inflammation and
aÏlergy (172). Furthermore, both classes TA and lB can bind Ras.GTP to a N-terminal
region in pi 10. leading to P13-K activation (173). The ability of Ras to regulate P13-K may
be important in both Ras-mediated cellular morphology and DNA synthesis (174).
Class II P13-Ks consists of two major mammalian subclasses, Œ and 3, and by definition
they contain a carboxy-terminal C2 domain. a protein module originally observed in PKC
molecules, where it confers phospholipid binding. There are no known regulatory subunits
in this class, which may not be required, since the size of the catalytic subunit of class II is
about twice the size of classes I and III. This family contains several members. including
m-cpkJpl7O, and its human homologue P13-K-C2Œ. as well as human P13-K-C213 or
HsC2PI3-K and P13-K-68 D/cpk identified in Drosophila (172). In vitro studies have
shown that P13-K-C2Œ prefers Ptdlns as its substrates but it also phosphorylates PI4P and
to a lesser degree. PI(4.5)P2. On the other hand. P13-K-C213 highÏy prefers Ptdlns. poorly
phosphorylates PI4P and has no effect on PI(4ï)P2. Although Class II P13-Ks have flot
been studied extensively, there is evidence that PI3-K-C23 can be stimulated via activated
integrin in platelets (172).
Class III P13-Ks is the only class of enzymes present in yeast: therefore, it is thought to
represent the primordial P13-K that gave to the other class. PI is the only substrate
recognized by this class and is phosphorylated to generate PI3P (172). The catalytic
subunit size ofthis Class III P13-K is similar to that of class I. The structure ofthe catalytic
subunit Vps34p. present in yeast, and its human homologue contains a carboxy-terminal
catalytic phosphatidytinositoikinase (PIK) domain as well as a regulatory binding domain.
The regulatory subunit of this class, Vpsi5p/p150, contains an amino-terminal
myristylation signal, a Ser-Thr kinase domain. a series of Leu-rich repeats. and carboxy -
terminal WD motifs. Based on several studies in yeast. Class III P13-K is considered to
play a role in vesicular trafficking, osmoregulation and endocytosis (175).
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In addition to its lipid kinase activity, P13-K has protein kinase activity and bas been
shown to phosphorylate the regulatory subunit p8 at Ser 60$ in the inter-SH2 domain
(176) as welI as insulin response sequence-l (169). Recently it was found that the
pli 07/TOR hybrid molecule that Iacks lipid kinase activity activated the MAPK cascade,
but failed to induce PKB activation, and suggesting that the protein kinase activity of P13-K
is Iinked to MAPK activation while its lipid kinase activity is crucial to activate PKB (169).
The effects ofphospholipids generated by P13-K in celis are mediated througb their specific
binding to at Ieast two tipid-binding protein dornains, the fYVE (Fabi, YGLO23, Vps27,
and EEA1) and PH domains. While FYVE dornains interact selectively with PI3P, the PH
dornains bind P13,4P2 and P13,4,5P3. Phosphoinositide-binding PH dornains are found in
nurnerous proteins. including PDK and PKB. which are mediators of class lA P13-K
signalling (f ig. 6) (177).
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Figure 6: Schematic representation of PKB activation and its physiological role
PT3-K is activated while it’s recruited to phosphorylated-IRS-1. P13-K catalyzes the
phosphorylation of phosphatidylinositol 4, 5 biphosphate (PIP2) leading to the formation of
phosphatidylinositol 3, 4, 5 triphosphate (PIP3). PIP3 recruits PH domain containing
proteins to the plasma membrane including PKB, PDK-1 and probably. the putative PDK
2, where PKB becomes phosphorylated and activated. PKB contribute to a variety of
cellular responses, including ceil growth. celi survival and metabolism by targeting
different substrates. PIEN, a lipid phosphatase. dephosphorylates PIP3 to PIP2 and thus
inhibits activation of PKB. (Abbreviations are defined in the list of abbreviations)
* Adapted/Modified from (169;182;186;301).
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1.6.1. 4-Protein kinase B (PKB
PKB was originally named Akt because it was the product of the acute transforniing
retrovirus (Akt-8) gene isolated from an AKR thymoma (17$). Sequence analysis of the
viral oncogene and its cellular homologue revealed that it encodes a Ser/Thr kinase (179).
Akt was also cloned by two different groups and was named RAC (Related to A and C
kinase) by Coffer et al. (180) and PKB by Jones et al. (181). To date, the protein is most
commonly referred to as Akt or PKB.
PKB, a 57 kDa protein, was so called because of its high homology with protein kinase A
(PKA) and PKC. It is known to exist as three isoforrns, a, j3 and y (Aktl, Akt2 and Akt3,
respectively) widely expressed in most mammalian ceils (182;1$3). Each isoforrn
possesses three functional distinct regions: an amino-terminal PH domain. a central
catalytic Ser/Thr kinase domain and a carboxy-terminal regulatory domain that contains the
hydrophobic motif(HM) (169). The kinase domain ofPKB, located in the central region of
the enzyme, bas high similarity with other AGC kinases such as PKA, PKC, 70S61 and
90rsk and contains the conserved Thr residue whose phosphorylation is required for
enzymatic activation. This threonine residue is flanked between highly conserved DFG and
API motifs in the activation ioop. which lies in the C-lobe of the kinase dornain. The PH
dornain of PKB interacts with similar affinity witb membrane lipid products such as PI(3,
4)P2 and PI(3.4,5)P3 produced by P13-K. Point mutation in the PH dornain of PKB reduces
its interactions with phosphoinositides as well as its activation by its upstream activator,
PDK-1. These studies suggest that the PH domain of PKB plays a significant regulatory
role in both membrane transiocation and recognition by upstream kinases.
The second important regulatory domain of PKB is a carboxy-terminal of around 40 amino
acids. Ibis region possesses the f-X-X-F/Y-S/T-Y/f (HM) (where X is any amino acid)
that is characteristic ofmany other AGC kinases. Phosphorylation ofthe Ser or Thr residue
in this HM is necessary for full activation. In ail mammalian PKB isoforms. this motif is
identical, and is very important, because a deletion mutant motif cornpletely abolishes PKB
enzymatic activity. Interestingly, rat PKBy/Akt3 and the human PKBy-1 splice variant do
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flot have this motif indicating that activation of these variant kinases occurrs via an
alternative rnechanisrn independent of Ser/Thr residues in the HM. further recent evidence
shows that the HM bas a dual role in regulating kinase activity. In addition. based on the
biochernical and crystat structure PKB, it is suggested that the HM serves as an allosteric
regulator of catalytic activity. Thus, the HM provides stability to the catalytic activity core
due to intramolecular interaction between the phosphorylated HM and its acceptor
structure. called the hydrophobie groove forrned by aB- and (XC- helices. In addition, the
activation ioop becomes ordered due to interactions witb the OEC helix.
Phosphorylation site mapping of PKB from quiescent or IGF-1 revealed that while Ser 124
and Thr 450 are constitutively phosphorylated and seem to contribute to stabilization ofthe
proteins. phosphorylation of Th30$ in the activation ioop and Ser 473 in the carboxy
terminal site is detected in stirnulated celis (169). The C terminal PH domain in PDK-1
binds phospholipids with lO-fold higher affinity than the PKB PH dornain, which probably
explains the constitutive localization of PDK-1 at the plasma membrane. Therefore, the
following scenario for PKB activation has been proposed (f ig. 6): P13-K activation leads to
the production of PI(3. 4)P2 and PI(3.4.5)P3 at the inner leaflet of the membrane. These
phospholipids interact witb PKB and cause its transiocation to the inner membrane wbere
PDK-1 is located. furthermore, it is thought that binding of 3’-phosphoinositides to PKB
changes its conformational status, making the regulatory residues more accessible to
phosphorylation. The PH domains might also mediate protein proximity between PKB and
PDK-1 through homodimerization. PDK-1, believed to be constitutively active.
subsequently phosphorylates Thr308 in PKB (184). which stabilizes the activation ioop in
an active conformational form. Phosphorylation of Thr 30$ is a prerequisite for kinase
activation, but phosphorylation of Ser 473 is required as well for full PKB activation. The
putative Ser 473-PKB kinase called PDK-2, remains to be identifled.
At least 13 substrates have been identified so far in mammalian celis (169:170). AIl
identified substrates possess the same basic motif, RXRXXS/T, where X is any amino acid,
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and S/T is the phospho;ylation site. This consensus sequence is based on the sequence
around the phosphorylation on GSK-3F3. the first identified substrate.
PKB contributes to a variety of cellular responses. including ceil growth. ceil survival and
metabolism (fig. 6 and 7) (170;1$2;1$3). The downstream targets ofPKB invo!ved in ce!!
death regu!ation include the forkhead transcription factors, the pro-apoptotic Bd-2 family
member BAD, and the cyclic AMP response eternent-binding protein (CREB). GSK-313.
phosphodiesterase-3B (PDE-3B). mTOR. the forkhead member FKHR. the cyclin
dependent kinase inhibitor p21 and possibly Raf-1 are targets involved in mediating
carbohydrate metabolism and ce!! cycle regu!ation. In addition, phosphory!ation of
endothe!ial nitric oxide (eNOS) and breast cancer susceptibility-1 (BRCAI) by PKB might
mediate angiogenesis and DNA repair.
In the following sections, we focus on the role of PKB in the regulation of carbohydrates
(F ig. 7).
1.6.1.4.] -Role ofFKB 117 glucose transport
Accurnulating evidence implicates PKB in enhancing insu!in-i nduced glucose transport
through its effect on insulin sensitive glucose transporter isoform (GLUT-4). In the basal
state, GLUT-4 is located in the intrace!!u!ar vesic!es which are trans!ocated to the plasma
membrane in response to insu!in, thereby increasing the number of transporters avai!ab!e
and thus glucose uptake (fig. 7) (185;186). Different molecular approaches suggest that
PKB is a mediator of insu!in action in this process (186). For example. PKB rcndered
constitutively active by membrane-targeting mimics insulin by increasing the rate of
GLUT-4 translocation and glucose transport in the absence of insu!in (187) whereas PKB
inhibition by microinjection of a PKB substrate peptide or an antibody to PKB suppresses
insu!in-stimulated GLUT-4 translocation to the plasma membrane in muscle and fat ce!!s
(188;1$9).
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1.6.1.4. 2-RoÏe ofPKB in glycogen synthesis
Glucose uptake activated by insulin is ultimately stored as glycogen in skeietal muscle.
Glycogen synthase (GS) plays a pivotai role in this processes by catalyzing the final step in
glycogen synthesis. The regulation of GS is complex and involves allosteric activators.
transiocation to the plasma membrane in the presence of glucose metabolites and insulin.
inhibitory phosphorylation on Ser residues by different kinases (PKA, PKC and G$K-3),
and activation of dephosphoryiation by the Ser-Thr phosphatase PP 1. Therefore, a model
by which GS wili be active and leads to glycogen synthesis is via phosphoryiation of GSK
3 by PKB on Ser 9 which resuits in the inhibition of its cataiytic activity (190) (Fig. 7).
GSK-3 phosphorylates four Set residues on GS, and PKB-mediated inactivation of GSK-3
contributes to a reduction of GS phosporylation and increase in GS and giycogen synthesis
activation (191). In adipocytes. mutation of GSK-3 as a PKB-insensitive form results in
suppression of insulin-stimuiated GS activity. In addition. adipocytes transfected with
constitutively active PKB significantly inhibit GSK-3 activity and induce GS activation
whereas the same ceils transfected with dominant inhibitory PKB show 50% inhibition of
insulin-stimuiated GS activation. Nonetheless. further work is needed to suggest the
absolute contribution of PKB in the regulation of GS because severai signaling moiecuies
that are influenced by PKB moduiate this process.
1.6. 1.1. 3-Role ofFKB in gluconeogenesis
De novo synthesis of glucose in the iiver from precursors such as lactate, giuconeogenic
amino acids, and glycerol is a central mechanism that provides the organism with glucose in
tirnes of starvation. On the other hand, when glucose is directly available from externai
resources. gtuconeogenesis needs to be shut off. PEPCK and G6Pase are implicated in
regulation ofthe early and terminal steps ofgiuconeogenesis, respectively. Indeed, PEPCK
and G6Pase appear to be positively regulated at the level of transcription (no allosteric
modification) by cAMP or glucocorticoid signaling. Actually, insulin can suppress
glucocorticoid and cAMP signaling-stimulated glucose production by downregulating the
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(Abbreviations are defined in the Ïist of abbreviations)
* Adapted/Modified from (182:186).
Figure 7: Recapitulative schema showing a rote of PKB in the regutation of
carbohydrate metabolism
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transcription of PEPCK and G6Pase, and PKB bas been proposed as mediator of insulin
regulated gluconeogenesis (192). G6Pase and PEPCK promoters are known to contain so
calÏed insulin-responsive element (IRE), but the transcription factors that bind to these
regions have flot been identified. In mammalian celis, the DAF-16 homologue Foxol
(known as Forkhead trasncription factor. FKHR) have been found to be phosphorylated by
PKB at three conserved Ser or Thr residues within the PKB consensus phosphorylation sites
(RXRXXS/T), namely 1hr24, Ser256, and Ser319 (Fig. 7) (193). Phosphorylation in these
three places resuits in transcriptional inactivation and nuclear export of FKHR (194).
Electrophoretic mobility shifi assays have provided evidence of FKHR binding to insulin
responsive sequences in the G6Pase promoter, and reporter gene analysis has demonstrated
transactivation of the PEPCK and G6Pase promoter in vitro (195). In addition,
overcxpression of FKHR markedly increases the expression of the endogenous G6Pase
transcript in H4 rat hepatoma and LLC kidney epithelial cells. The overexpression of
dominant negative FKHR mutants that are not regulated by PKB impairs the suppression of
G6Pase gene transcription by insulin. In addition. the overexpression of a constitutively
active FKHR mutant, which is resistant to inactivation by insulin. increases PEPCK and
G6Pase expression and resuits in elevated fasting blood glucose concentrations (192).
A potential role for GSK-3 in the regulation of gluconeogenesis has been suggested from
the use of specific inhibitors (Fig. 7). These compounds decrease hepatic glucose
production in fasted falfa rats and induced hepatic glycogen synthesis (196). The decrease
in hepatic glucose production in vivo afler inhibition of GSK-3 might be due to suppression
of PEPCK and G6Pase gene expression. It should be noted that pharmacological inhibition
of GSK-3 activity in hepatorna ceils was found to reduce gluconeogenesis and hepatic
glucose output (197). Thus, the molecular events underlying the regulation ofPEPCK and
G6Pase gene expression by GSK-3 are unclear. PKB-rnediated GSK-3 phosphorylation
and inhibition couÏd be one model by which PKB regulates glucose output.
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1.6. 1.4. 4-Role ofFKB in protein synthesis
Muscle and fat are two prirnary sites of insulin-dependent protein synthesis. Insulin
regulates protein synthesis by stirnulating initiation and elongation steps. Several studies
have shown that PKB plays a crucial role in modulating key-cornponents implicated in
translational activity (fig. 7) (182). In 313-LI adipocytes, putative dorninant-inhibitoiy
PKB mutant protein blocks insulin-stimulated protein synthesis. In contrast, a constitutive
active PKB increases protein synthesis in the absence of insulin in L-6 muscle cells and
313-LI adipocytes. eIf-4E. a lirniting initiation factor, binds to the 7-methylguanosine cap
and directs mRNA to the 40S ribosomal subunit. In quiescent celis, eIf-4E is sequestered
by 4E-binding protein (4E-BP1)/PHAS-I. Activation of mTOR, a 4E-BP1 kinase.
deactivates 4E-BPY. releases eIf-4E. and promotes translation initiation. Therefore, one
model posits that PKB activates mTOR by the phosphorylation of Ser 2448. In another
model, PKB indirectly regulates the activity of eIf-2B, the guanine nucleotide exchange
factor for eIF-2, through its downstrearn target GSK-3. GSK-3 inhibits eIF-2B by its
phosphorylation on Ser 540 while PKB-mediated phosphorylation and inactivation of
GSK-3 on Ser 23 and Ser 9 increase the exchange activity of eIf-2B and prornote the
recruitment of initiator tRNA to the 40S ribosorne.
Ihe phosphorylation of ribosomal S6 protein by 70S6K enhances translation by increasing
the interaction of the 40S ribosornal subunit with a select population of rnRNA containing
5’-IOP (terminal oligopyrimidine). A constitutively active PKB leads to activation of
70S6K and an increase in ribosornaï 56 protein phosphorylation, but this hypothesis is not
well- established because genetic experiments in Drosophila have shown that the activity of
S6K is independent ofthe presence ofa functional PKB gene.
1.6. 1.4. 5-RoÏe ofFKB in antiÏipoÏysis
Ihe role of insulin in adipocytes is primordial for the regulation of lipolysis (Fig. 7).
Hormone-sensitive lipase (HSL) which controls triglyceride (1G) breakdown in adipose
tissue, is activated by PKA-rnediated phosphorylation, and PKA activity is increased by
cAMP. The cyclic nucleotide phosphodiesterase PDE-3B. phosphorylated and activated on
3$
Ser 273 by PKB. reduces cAMP concentrations and decreases HSL activity (19$). In
contrast, another report demonstrates that 1-(5 chloronaphthalenesulfonyl)-1H-hexahydro-
I, 4-diazepine (ML-9), a powerful inhibitor ofPKB activity in different celis as well as of
recombinant PKB, prevents the stimulatory effect of insulin on glucose transport and
protein transiocation but flot the antilipolytic effect in rat adipocytes (199).
1.6.1.4. 6-Role ofPKB in lipogenesis
Lipogenesis, the conversion of incoming glucose to fatty acid, is regulated by insulin.
Several works have demonstrated a role for PKB in insulin-induced !ipogenesis (Fig. 7)
(186). Inhibition of GSK-3 by PK3 rnight be involved in this effect. GSK-3
phosphorylates ATP citrate !yase on Thr 446 and Ser 450 and decreases its activity (200).
This enzyme catalyzes the conversion of citrate to acetyl CoA in the cytosol. In addition. a
study by Wang et al. revealed that insulin stimulation of the fatty acid synthase (FAS)
promoter is mediated by the P13-K pathway and that PKB/Akt a downstream effector (201).
FAS catalyzes several steps in the conversion of ma!onyl-CoA and acetyl-CoA to long
chain fatty acids. furthermore. recent studies have shown that PKB induces transcription
of enzyme implicated in cholestero! and fatty acid biosynthesis via activation of a major
transcription factors called stero!-regtilatory element binding proteins (SREBPs). These
SREBPs regulates genes involved in fatty acid and cholestero! synthesis (202).
1.6.1.5- Tue Mitogen Activated Protein kinase (MAPK) path way
MAPKs a family of Ser/Tlw protein kinases widely conserved among eukaryotes, are
involved in many cellular responses such as ce!! proliferation. cell differentiation, ce!!
movement and ce!! death (203;204) . In mamma!ian ce!ls, five MAPK farnilies have been
identified. including ERKY/2. Jun N-terminal kinase 1, 2 and 3 (JNKI/2!3) also called
stress-activated protein kinase (SAPK). p38a43/y/, ERK5 and ERK7. These pathways are
characterized by the fol!owing genera! system: Stirnu!us — MAPKKK — MAPKK—
MAPK—* responses. The MAPKKKs, which are Ser/Thr kinases, are oflen activated
tlwough phosphory!ation and/or as a resu!t of their interaction with a smal! GTP-binding
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protein ofthe Ras/Rho family in response to extracellular stimuli. Activated-MAPKKKs
phosphorylate and activate MAPKK. which then stimulates MAPK activity through dual
phosphorylation on Yhr and Tyr residues located in the activation ioop of the kinases. Once
activated, MAPKs phosphorylate target substrates on Ser or Thr residues followed by a
proline; however, substrate selectivity is ofien conferred by specific interaction motifs
iocated on physiologicai substrates. Furthermore, MAPK cascade specificity is aiso
rnediated through interaction with scaffolding proteins which organize pathways in specific
modules through simuitaneous binding of several components.
The most extensively studied groups of vertebrate MAPKs to date are the ERKI/2, .TNKs,
and p38 kinases (203;204). ERKY/2 are stimuiated by mitogens such as polypeptide
growth factors (PDGF. CSf-1. IGF-1. etc.) as well as insulin and phorbol 12-myristate 13-
acetate (PMA). In contrast. SAPKs and p38 MAPK are potently induced by a wide variety
of stresses, including UV irradiation, gamma irradiation, anisomycin heat shock,
chernotherapeutic drugs. etc. but flot by mitogens. These two pathways are also activated
by ischemia or reperfusion following ischemia and by inflamrnatory cytokines.
Interestingly, epidermaÏ growth factor (EGf) can induce ail tlwee pathways, although its
potency is variable. In addition, GPCR can stimulate ail MAPK farnilies.
As discussed above, ERK1/2 is the principal MAPK pathway activated by insulin;
therefore, the following section wiIl provide a detailed account of its mechanism of
activation (Fig. 8).
The mammalian FRKI/2 pathway is constituted of the MAPKKKs A-Raf, B-Raf and Raf
1, the MAPKKs mitogen extracellular reguiated kinase 1 and 2 (MEK1/2), and the MAPKs
ERK-l and ERK-2. Other MAPKKKs, called MEKKI/2/3 and e mos, have also been
identified in this pathway. but their role in activation of the ERKY/2 pathway is lirnited
(205). The mechanism of ERK1/2 activation starts whith signais derived from activated
receptor tyrosine kinase (RTK) or GPCR to Raf/MEK!ERK through different isoforms of
the smail GTP-binding protein Ras. Ras is a 21 kDa molecular weight protein attached to
the cytopiasmic face of the plasma membrane by a famesyl group (206). The protein
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serves as a key “molecular switch” in cytoplasmic signalling pathways triggered by
activation of a variety of membrane receptors. In its inactive state. in unstimulated celis,
Ras is found to be associated with guanosine diphosphate (GDP) (Ras-GDP). As discussed
earlier, following activation of the IR and its substrates (e.g. Shc, IRS-1/2), Grb-2
associates with guanine nucleotide exchange factors such as SOS, and this causes the
release of GDP, and binding of GTP to Ras (forming Ras-GTP) (Fig. 8). The exchange is
accornpanied by a conformation change in Ras. allowing it to bind to a wide range of
downstream effector proteins. including isoforrns of the Ser/Thr kinase Raf. In fact. the
exact mechanism by which Raf is activated is stiil not completely clear, but it appears that
Ras binding as well as multiple phosphorylation events at the membrane are required.
Activated Raf binds to and phosphorylates the dual specificity kinases MEK-l and -2,
which in tum phosphorylate ERKI/2 within a conserved Thr-Glu-Tyr (TEY) motif in their
activation loop. Once activated. ERK1/2 can activate a number ofcytosolic proteins. such
as p9O through its praline directed Ser/Thr kinase activity or it can transiocate to the
nucleus where it can phosphorylate and activate a number of transcription factors involved
in immediate early gene (Fig. 8).
41
rr
In response to insulin, Shc or -IRS-1 becorne phosphorylated and binds Grb-2-SOS
complex leading to p2! ras stimulation by GTP loading with subsequent activation of Raf,
MEK. and two isozymic forrns of MAPK. ERK-1 and ERK 2. Activated MAPK
phosphorylates and activates a downstrearn ribosornal protein kinase, p90
t• Both ERKÏ/2
and 90rsk can be translocated to the nucleus where they can activate transcription
subsequent to the phosphorylation of several transcription factors. (Abbreviations are
defined in the Ïist ofabbreviations)
* Adapted/Modified from (203 ;204;30 1).
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Figure 8: Schematic diagram showing key steps involved in insulin-induced activation
of ERK1/2
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1.6.1. 6-Potentia! proteili tyrosine pIosphatases (PTPases) irnplicated in the litsu!bi
signaling cascade
PTPases serve as important regulators of the insulin signaling pathway by their abiiity to
catalyze the rapid dephosphorylation and inactivation of IR-13 subunit and IR substrates
(207).
PTPases can be divided into four classes: 1) ciassicai receptor PiPases (R-PlPases).
including leucocyte antigen receptor (LAR). PYP. PTP (type lia): PTPp, PTPic.
PTP2J/o (type TIb); PTPp; PIPa, PIPE (type IV); PTP/f3, PTPy (type V); 2) ciassical
non-receptor PiPases (NR-PlPases) including PIP1B, SHP-l, SHP2, PTP-PEST; 3) dual
specificity PlPases (DS-PTPases); and 4)low moiecular weight PTPases (20$;209). While
R-PlPases and NR-PTPases have specificity to phosphotyrosine residues. DS-PTPases
recognize phosphotyrosine, phosphopthreonine and phosphoserine residues. R-PlPases and
NR-PlPases fali into several subtypes based on their non-catalytic domain structures. R
PTPases, which have an extracellular domain. a single transmembrane segment and one or
two tandemly-conserved PTPase catalytic dornains are predorninantly found in the plasma
membrane, whereas NR-PlPases have a single PiPase domain with additional protein
segments and are iocalized to a variety of intraceliular cornpartrnents, including the cytosol,
plasma membrane and endoplasmic reticulum (ER). Ail PTPases contain at least one
conserved core of 230-250 amino acids that represent their catalytic domain. The PTPase
signature motif, VIHC SAGXGRXG, i.e (Vai/Ile) His-Giy-Arg-(Ser/Thr)Giy respectively,
possesses an invariant cysteine residue that is critical for PTPase activÏty. The cysteine
residues is essentiai to cataiyze the hydrolysis of protein phosphotyrosine residue by
forming a cysteinyl-phosphate intermediate.
The following sections briefly describe the involvement of major PlPases implicated in
modulation ofthe insulin-signaling pathway.
1.6.1.6. 1-PTPJB
PTPJB was the first PiPase discovered in the hurnan placenta (210). Expressed
ubiquitously. it is a type of NR-PTPase. PTPIB lias a molecular size of 50 kDa and
localizes predominantly in the ER tbrough a cleavable C-terminal domain. Genetic analyses
have revealed that PTP1B lias a single-copy gene map to the long arm of liuman
chromosome 20 in the region q13.1 to q13.2 that lias been linked to a quantitative trait
locus for obesity and insulin (209). PTPYB is believed to be a negative regulator ofinsulin
action because decrease in its expression level by a variety of strategies resulted in
increased insulin signaling and action. For example. osmotic loading of neutralizing
PTPYB antibodies in rat hepatoma celis increased insulin-induced IRS-l pliosphorylation,
P13-K activity and DNA synthesis (212). Moreover, glucose transport and GLUT-4
translocation are decreased in PTP1B-overexpressing celis (213:214). Reduction ofPTPIB
expression in FAO ceils by using antisense oligonucleotide (ASO) approach also caused an
increase in insulin-stimulated phosphorylation of PKB and GSK3 (215). A role ofPTPases
in insulin action and in the pathogenesis of diabetes bas been postulated on the basis of
studies showing that vanadium-based or other small molecule inhibitors of PiPases can
improve glucose homeostasis in rodent moUds of type I and Il diabetes mellitus and in a
small number of type II diabetic liuman subjects (19:60;123:216). In this regard. it is
noteworthy that the expression level of PTPases lias been shown to be irnpaired in rodent
models of type I and type 2 diabetes mellitus as well as in hurnan subjects (2 17-220).
Furtlier support for the involvernent of PTPase in insulin’ s action cornes from recent studies
demonstrating that reduction of the PiPase PTP-1B, by using antisense oligonucleotides
(ASO), normalizes Nood glucose and improves insulin sensitivity in diabetic rnice (221).
Furtlier proof for a role of PTP1B in insulin action comes from the studies using PTP1B
knock out mice that exhibit a heightened insulin signaling sensitivity, enhanced glucose
tolerance and resistance to high fat diet-induced obesity. hie enhanced insulin
responsiveness in the mice was due to an enhanced IR-phosphorylation(222;223).
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1.6.1. 6.2-LAR
LAR. a type of R-PlPases, is widely expressed in insulin-sensitive tissues (224). LAR
possesses two cytoplasmic catalytic domains linked by a unique hydrophobie
transmembrane stretching to a large extracellular segment. This extracellular segment
contains three immunoglobulin-like repeats and four to eight type III fibronectin repeats.
Treatment of intact celis with insulin resuits in increasing association between LAR and the
IR. In addition, high LAR expression level is detected in the fat tissue of obese patients
and in 3T3-L1 adipocytes pre-incubated with high glucose. LAR downregulation with
ASO enhances and prolongs insulin signaling in hepatoma ceils. while LAR overexpression
suppresses insulin action. Furthermore, engineered LAR overexpression in mouse skeletal
muscle suppresses IR signaling and causes insulin resistance. Also. in LAR-deficient mice,
insulin-sensitivity is increased in the fasting state. but there are also unexpected defects in
glucose homeostasis afler insulin treatment that are more consistent with insulin resistance
(209).
1.6.1. 6.3-RPTFa (LRF) and RFTFE
PTPŒ (LRP) and its closely related enzyme PTPE are expressed in insulin-sensitive tissues
(225). These phosphatases contain two cytoplasmic catalytic domains: a single
transmembrane domain and a short, highly-glycosylated extracellular segment.
Overexpression of the two PiPases in baby hamster kidneys (BHM) cells causes IR
dephosphorylation indicating that they are negative regulators of IR (209). Moreover.
overexpression of wild type PTPc in rat adipocytes diminishes insulin-induced GLUT-4
transiocation. In contrast. some other studies have shown that PIPa fails to play a
regulatory role in IR signaling. For example, blocking PIPa expression by ASO in 313-
Li adipocytes does not affect insulin-induced MAPK activation or DNA synthesisn and
PIPa-deficient mice do not incur any glucose homeostasis dysreguÏation.
1.6.1.6.4 SHP2
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SHP2 (also called PTPID, SH-PTP2, SH-PTP3, Syp and PTP2C) is a ubiquitously
expressed cytosolic PTPase (226). SHP2 is cornposed of two amino-terminal SH2
domains, a central phosphatase domain and a carboxy-terminal tau containing two tyrosyl
phosphorylation sites (208). In celi culture overexpression and yeast two hybrid system
studies, SHP2 binds to the IR and IRS-l. and IRS-I is also likeÏy to be a direct substrate.
In contrast, other investigators have failed to show a similar interaction between the IR and
wild type SHP2, whereas such interaction occurred between the IR and catalytically
inactive-SHP2. This suggests that the IR is also a direct substrate. However, another study
indicates that the IR is flot a substrate, but that SHP2 acts as an adaptor protein to link the
IR and IRS-1. There is a lack of consensus about a positive and/or negative role of SHP2
in regulating insulin signaling. Overexpression of dominant negative SHP2 blocks insulin
stimulated mitosis in 313-LI adipocytes and insulin-induced Ras activation. Furtherrnore.
overexpression of dominant negative SHP2 in rat adipocytes modestly impairs insulin
induced GLUT-4 transiocation. In contrast, disrupting binding between IRS-1 and SHP2
by mutating Tyr phosphorylation residues on 1RS-1 resuits in increased the Tyr
phosphorylation of IRS-1 and heightened insulin-dependent activation of P13-K as well as
protein synthesis but this mutation fails to alter MAPK activity and ceil proliferation.
Transgenic analyses tools have been used to explore SHP2 function. While SHP2(-/-)
homozygous nuil mice do not survive. SHP2(+/-) heterozygotes appear to be normal with
respect to glucose homeostasis, and IR and IRS-1 phosphorylation. In other studies,
transgenic mice overexpressing dominant-negative SHP2 exhibited impairment of insulin
sensitivity and reduced in IRS-1 phosphorylation as well as P13-K and PKB activity. Thus.
further work is needed to test whether SHP2 plays a major physiological role in insulin
signaling.
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1.6.1.6. 5Mitogen-activatedprotein kinase phosphatases (MKFs,)
MKPs are dual specifity phosphatases because they dephosphorylate MAPKs at both the
Tyr and 11w residues necessary for enzyrnatic activity. This family of phosphatases
contains at least nine members, including MKP-1 (also terrned CL100, 3CH134, Erp, and
hVH-1), MKP-2 (also known as hVH-2 and TYP-1), PAC-1, B23 (also tenned hVH-3).
hVH-5, MKP-3 (same as rVH6), MKP-4 and MKP-5. However. previous studies have
revealed that MKP-1, MKP-2. MKP-3 and PAC-1 are ail abic to inactivate ERKI/2 (227).
These MKPs are not expressed or present at low levels in quiescent celis. but they are
rapidly induced upon stimulation with agonists that include insulin, growth factors,
oxidative stress, heat shock, and UV irradiation and are thus defined as immediate-early
genes. Consistently, MKP-1 expression induced by insulin blocks both insulin-stirnuiated
ERK1/2 activity and ERK1/2-dependent gene transcription (22$). In addition. MKP-1 and
MKP-4 have been shown to have a rote in regulating adipocyte differentiation and insulin
stimulated glucose uptake in adipocytes (229;230). Furthermore, recent studies have
suggested that MKP-3 is highly expressed in the livers of insulin-resistant and diabetic
animais and it plays a role in regulating gluconeogenic gene expression and hepatic
gluconeogenesis and thus, dysregulation of MKP-3 expression and/or function in liver may
contribute to the pathogenesis of insulin resistance and type II diabetes (231). Taken
together, these results indicate that MKPs are negatively irnplicated in the regulation of
insulin signaling and, consequently, may contribute to the pathogenesis of insulin
resistance.
1.6.1.6.6-FTEN
PTEN (phosphatase and tension homologue deleted on chromosome 10) contains the
sequence motif that is highly conserved in members of the PTPase family (232). PTEN has
been shown in vitro to possess phosphatase activity on phosphotyrosyl and
phosphotbreonyl-containing substrates as well as PIP3, a product of P13-K. Thus, PTEN
dephosphorylates the 3’-OH position on the inositol ring in PIP3. Consequentiy, the
hydroiysis of generated PIP3 inhibits the activation of PKB. a key mediator of insulin
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action. Consistent with this, hyperactivation of the P13-K/PKB pathway also appears to
be the main resuit of PTEN deletion in mammalian systems. Specific inhibition of PIEN
expression by ASO resuits in the normalization of blood glucose in db/db and ob/ob mice
(233). furtherrnore, deletion ofPTEN in the liver leads to increased insuÏin sensitivity and
improved overali glucose tolerance (234). In addition; mice lacking PTEN in adipose has
been shown to be hypersensitive to insulin and resistant to STZ-induced diabetes (235).
These studies suggest that PTEN has an important role in the insulin-signaling pathway.
1.6.2-Effect of vanadium on IR and IRS-1 phosphorylation
$ince vanadium saits are potent inhibitors of PTPases (236), and increased tyrosine
phosphorylation of the IR-f3-subunit is critical for its activation (127;129). vanadium has
been suggested to cause IR-PTK activation by preventing dephosphorylation of the IR-E3-
subunit. In fact, an earlier study showed that vanadate stimulated tyrosine phosphorylation
of the IR-13-subunit in rat adipocytes (39), and it was aÏso dernonstrated that NaOV
treatrnent partially reversed the decreased tyrosine phosphorylation of the IR-t3 subunit in
STZ -diabetic rats without significantly affecting IR-PTK activity in the liver (237).
However, subsequent experiments in adipocytes (42) and IR-overexpressing Chinese
Hamster Ovary ceils (CHO-KIR) (90;238) did not detect any change in IR-f3-subunit
tyrosine phosphorylation in response to either NaOV or VS (90;238). Sirnilar observations
were made in the rat diaphragm where NaOV did flot stimulate tyrosine phosphorylation of
the IR-13-subunit (41). These and other studies (101;117;239) indicated that tyrosine
phosphorylation ofthe IR-13-subunit and IR-PTK activation may flot be early events leading
to the insulin-like effects ofinorganic vanadium salts (32:240).
Further evidence for the lack of an involvement of IR-PTK in mediating the effect of VS on
the phosphorylation of various components of the insulin-signaling cascade has been
obtained in CHO celis overexpressing an inactive form of IR-PTK (CHO-1012). The PTK
inactive IR was generated by the mutation of lysine 1018 in the ATP-binding domain of the
IR-3-subunit to alanine, which inactivated its ATP-binding ability and therefore PTK
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activity (143). Both insulin and VS enhanced the phosphorylation ofERK1/2, PKB and
GSK-313 in CHO-HIR overexpressing wild type human IR. However, in CHO-101$ celis,
only the insulin response was significantÏy attenuated, whereas no alteration in VS-induced
phosphorylation of these signaling molecules was detected. These data further confirmed
that the VS effect was independent of IR-PTK activity. It should be noted that, unlike the
inorganic saits of vanadium. pervanadate- or peroxovanadium-mediated insulin-mimetic
actions have been associated with IR-PTK activation and enhanced tyrosine
phosphorylation of the IR-13 subunit (11:42). Similarly. BMOV was found to increase the
tyrosine phosphorylation oftlie IR-13 subunit (241). In rat adipocytes. the possible role ofa
NaOV—stimulated, staurosporine-inhibitable cytosolic and particulate form of PTK in
vanadium actions lias been suggested (242;243). This PTK has not been characterized in
detail, and we do not know if it is unique to adipocytes. or if a similar PTK is expressed in
other ceil types.
Despite no effect on tyrosine phosphorylation of the IR-13-subunit by vanadium saits,
several studies have reported a stimulatory action of VS and NaOV on the tyrosine
phosphorylation of IRS-1 (90) and activation of its associated P13-K activity ($7;90). The
putative PTK responsible for IRS-1 phosphorylation in response to VS remains unknown at
present. However, some authors have reported that vanadium compounds could activate
EGf receptor (EGFR) (244245) and non-receptor PTKs. such as focal adhesion kinase
(246), which may contribute to IRS-1 phosphorylation.
1.6.3-fffect of vanadium on MAPK pathway
As stated earlier, NaOV and VS have been shown to stimulate phosphorylation and
activation ofthe MAPK farnily member ERK1/2 in severaÎ ce!! types. incÏuding CHO-HIR
(247) and adipocytes (248). VS-induced ERKI/2 activation was associated with sequential
stimulation of upstream components of the ERK1 /2 signaling pathway, narnely, MEK- 1, e
Raf and c-Ras (247;24$). Interestingly. in these studies, wortmairnin and LY294002, both
pharmacological inhibitors of P13-K activity. completely attenuated VS stimulation of the
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ERKÎ/2 pathway (247;248), indicating an essential role of this Ïipid kinase in
propagating VS-induced responses in the Ras/Raf!MEK!ERK1/2 pathway. Recently, the
involvement of p38 MAPK. anotber member of the MAPK family. was demonstrated in
vanadium-induced glucose uptake in cardiomyocytes (249).
1.6.4-Effect of vanadium on the P13-K pathway
A critical role of vanadium-induced P13-K activation in mediating VS- and NaOV-induced
stimulation of glucose uptake (74;250). GLUT-4 transÏocation(87;25 1) and glycogen
synthesis (89:247) bas been suggested in several ceil types by using P13-K inhibitors.
Consistent with tbis suggestion. both VS and NaOV were found to increase the IRS/ p85
association, leading to activation of P13-K activity in CHO-HIR and adipocytes
(87:90;250). PKB was also shown to be activated in response to VS in CHO-IR (247). and
to NaOV in adipocytes (250), L-6 myotubes (75) and aduit cardiomyocytes (251). In CHO
HIR ceÏÏs, VS enhanced PKB phosphorylation at Ser 473 and Thr 308 residues. Since PKB
bas been implicated in mediating the physiological response of insulin on glucose uptake
and glycogen synthesis. it is possible that vanadium-induced activation of the P13-KIPKB
signaling system is one of the mechanisms that contributes to the insulin-like effects of
vanadium compounds. In contrast. some studies bave indicated the involvement of a P13-
K-independent pathway in vanadium-induced glucose transport (74:75). The nature of this
P13-K-independent pathway remains elusive at present, but may perhaps involve the
CAP/APS/Cbl/TC I 0-dependent mechanism (134). However, to date vanadiurn-induced
tyrosine phosphorylation of Cbl bas not been demonstrated.
As discussed in the above sections. PKB-catalyzed phosphorylation of its downstream
substrates, such as FKHR and its orthologs (193;252),as well as GSK-3 (190), results in
their inactivation (190:193;252). Since fKHR and GSK-3 inactivation reduces the gene
expression oftwo key gluconeogenic enzymes. PEPCK (197) and G6Pase (253). it may be
postulated that tbe vanadium-induced effect on this pathway contributes to the suppression
of gluconeogenesis observed in response to vanadium (55:98:104; 1 05:107-109). Affempts
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have also been made to establish correlations between the glucoregulatory response of
vanadium and its actions on various components of the insulin-signaling system under in
vivo conditions. VS therapy of type 2 diabetic patients was found to modify several
components involved in insulin signaling, which included increases in basal IR and IRS-1
phosphorylation. and P13-K activation in muscle homogenates (63). SimilarÏy. NaMV
treatrnent of diabetic subjects stimulated basal 70s6k and MAPK activity in circulating
mononuclear monocytes (110). However, in contrast to these clinical studies, treatment of
STZ-diabetic or falfa Zucker rats with BMOV was not associated with any significant
alteration in the activation status of P13-K (254). PKB (255) or GSK-3 (96) in skeletal
muscle. Such apparent discrepancies between the in vitro and in vivo effects of vanadium
on insulin-signaling pathways and the divergent responses observed in rodent versus human
investigations into the role of various components of the signaling system in its
glucoregulatory capacity remain to be clarified. It may, however, be possible that in vivo
and in vitro effects of vanadium are different, and that additional or alternative mechanisrns
contribute to these actions of vanadium.
1.6.5-PTPases as targets of vanadium action
The precise mechanisrn by which vanadium stirnulates the tyrosine phosphorylation of IRS
1, ultimately leading to activation of the Ras/Raf/MEKIERKÏ/2 and P13-K’PKB signaling
systems, is also not known. However, it has been suggested that vanadium saits, by
inhibiting PTPase activity, can cause an increase in the phosphotyrosine content of IRS-1
($7;90), and thus stimulate the insulin-signaling pathway (Fig. 9). Support for this notion
cornes from studies in which in vitro treatment of hepatocytes (256) and hepatoma ceils
(257) and in vivo therapy of diabetic rodents with various vanadium compounds
(239;25$;259) were found to inhibit the activities of several PIPase forrns, including SH2
dornain-containing PTPase (SHP2) (256), PTPIB (259) and total PTPase (239;256-258).
In contrast to the effects on isolated celis and diabetic animal models, no significant
influence on total PTPase activity was noted in muscle homogenates from VS-treated
hurnan subjects (63). The reason for this discrepancy is not clear. but it is possible that
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only some specific PTPases are targets for inhibition by vanadium, which may flot be
detectable in crude tissue extracts containing rnany different forms of PTPases. Since the
expression levels ofPlPases, including PTPIB, are impaired in rodent models ofdiabetes
(207), and the reduction of PTP 1 B by ASO has been shown to improve insulin sensitivity
in ob/ob and db/db mice (221). the ability of vanadium to inhibit PTPase activity may be
one of the mechanisms b)’ which it exerts insulin-mimetic and anti-diabetic actions. Since
PTEN demonstrated to be a potent negative regulator of insulin signaling and insulin
sensitivity (233-235), another target of vanadium could be PIEN.
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Figure 9: Schematic model showing potential targets of vanadium (V) action in
relation to the insulin-signaling cascade
Protein Tyrosine Phosphatases (PiPases) or Ïipid phosphatase (PIEN) is (are) possible
potential targets of vanadium (V). PTPase (e.g. PTP-1B or SHP-2) inhibition is capable of
preventing the dephosphorylation of IRS, and thereby increases the tyrosine
phosphorylation level. PTEN inhibition could prevent the dephosphorylation of PIP3,
which is important for the activation ofPDKI/2 and PKB. (Abbreviations are defined in the
list of abbreviations)
* Adapted/Modified from (301).
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1.6.6-Reactive oxygen species (ROS) as a potentiai mediator of vanadium action
Accumulating evidence indicates that reactive oxygen species (ROS superoxide anion
radical O2, H202, and hydroxyl radical 0H) may function as intracellular messengers to
modulate signaling pathways. The changes of intracellular ROS have been detected in a
variety of cells stimulated with cytokines. growth factors. and insulin (260-265).
furtherrnore, insulin stimulation has been shown to elicit a rapid production of H202, an
important redox molecule that enhances the tyrosine phosphorylation of IR and IRS-l
(264). Exogenous H202 has also been shown to mirnic many physiological effects of insulin
such as glucose transport (266), lipogenesis (267) and lipolysis (26$). The precise
mechanism by which H202 exerts its insulin-like effects remains unclear; however, its
ability to inhibit the activities of many PlPases. such as PTPYB (269). SHP-2 (270) and
PTEN (271 ;272) may contribute as a potential mechanism. Similar to insulin. treatment of
celis with vanadium results in the generation of ROS such as 02 and H202 (273;274). The
mechanism by which vanadium mediates generation of ROS involved the reduction of
molecular oxygen to 02 by both a flavoenzyrne-containing NADPH complex and the
mitochondria electron transport chain during the one-electron vanadate (V(V)) reduction
process. The 0=2 in tum generated H202, which reacted with vanadyl (V(IV)) to generate
•OH radical through a Fenton-type reaction (V(IV) + H202 —* V(V) + 0H + 0W)
(273;274) (Fig. II /Annexe). A role ofROS as a mediator of vanadium-induced MAPKs
phosphorylation in human lung (275) and in rat lung myofibroblasts (276) has been shown
by utilisation antioxydants such as N-acety-L-cyleine (NAC) (a general antioxidant) and
catalase (a specific I-1207 inhibitor). In addition, we have shown that in both CHO-IR and
HepG2 cells, Diphenyleniodonium Chloride (DPI), an NADPH oxidase inhibitor,
significanlty bolcked VAC-, BMOV- and VS- induced PKB phosphorylation (fig. I!
Annexe). Moreover, ROS was also shown to contribute to of nuclear factor of activated I
celis (NFAT) activation in response to vanadate (277). Therefore, R0S generation induced
by vanadium may serve as a potential rnechanism for its insulin-like effects.
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1.6.7-Other PTKs than the IR as potentiaJ targets of vanadium
Evidence lias also accurnulated to indicate that the activation of many signaling processes
requires inter-receptor communication. It is well-established that the stimulation of GPCRs
can activate signaling from receptor PTK (R-PTK) by a process terrned transactivation.
Indeed, in recent years, it lias become apparent tliat transactivation is a general
phenomenon that has been demonstrated for rnany unrelated GPCRs and R-PTKs. for
example. the EGFR is a well-characterized target of receptor transactivation. receiving
signais from GPCRs, cytokine receptors, and other RIKs (27$). Using the human liver celi
une HepG2, tyrosine phosphorylation of the EGfR was increased 3-fold upon insulin
treatment, rnost likely due to transactivation by the activated IR and 10F-1 R lieterodimer
complex (279). Thus. it is possible that vanadiurn-induced signaling responses may be
mediated through tlie activation of other growth factor receptor-PTKs.
In the following sections we will describe some ofthese PTKs.
1.6.7. 1-Epidernrn! growth factor receptor (EGfR)
The EGFR is a receptor tyrosine kinase that is ubiquitously expressed in different cell types,
with the rnost abundant expression in epithelial cells and rnany cancer cells. The EGFR
belongs to a family containing three other members (ErbB2, ErbB3, and ErbB4) that
undergo liomodimerization or heterodimerization to induce autophosphorylation and
receptor tyrosine kinase activation in response to ligand binding (280). Since Daub et al
(2$ 1), identified the EGFR to be essential for endothelin-1. thrombin and lysophosphatidic
acid -induced MAPK activation and c-fos gene transcription in 1996, several studies have
demonstrated that tlie GPCR mediates EGFR transactivation. In addition to GPCRs,
members of the cytokine superfarnily have been reported to increase EGFR tyrosine
phosphorylation and the EGFR-Grb2 association in the mouse liver in vivo. In this case. the
EGfR was directly phosphorylated by Janus tyrosine kinase 2 (Jak2), wliici couples
cytokine stimulation to MAPK activation and c-fos gene transcription via the transactivated
EGfR. In addition, several receptor PTKs including platelet-derived growth factor receptor
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(PDGFR), IGF-1R and intcgrins as well as non receptor PTK sucb as c-Src (2$2;283)
have been shown to transactivate the EGFR (272).
1.6. 7.2-Platelet growthfactor receptor (PDGfR,)
PDGFR is a receptor with intrinsic tyrosine kinase activity that regulates several functions
in normal celis and is widely expressed in various malignancies. PDGFRs are expressed on
erythroid and myeloid precursors in bone marrow as well as in monocytes.
megakaryocytes, fibroblasts. endothelial celis. osteoblasts. and guai ceils in (284). PDGfR
has two isoforms. PDGFR-a and PDGFR-f3. that differentiaHy bind different PDGF
members. Ligand binding induces receptor homo- or hetero-dirnerization, activation and
autophosphorylation of the tyrosine kinase dornain (284). PDGFR-Œ and PDGfR-13 also
dimerize with EGfR, which can be stimulated by PDGF. and EGF stimulation has been
shown to increase the tyrosine phosphorylation of PDGFR-13 and subsequent recruitrnent of
P13-K to the PDGFR.
1.6. 7.3-Insuli,,-like growth factor 1 receptor
IGF-YR is a tyrosine kinase reccptor that is structurally very sirnHar to the IR. In fact. in
cells that express both receptors, hybrid receptors appear to forrn readily. aithough the
biological consequence ofthese hybrids is not clear (285). In response to IGF-1, IGF-1R
activation mediates turnor celi proliferation, motiiity, and protection from apoptosis. Recent
work bas suggested a role of IGF-1R transactivation in mediating Ang II responses
(286287).
1.6.7. 4-c-Src
c-Src protein was the flrst tyrosine kinase to be discovered (288). c-Src kinase has a
structure cornposed oftwo binding domains. SH2 and SH3, in addition to a catalytic kinase
domain. The N-terminal region is myristylated. so that the protein is associated with the ceil
membrane. c-Src kinases are normally inactive by an autoinhibitory interaction between
the SH2 domain, before the cataiytic kinase domain, and a C-terminal phosphotyrosine
residue (Tyr 527), whiie the SH3 domain interacts with the linker region between the SH2
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domain and the N-terminal kinase lobe. SH2 and SH3 intramolecular interactions
repress kinase activity by dispiacing the CŒ helix in the N-terminal lobe and by positioning
the activation ioop to block access to the active site. c-Src activation of requires
dephosphorylation ofphosphorylated Tyr 527 foÏÏowed by binding through its SI-12 domain
to specific tyrosine autophosphorylation sites in ligand-stimulated R-PTK. resulting in SH2
dispiacement from phosphorylated Tyr 527 or by binding of the SH3 domain to Pro-X-X-
Pro motifs in target proteins. This actions resuits in autophosphorylation in trans of the
conserved activation loop Tyr 416 and stabilization ofthe active conformation (28$). c-Src
can be activated by various extracellular signaIs through R-PTK. integrins. GPCRs. and
cytokine receptors (288). It can modulate a variety of cellular functions, including
proliferation, differentiation, survival, adhesion. morphological changes, and migration. e
Src also plays a primordial role as mediator of GPCR-induced EGFR transactivation as
well as in cross-talk between different signaling pathways (272). For example, it mediates
EGFR transctivation in response to H202 (282) and PMA (283) and transactivation IGF-1R
in response to AngIl (287).
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17-OBJECTIVES 0F THE PRESENT STUDY
As discussed above, vanadium compounds have been found to exert anti-diabetic effects in
rodent models of type I and type II diabetes mellitus as well as in a lirnited number of
studies in human diabetic subjects. These compounds have been shown to enhance and/or
mimic insulin action. which includes increasing glucose transport, glycogen synthesis and
lipogenesis as well as inhibition of gluconeogensis and lipolysis. In cellular in vitro
system, the molecular mechanism of vanadium compounds correlates with the activation of
different components of the insulin signaling pathway, such as P13-K and MAPK.
However, the precise rnechanism by which vanadium compounds enhance/mimic the
insulin-like effects is stiil poorly characterized. Thus. the purpose of the present studies
was to elucidate the molecular mechanism of vanadium in different circurnstances:
1) VS have been demonstrated to enhance insulin action, but the molecular mechanism
of the insulin-enhanced effects of these saits is not known. Therefore, the first
objective of the present studies was to examine if VS-induced effects on insulin
action are associated with enhancement or augmentation in the activation state of
key components ofthe insulin signaling pathway.
2) As discussed in the introduction. the superiority of OVC as antidiabetic agents
versus inorganic vanadium compounds is well-documented but the molecular
mechanism remains elusive. Therefore. delineating the mechanism of the higher
efficiency of OVC over inorganic vanadium compounds was the second objective
of our investigations.
3) The third objective vas to define the upstream events responsible for activating the
insulin signaling pathway by BMOV a widely-studied insulino-mimetic OVC.
4) As mentioncd earlier. vanadium-induced production of ROS such as H202 has been
shown to mediate its cellular effects in rnany ceils. Therefore, the fourth objective
5$
of this study is to examine if IT2O2 shares some common features with vanadium,
in regards to the role of protein tyrosine kinases as modulators of its effect.
Arcli. Biochern.Biophys 420 (1): 9-17, (2003).
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2.1 ABSTRACT
Vanadium saits such as vanadyl sulfate (VS), potent inhibitors of protein tyrosine
phosphatases, have been shown to mimic, augment and prolong insulin’s action. However,
the molecular mechanism of responses to these saits is not clear. In the present studies, we
examined if VS-induced effects on insulin action are associated with enhancernent or
augmentation in the activation state of key components of the insulin signaling pathway.
Treatment of insulin receptor-overexpressing ceils with insulin or VS resulted in a time
dependent transient increase in phosphorylation and activation of extracellular signal
regulated kinases 1 and 2 (ERK 1/2) that peaked at about 5 min. then declined rapidly to
about baseline within 30 min. However. when the ceils were treatcd with VS before
stimulation with insulin, sustained ERK 1/2 phosphorylation and activation were observed
well beyond 60 min. VS treatment also prolonged the insulin-stimulated activation of
phosphatidylinositol 3-kinase (P13-K), which was associated with sustained interaction
between insulin receptor substrate-1 (IRS-1) and the P8 subunit ofphosphatidylinositol 3-
kinase (P13-K) in response to insulin. These data indicate that prolongation of insulin
stimulated ERK 1/2 and P13-K activation by VS is due to a more stable complex formation
of IRS-1 and the p85Œ subunit which may, in tum, be responsible for its ability to enhance
and extend the biological effects of insulin.
Keywords: Insulin, Vanadium, Insulino-mimesis, Phosphatidylinositol 3-Kinase, Mitogen
activated protein kinases, Protein tyrosine phosphatases.
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2.2-INTRODUCTION
Insulin is the prirnary hormone involved in glucose homeostasis. and an absolute or relative
lack of its secretion or action leads to aberrant glucose metabolism and diabetes. Insulin’
action is triggered by binding to its receptor on the cdl membrane oftarget tissues. Insulin
binding to the Œ-subunit of the insulin receptor (IR) resuits in conformational changes that
activate intrinsic protein tyrosine kinase (PTK) activity of the 13-subunit by its
autophosphorylation in multiple tyrosine residues [1.2]. Once activated. the IR can
phosphorylate several cytosolic insulin receptor substrates (IRSs) in tyrosine residues
which function as docking proteins for src homology 2 dornain-containing signaling
proteins (reviewed in [3]). These proteins include growth factor receptor binder 2 (Grb-2)-
mammalian son of sevenless (SOS) complex [4]. with Grb-2 being growth factor-binding
protein, SOS being a guanine nucleotide exchange factor foi’ guanosine triphosphate (GTP)
binding protein. and the 85-kDa regulatory subunit of phosphatidylinositol 3-kinase (P13-
K). a lipid and protein kinase [51.
The IRS-associated complex initiates two signating pathways. In one pathway, binding of
the Grb-2-SOS complex to IRS-l leads to p2lras stimulation by GTP loading with
subsequent activation of Raf, mitogen-activated protein kinase kinase (MEK) and two
isozymic forrns of mitogen-activated protein kinase (MAPK). p44m (extracellular signal
regulated kinase-1, ERK-1) and 42n1aPk (ERK 2) [2,4]. Activated MAPK phosphorylates
and activates a downstream ribosomal protein kinase, 90rsk [6]
Another pathway that radiates from the IRS complex upon insulin stimulation involves P13-
K activation [2]. P13-K phosphorylates phosphatidylinositol lipids at the 3 position of the
inositol ring and generates 3-phosphorylated forms of PI such as phosphatidylinositol 3, 4,
5 (PIP3) [7] which are involved in the activation of PIP3-dependent kinase (PDK) and
related serine/threonine protein kinases responsible for the phosphorylation and stimulation
ofseveraÏ downstream signaÏing protein kinases such as protein kinase 3 (PKB). 70s6I [8]
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protein kinase-zeta [9] and glucocorticoid-inducible kinase [10]. Activation of these
serine/tlweonine protein kinases bas been irnplicated in rnany ofthe physiological responses
of insulin at the level of glucose transport, glycogen synthesis and protein synthesis [11-
17].
Enhanced tyrosine phosphorylation of IR and IRSs is critical for the initiation of insulin
signaling. whereas tyrosine dephosphorylation of IR and its substrates can attenuate and
terminate insulin’s action (reviewed in [18,19]). IR and IRS-1 dephosphorylation is
catalyzed in vitro by several protein tyrosine phosphatases (PTPases) that consist of
cytoplasmic and transmembrane receptor-type PTPases [19]. A possible role of PTPases in
insulin action and in the pathogenesis of diabetes lias been postulated on the basis of studies
showing that vanadium-based or other small molecule inhibitors of PTPases can improve
glucose homeostasis in rodent models of type I and II diabetes mellitus and in a srnall
number of type 2 diabetic human subjects [20-23]. In this regard. it is noteworthy that the
expression level of PTPases has been shown to be impaired in rodent models of type 1 and
type 2 diabetes mellitus as well as in human subjects [24-27]. further support for the
involvement of PiPase in insulin’s action cornes from recent studies demonstrating that
reduction of the PiPase PTP-IB. by using antisense oligonucleotides, normalizes blood
glucose and improves insulin sensitivity in diabetic mice [28]. In addition. the ability of
vanadium saits, potent PTPase inhibitors, in lowering hyperglycernia and improving insulin
sensitivity in animal models of diabetes mellitus and in human subjects [20,22,29] has
generated interest in exploring the molecular mechanisrns of vanadium action.
We have shown earlier that vanadium saits. such as sodium orthovanadate and vanadyl
sulfate (VS), mimic insulin and activate several key components. such as P13-K and
ras/MAPK. of the insulin signaling pathway [15.30-32]. Sodium orthovanadate lias also
been reported to enhance and prolong insulin-stimulated activation of IR-PTK and
lipogenesis in rat adipocytes [33]. However. the precise signaling steps responsibte for
these responses to vanadium remain poorly characterized. Therefore, in the present studies,
we investigated if the vanadium-induced effects on insulin action are associated with an
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enhancernent or augmentation in the activation state of ERK 1/2 and P13-K-two key
elernents ofthe insulin signaling pathway.
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2.3-MATERIALS AND METHODS
Materials
Chinese hamster ovary ceils overexpressing human insulin receptor (CHO-HIR ceils) were
a kind gifi from Dr. Morris F. White (Joslin Diabetes Center, Boston, MA). Insulin was
obtained from Eh LilIy Co. (Indianapolis. IN). VS from Aldrich Chemical Co. (Milwaukee.
W1). and polyclonal ERK-2 antibody. monoclonal antiphosphotyrosine antibody (4Gb).
IR and IRS-1 antibodies from Upstate Biotechnology (Lake Placid, NY). Phospho-specific
p44/p42 antibody was from New England BioLabs (Beverly, MA), protein A sepharose
beads from Pharmacia Biotech Inc. (Mississauga, Ontario, Canada). and the enhanced
chemjluminescense (ECL) detection system kit was from Amersham Pharrnacia Biotech
(Baie d’Urfé, Quebec. Canada). MAPK phophatase-1 (MKP-1) and p antibodies were
purchased from Santa Cruz Biotech (Santa Cruz, CA). Silica gel-60 plates were obtained
from Merck & Co. Inc. (Rahway. NJ).
Methods
Ce!! culture
Celis were maintained in HAM’s F-12 medium containing 10% fetal bovine serum. They
were grown to confluence in 100 mm plates and incubated in serum-free F-12 medium for
16 h prior to the experiment [15].
ERK activity
ERK catalytic activity was measured as described earlier t31 1. Briefly, cells subj ected to
various experimental treatments were lysed in buffer A (25 mM Tris-HC1. pH 7.5, 25 mM
NaC1, 1 mM Na orthovanadate, 10 mM Na fluoride. 10 mM Na pyrophosphate, 20 nM
okadaic acid, 0.5 mM ethylenebis-(oxyethylenenitrilo)-tetraacetic acid (EGTA), 1 mM
phenylmethylsulfonyl fluoride, 10 tg/ml aprotinin, and 1% Triton X-100, and the lysates
were clarified by centrifugation to remove insoluble material. The clarified lysates,
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normalized to contain equal amounts of protein (100 g), were incubated for 4 h at 4°C
with 5 tg of ERK-2 antibody pre-adsorbed to protein A-Sepharose beads. The immune
complex was coiiected by centrifugation, foilowed by washing 3 times with buffer A and
once with buffer B (20 mM Hepes tN-(2-hydroxyethyl) piperazine-N’-2-ethanesulfonic
acid), pH 7.4. 10 mM MgC12. I mM dithiothreitol (DTT), 10 mM -glycerophosphate). and
40 jil of kinase buffer (25 mM Tris-HC1. pH 7.4, 10 mM MgC12. 2 mM MnC12. I mM DTL
1 M staurosporine, 0.5 mM EGTA and 10 tl myelin basic protein (MBP) (1 mg/rnl)) were
added. The reaction was initiated by adding 5 tl of I mM adenosine 5-triphosphate (ATP)
containing 0.5 iCi [i-32P]-ATP (specific activity 3.000 Ci/mrnol: Amersham). Afier 12
min at 30°C, the reaction was stopped by spotting an aliquot of the supernatant on P-$1
filter paper which was washed in 0.5% phosphoric acid and counted for radioactivity [30].
P13-K assay
The clarified ceil lysates were subjected to immunoprecipitation with 2 ig 0fp$5Œ antibody
for 2 h at 4°C. followed by incubation with protein A sepharose for an additional 2 h. The
immunoprecipitates were washed and subjected to P13-K assay. as described earlier [15].
The phosphorylated lipid products were extracted and separated by ascending thin layer
chromatography t15]. The radioactivity in the spots corresponding to P13-phosphate were
quantified by Phosphorlmager (Molecular Dynarnics. Sunnyvale, CA).
Immunoprecipitatiolt
The clarified ccli lysates. normalized to contain equal amounts of protein (500 jig). were
subjected to immunoprecipitation with I ig of IRS-1 antibody for 2 h at 4°C, followed by
incubation with protein A sepharose for an additional 2 h. Irnmunoprecipitated IR$-1 was
collected by centrifugation, washed 2 times with buffer A and once with phosphate
buffered saline. The IRS-1 immunoprecipitates were electrophoresed on 7.5% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing
conditions, transferred to PVDF membranes. and incubated with polyclonal p8
5Œ antibody
(1:4,000) or a polyclonal IRS-1 antibody (1:2.000). Proteins were detected by a horse
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radish peroxidase-conjugated second antibody and visualized with an ECL detection kit
[32].
Intmunoblotting
The clarified ceil lysates normalized to contain equal amounts of protein were
electrophoresed on 12% SDS-PAGE under reducing conditions. transfelTed to PVDF
membranes. and incubated with monoclonal antiphosphotyrosine antibody (1:1.000). a
polyclonal phospho-specific p44/p42 ERK 1/2 antibody (1:2.000). a polyclonal ERK 1/2
antibody (1:8,000) or a polyclonal MKP-1 antibody (1:500), followed by incubation with a
horse radish peroxidase-conjugated second antibody. The antigen—antibody complex was
visualized with an ECL detection kit. The immunoblots were quantified by densitornetric
scanning using NIH ImageJ software [32].
IR rnd IRS-1 tyrosine phosphoryhition
The clarified lysates, normalized to contain equal arnounts of protein, were pre-cleared with
protein A sepharose for 30 min and incubated with either IR or TRS-1 antibody for 4 h at
4oC. Immunoprecipitates were collected with protein A sepharose, washed 3 times with 50
mM Hepes buffer, pH 7.5. containing 0.1% Triton X-100 and 0.1% SDS, and 2 times with
the above buffer without SDS. The immunoprecipitate was solubilized by boiling in 2 x
sample buffer for 10 min. electrophoresed on 10% SDS-polyacrylamide gels. and
immunoblotted with antiphosphotyrosine antibody (1:1.000) [151. The blots were
visualized with an ECL detection system [32].
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2.4-RESULTS AND DISCUSSION
Effect of VS on insulin-stimulated ERK 1/2 activation
ERK 1/2 activation constitutes a key step in the insulin signaling pathway [2]. we first
examined if VS can prolong the effect of insulin on this signaling component. Therefore.
insulin receptor over-expressing CHO-HIR ceils were used in these studies. and the
activation status of ERK 1/2 was assessed with a phospho-specific antibody of ERK 1/2.
This antibody reacts with only phosphorylated (Thr202 and Tyr204) and activated forrns of
ERK 1/2. As shown in figure lA, treatment of CHO-HIR ceils with 100 nM insulin
resulted in transient activation of ERK 1/2. as judged by enhanced phosphorylation.
ERK 1/2 phosphorylation was rapid peaking at 5 min and declining to just above baseline
at 15 min. with almost complete dephosphorylation in 2 h. A similar transient increase
ERK 1/2 phosphorylation was seen in CHO-HIR celis stimulated with 100 tM VS. except
that the intensity of phosphorylation was sHghtly lower than in insulin-stimuÏated ceils, and
a second phase of enhanced phosphorylation was detected at 2 h (Fig. I B). However, when
the cel]s were pretreated with 100 iM VS for 15 min prior to stimulation with 100 nM
insulin. a rise in ERK 1/2 phosphorylation was evident as early as 1 min afier the addition
of insulin. with a peak at 2 min (fig. IC). In these celis, the level of ERK 1/2
phosphorylation decÏined slightly at 15 mm, but was restored to just below peak levels at
the 30- to 120-min time points (Fig. 1C). It is noteworthy that at ail the tirne points tested,
the magnitude of ERK 1/2 phosphorylation was significantly more robust than that
observed with either insulin (Fig. lA) or VS alone (Fig. lB). The reason for this biphasic
response remains unexplained at this moments and would require additional work. As
shown in the bottom panel of the immunoblots. none of the experimental conditions altered
the total amount ofERK 1/2.
In contrast to CHO-HIR celis, the effect of vanadate on ERK 1/2 phosphorylation and
activation in rat adipocytes was not transient but remained sustained for up to 20 min [34].
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In these studies however, no attempts were made to investigate if at later time points this
response was modified [34]. Furthermore. vanadate did flot exert any enhancing effect on
insulin-stimulated ERK 1/2 activation in adipocytes during the 20 min time period ofthe
study [34]. The reason for these discrepancies are not clear but it may possible that
vanadium exerts a ceil-type specific response.
b determine if the pattern of ERK 1/2 phosphorylation observed in the experiments
described above correlated with the catalytic phosphokinase activity of ERKs. lysates
prepared from ceils stirnulated for the sarne time periods with insulin, VS and VS foÏÏowed
by insulin were assayed using MBP as exogenous substrate [30]. As seen in Figure 2,
similar to the effect on ERK 1/2phosphorylation, ERK 1/2 catalytic activity in response to
insulin. VS as well as VS plus insulin (VS fotlowed by insulin treatment) peaked at 5 min.
then declined to just above baseline in insulin- and VS-stimulated celis (Figs. 2A and 2B).
h is noteworthy that in VS-stirnulated celis, there was a graduai recovery afier 60 min
which reached about 80% of peak stimulation at 2 h (Fig. 2B). This recovery of ERK 1/2
activation correlated with the second phase of enhanced ERK 1/2 phosphorylation in
response to VS (Fig. 13). Thus. in contrast to insulin. VS exhibited a second phase of
ERK 1/2 phosphorylation and activation. The reason for this second phase of activation is
flot clear but may be attributed to the generation of peroxovanadium due to the production
of reactive oxygen species (ROS). Vanadyl is known to react spontaneously with oxygen
to generate superoxide anion (02). a ROS [35] leading to the formation of peroxovanadyl
complexes [36]. We have tested a potential role of ROS generation in VS action by
utilizing diphenylene iodonium (DPI), an inhibitor ofNADPH oxidase and ROS scavenger.
Pretreatment of ceils with DPI prior to stimulation with VS and insulin was found to
allenuate ERK 1/2 phosphorylation (data flot shown). Recent studies have demonstrated
that ROS generation plays a critical role in activation ofthe insulin signaling pathway [37].
Therefore, it is possible that increased ROS generation afler long incubation with VS might
be responsible for the second phase of ERK 1/2 phosphorylation.
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In VS + insulin-treated cells, the decline in ERK 1/2 catalytic activity was minimal
(about 10%). and this level of activation (about 80-90% of the peak value) was sustained
for up to 2 h of incubation (Fig. 2C). On the other hand. the level ofERK 1/2 activation in
ceils stirnulated with insulin only declined afier 15 min and remained at about baseline
(Fig. 2A). Thus, pretreatrnent of ceils with VS prolonged the duration of ERK 1/2
activation in response to insulin.
fffect of insulin on MKP-1 expression
MKP-1 is a dual specificity phosphatase which dephosphorylates MAPK at both the
tyrosine and threonine residues necessary for ERK 1/2 activation t3$,39]. Stimulation of
fibroblasts overexpressing the human insulin receptor by insulin bas been sbown to
increase MKP-1 mRNA and protein levels. resulting in the attenuation of MAPK activity
[40,41]. Therefore, we investigated if VS was exerting its effect by altering MKP-1
expression in CHO-HIR cells. As shown in Figure 3A, MKP-1 protein expression was
detectable even in unstimulated cells, and this level of expression was not changed
significantly by insuÏin treatment up to 60 min. A sirnilar pattern of MKP-1 protein
expression was detected in celis treated with VS followed by insulin (Fig. 3B). It thus
appears that alteration in MKP-1 expression may flot contribute to the observed effects of
VS on sustained ERK 1/2 phosphorylation in CHO-HIR cells by insulin. Since MKP-1
expression in response to insulin is transcriptionally regulated [401, we sought to determine
if blocking MKP- 1 transcription by actinomycin-D. an inhibitor of RNA synthesis. would
modify the ERX 1/2 phosphorylation pattem in response to either insulin alone or VS plus
insulin. Actinomycin-D pretreatment, however, did not affect the time course of ERK 1/2
phosphorylation (data not shown). A sirnilar result was observed with cycloheximide, a
protein synthesis inhibitor (data not shown). These results suggest that the rapid decline in
ERK 1/2 phosphorylation by insulin was not transcriptionally or translationally regulated.
In addition, our earlier studies demonstrated that the effect of VS on ERK 1/2
phosphorylation was mediated by activation of MEK, which is an upstream kinase
responsible for phosphorylating the threonine and tyrosine residues of ERK 1/2 [32J. Thus,
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it appears that in CHO-HIR celis, the outcorne of VS on ERK 1/2 phosphorylation and
activation is achieved by enhanced MEK phosphorylation and not by inhibiting its
dephosphorylation by MKP-1. This notion is supported by the studies in which VS or
vanadate was found to enhance MEK activation in CHO-HIR cells [32] and MEK
phosphorylation in rat adipocytes [34].
Effect of VS on insulin-stimulated P13-K activation
We have shown earlier that VS-induced stimulation of ERK 1/2 phosphorylation and
activation is not due to decreased ERK 1/2 dephosphorylation, but is rnediated by
sequential stimulation of elements upstream of the ERI( 1/2 activation cascade [32]. VS or
vanadate bas also been found to stimulate P13-K activity in CHO-HIR ceils [32] and in
adipocytes [34,42.43] and the use of P13-K inhibitors has indicated that P13-K is an
upstream regulator of the ERK 1/2 activation cascade in these celis [32]. We, therefore.
investigated if prolongation of insuÏin-stimuÏated ERK 1/2 activation by VS is associated
with sustained activation of P13-K activity. P13-K activity in ceils treated for various tirne
periods with insulin, VS and VS followed by insulin was rneasured in p$5Œ
immunoprecipitates from celi lysates [32]. As shown in Figure 4A, insulin stimulated P13-
K activity in a time-dependent manner. P13-K activation peaked within 1 min of exposure
of ceNs to insulin. and gradually declined to just above baseline at 30 min. This low level
of activity was maintained for up to 120 min. A similar pattern of P13-K activation in
response to VS was observed except that the peak was detected only afier 5 min of
treatment of ceils with vs and was slightly less robust as compared to insulin alone (Fig.
43). Furthermore, VS-induced activation of P13-K was biphasic, declining to just above
baseline at 30 min but showing reactivation at 60 and 120 min of incubation (Fig. 43). It
should be noted that the biphasic impact of vs on P13-K activation was similar to its effect
on ERK 1/2 phosphorylation and activation (Figs. 1 B and 23). In contrast to the transient
action ofinsulin, and the biphasic outcome of vs. analysis of P13-K activity in ceils treated
with vs prior to stimulation with insulin revealed that VS pretreatment prolonged the
duration of insulin action, and resulted in sustained P13-K activation (Fig. 4C). The
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prolongation of insulin-stimulated P13-K activation by VS (Fig. 4C) correlated well with
the effect of VS on insulin-induced ERK 1/2 phosphorylation and activation (Figs. IC and
2C). However. one notable difference was that despite a sustained activation of P13-K
observed in VS plus insulin treated ceils. ERK 1/2 phosphorylation stiil declined slightly at
15 min (Fig. 1C). The precise reason for this decline is not clear but may be attributed to
its rapid dephosphorylation by ERK 1/2-specific PTPases other than MKP-1. Alternatively
a potential role of a P13-K-independent pathway in this response may be suggested.
however. il should be noted that pharmacological inhibition of P13-K activity has been
shown to completely abrogate ERK 1/2 activation and phosphorylation induced by insulin
and VS [32,34].
Effect of VS on insulin-induced association ofp85”with IRS-1
-
. . .
. .
.Since Pb-K activation requires association of its p regulatory subumt with IRS-1, we
next deterrnined if the sustained P13-K activation by insulin in VS-pretreated cells was due
to a prolonged association 0fpX5Œ with IRS-1. As shown in Fig. 5A, insulin induced an
increase in the association of IRS-1 with p within 5 min of treatment, which peaked at
15 min and then decreased to almost basal levels within 60 min. Similar to insulin.
treatment of cells with VS alone resulted in complex formation between 85a and IRS-1
which peaked at 5 min (Fig. 5B). However, as compared to insulin treated ceils, in VS
treated celis, the magnitude of p85Œ/IRS1 association was less and, a biphasic effect was
observed i.e. a slight decline in p85/IRS-1 association at 15 min followed by an
enhancernent in ps binding to IRS-1 at 30 min and 60 min (Fig. 53). On the other hand,
in ceils pretreated with VS. insulin—induced association of p8 with IRS-1 was sustained
for up to 60 min (Fig. 5C). Thus. it is possible that the p85’/IRS-1complex is more stable in
the presence of VS and contributes to prolongation of P13-K activity by insulin (Fig. 4C)
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Effect of VS on insulin-stimulated tyrosine phosphorylation of IR and IRS-1
Since the insulin response is mediated through enhancement in the tyrosine
phosphorylation ofIR and IRS-1 [2,7], we examined the effect of VS on insulin-stimulated
tyrosine phosphorylation of IR and IRS-1. Insulin treatment of celis resulted in a rapid
increase in phosphotyrosine content ofIR (Fig. 6A) and IRS-1 (Fig. 6C). Maximum IR and
IRS-1 phosphorylation was detected within I min of insulin stimulation, and this level did
not change significantly (Fig. 6) for up to 120 min. It is interesting that the decline in
ERK 1/2 and P13-K activation observed in insulin-stimulated celis at 15 min (figs. lA. 2A
and 4A) was flot associated with a sirnilar decrease in the tyrosine phosphorylation of either
IR or IRS-1 (Fig. 6). In fact, at this time point. the global tyrosine phosphorylation ofIR or
IRS-1 was alrnost the same as that occurring at I min afier insulin stimulation. Thus. it
appears that enhanced tyrosine phosphorylation of IR and IRS-1 is critical for initiating the
insulin signal. but may flot have a significant role in regulating the duration of the response.
Since VS pretreatrnent of cells prior to stimulation with insulin failed to alter the global
tyrosine phosphorylation status of IR (Fig. 6B) or IRS-1 (Fig. 6D). while prolonging the
duration of insulin-induced ERK 1/2 and P13-K activation, it is possible that VS exerts
these effects by inhibiting the dephosphorylation of specific phosphotyrosines in IR or IRS
I or other proteins acting upstream of P13-K in the insulin signaling pathway. One
consequence of this effect is the sustained association of IRS-1 with the $5a subunit and
P13-K activation. In contrast to the work presented here. vanadate was found to augment
insulin-stimulated IR-PTK activity in rat adipocytes [331. The reason for this discrepancy
is not clear but it is possible that IR overexpressing cells respond differently than normal
adipocytes. Further work is needed to define the precise mechanism by which VS modifies
insulin-induced signaling pathways.
In surnrnary, an important finding of the present study is that VS, a PiPase inhibitor and
insulinornimetic agent, increased the magnitude and duration of insulin-stimulated ERK 1/2
and P13-K activation. This effect of VS on insulin response was associated with an
enhanced interaction of IRS-1 with the p8 subunit of P13-K which appeared to be
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responsible for a sustained activation of P13-K. Since P13-K activation has been
implicated in insulin-induced activation of glucose transport and lipogenesis. the results of
the present investigation provide a mechanistic basis for the observed augmentation of
insulin-induced lipogenesis [33] and glucose transport [44] by vanadate. Taken together,
the present work provides first evidence suggesting that prolonged activation of ERK 1/2
and P13-K, key components of the insulin signaling pathway, contributes to the molecular
mechani sm of the insulin-enhancing effect of this vanadium.
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2.6-FIGURE LEGENDS
figure 1: VS delays the dephosphorylation of ERX 1 and ERK 2 in insulin-stimulated
cells. Confluent, serum-staiwed CHO-HIR ceils were incubated with 100 nM insulin (A),
100 jiM VS (B) or 100 jtM VS for 15 min followed by 100 nM insulin (C) for the indicated
times. The celis were lysed and lysates subjected to immunoblotting using phospho
specific (Thr202/fyr204)-ERK 1/2 antibodies (upper immunoblot) or total ERX 1/2 (lower
immunoblot). The arrows indicate the position of phosphorylated, p-ERK 1/2 or total ERK
1/2. The bottom panel shows the densitornetric quantification of phospho-ERK 1/2 bands.
The results are representative of 3 independent experirnents and are expressed as a
percentage of the maximum.
Figure 2: VS prolongs the duration ofinsuÏin-induced ERK 1/2 activation. Confluent,
serum-starved CHO-HIR celis were incubated with 100 nM insulin (A), 100 tM VS (3) or
100 M vs for 15 min followed by 100 nM insulin (C) for the indicated times. The ceils
were lysed and lysates were analyzed for the phosphokinase activity of ERKs using MBP
as exogenous substrate. Parallel samples were analyzed by immunoblotting to determine
the total amount of ERK 1/2 and a representative blot is shown in the bottom panel. The
resuits are mean + SE from 3 separate experiments and are expressed as a percentage of the
maximum.
Figure 3: MKP-1 levels are not modified by insulin or vs plus insulin.. Confluent, serum
starved CHO-HIR ceils were incubated with 100 nM insulin (A) or 100 1iM vs for 15 min
followed by 100 nM insulin (B) for the indicated times. The ceils were lysed, and the
lysates subjected to immunoblotting using MKP-1 antibody. A representative immunoblot
from 3 independent experiments is shown.
figure 4: vs prolongs the duration of insulin-induced activation of
phosphatidylinositol 3-kinase (P13-K). Confluent. serum-starved CHO-HIR cells were
incubated with 100 nM insulin (A), 100 jiM VS (B) or 100 jiM vs for 15 min followed by
80
100 nM insulin (C) for the indicated times. The ceils were !ysed, and the ce!! !ysates
were subjected to immunoprecipitation using p8 antibodies. P13-K activity was rneasured
in pS5Œ immunoprecipitates with phosphatidy!inositol (PI) as substrate and [y-32P] ATP as
phosphoryl group donor. The arrow marks the position of P13-P. Parallel samples were
analyzed by immunoblotting to determine the total arnount of p8 and a representative blot
is shown in the middle pane!. The resu!ts are representative of 3 separate experiments and
are expressed as a percentage ofthe maximum.
f igure 5: VS prolongs the duration of insulin-induced binding of p$5Œ to IRS-1. Confluent,
serum-starved CHO-HIR ce!!s were incubated with 100 nM insu!in alone (A), 100 1iM VS
(B) or 100 iM VS for 15 min fo!lowed by 100 nM insu!in (C) for the indicated tirnes. The
ceils were lysed and equa! arnounts of clarified lysates subjected to immunoprecipitation
using IRS-1 antibodies. IRS-1 immunoprecipitates (IP) were immunoblotted (13) with
either anti- p8 (upper panel) (1:4.000) or with IRS-1 antibody (middle panel) (1:1,000).
The bottom panel shows the densitometric quantification of 85a bound to IRS-1. The
resufts are representative of 3 independent experiments and are expressed as fo!d increase
over controle (0 mm) which was arihitrari!y set set at 1.0
figure 6: IR and IRS-1 phosphorylation on tyrosine are not altered by insu!in or VS plus
insulin. Confluent. serum-starved CHO-HIR cells were incubated with 100 nM insulin
alone (A. C), or with 100 iM VS for 15 min followed by !00 nM insulin (B, D) for the
indicated times. The ce!!s were lysed and equa! amounts of cÏarified lysates subjected to
immunoprecipitation using IRS-1 or IR antibodies. The immunoprecipitates (IP) were
irnmunoblotted with antiphosphotyrosine antibody (upper panels) or IR or IRS-1 antibodies
(lower pane!s in each section). A representative immunob!ot from 3 independent
experiments is shown.
$1
Abbreviations
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31-ABSTRACT
Organo-vanadium compounds (OVC) have been shown to be more effective than
inorganic vanadium compounds in arneliorating glucose homeostasis and insulin
resistance in rodent models of diabetes mellitus. However, the precise molecular
mechanism OVC efficiency remains poorly defined. Since inorganic vanadium
cornpounds have been found to activate several key components of the insulin signaling
cascade, such as protein kinase B (PKB). the objective of the present study was to
investigate if stimulation of PKB and its downstream targets glycogen synthase kinase-3
(GSK-3), are responsible for the more potent insulinornimetic effects of OVC. Arnong
several vanadium compounds tested, vanadium (IV) oxo bis (acetylacetonate) and
vanadium (IV) oxo bis(maltolato) markedly induced the phosphorylation of PKB as well
as GSK-313 cornpared to vanadyl sulfate (VS). an inorganic vanadium saits in Chinese
hamster ovary ceils overexpressing the insulin receptor (IR). Furthermore, the OVC were
stronger inhibitors of protein tyrosine phosphatase (PiPase) activity than VS. The higher
PTPase inhibitory potential of the OVC was associated with more robust tyrosine
phosphorylation of several cellular proteins. including the 1R13 subunit and insulin
receptor substrate-l tIRS-1). In addition, greater 1RS1/ps5a interaction xvas elicited by
the OVC than by VS. These data indicate that the higher PTPase inhibitory potential of
OVC translates into greater phosphorylation of PKB, GSK-313, which, in turn, may
contribute to a more potent effect ofOVC on glucose horneostasis.
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3.2-INTRODUCTION
Compounds of the trace elernent vanadium have been demonstrated to exert a variety of
insulin-like effects in in vitro and in vivo systems [1]. including their ability to improve
glucose homeostasis and insulin resistance in animal models of diabetes mellitus [1-3]. In
addition, several reports have documented vanadium therapy-induced improvements in
liver and muscle insulin sensitivity in a number of type II diabetic human subjects [4-2].
Vanadium cornpounds have also been shown to stirnulate glucose uptake [9-1 1],
glycogen synthesis [9, 12-15] and lipid synthesis [16, 17] in muscle, adipose and hepatic
tissues. They inhibit gluconeogenesis, the activities of the gluconeogenic enzymes
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) in
the liver and kidneys [9. 1$-20] as well as lipolysis [17, 21] in fat celis. At the cellular
level. vanadium activates key elements of the insulin signaling system: tyrosine
phosphorylation of insulin receptor substrate-1 tIRS-1) [22] and activation of pathways
such as extracellular signal-regulated kinase (ERK1/2) [23. 24], phosphatidylinositol 3-
kinase (P13-K) [22. 25] and proteine kinase B (PKB) [23. 26]. These effects are believed
to be secondary to its ability to inhibit protein tyrosine phophatase (PiPase) activity [27].
PKB plays a criticai foie ifl insulin-induced glucose transport, giycogen synthesis,
proliferation and ccli survival [28]. It is phosphoryiated on serine 473 and threonine 308
residues by P13-K-dependent kinase t2$, 29] resulting in its full activation. Activated
PKB phosphorylates several downstream targets, such as glycogen synthase kinase-3 beta
(GSK-3J3) and forkhead transcription factor (fKHR). GSK-3F3 is phosphorylated by PKB
on serine 9, and this phosphorylation Ieads to the inhibition of its catalytic activity [30].
GSK-313 piays an important role in the regulation of glycogen synthesis and regulates
gluconeogenesis by altering the gene expression of PEPCK and G6Pase [31]. Vanadium
treatment bas been found to decrease the heightened expression and/or activity of PEPCK
and G6Pase in isolated cells as well as in diabetic rats [18-20. 32. 33]. Recent studies
have revealed that in comparison to inorganic vanadium compounds, such as vanadyl
sulfate (VS), sodium metavanadate (NaMV) and sodium orthovanadate (NaOV), organo
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vanadium complexes (OVC) of vanadium such as vanadium (IV) oxo bis
(acetylacetonate) (VAC) and vanadium (IV) oxo bis(maltolato) (BMOV) are more
potent in lowering blood glucose in rodent models of diabetes mellitus [18, 34, 35}.
However, the molecular mechanism responsible for the stronger insulinomimetic effect
of OVC over inorganic vanadium saits remains unknown. Therefore. the aim of the
present study xvas to investigate if the insulinomimetic and antidiabetic actions of OVC
could be attributed to their ability to enhance PKB and GSK-313 phosphorylation.
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3.3-MATERIALS AND METHODS
Materials
Chinese hamster ovary ceils overexpressing human insulin receptor (CHO-HIR celis)
were a generous gifi from Dr. Morris F. White (Joslin Diabetes Center, Boston. MA).
Insulin was from Eh Lilly Co. (Indianapolis. IN). VS. NaOV and NaMV were from
Atdrich Chemical Co. (MiÏwaukee, WI). and the OVC were kindÏy donated by Dr.
Debbie Crans (Colorado State University, Fort Collins, CO). Polyclonal insulin receptor
beta-(1R13) subunit antibody, monoclonal antiphosphotyrosine antibody (PY99),
polyclonal phospho-GSK-313 (Ser9) antibody and polyclonal GSK-3j3 antibody were
purchased from Santa Cruz Biotech (Santa Cruz, CA). Polyclonal phospho-PKB (Ser473)
and polyclonal PKB antibody were from Celi Signaling (Beverly, MA). Polyclonal IRS-1
antibody and polyclonal p8 antibody were from Upstate Biotechnology (Lake Placid,
NY). The enhanced chemiluminescense (ECL) detection system kit was from Amersharn
Pharmacia Biotech (Baie d’Urfé, Quebec, Canada).
Methods
Ceil culture
CHO-HIR celis were maintained in HAM’s F-12 medium containing 10% fetal bovine
serum, and rat 1 fibroblast overexpressing HIR and protein tyrosine phosphatase I B
(PTPÏB) ceils (HircA) were maintained in DMEM:F-12 medium containing 10% fetal
bovine serum. The celis were grown to confluence in 60-mm plates and incubated in
serum-free medium for 16 h prior to the experiment [23).
Immunoblotting
Cells subjected to various experirnental treatments were lysed in buffer A (25 mM Tris
HCL pH 7.5. 25 mM NaC1. 1 mM NaOV, 10 mM Na fluoride, 10 mM Na pyrophosphate,
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20 nM okadaic acid, 0.5 mM ethylenebis-(oxyethylenenitrilo) tetraacetic acid. 1 mM
phenylmethylsulfonyl fluoride, 10 tg/ml aprotinin. and 1% Triton X-100, with the
lysates being clarified by centrifugation to remove insoluble material. The clarified ccli
lysates norrnaiized to contain equal arnounts of protein were subjected to 7.5% or 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing
conditions, transferred to PVDF membranes, and incubated with the indicated antibodies.
Proteins were detected by a horse radish peroxidase-conjugated second antibody and
visualized with an ECL detection kit [231.
Immunoprecipitation
The clarified celi lysates, nomialized to contain equal arnounts of protein (500 ig). were
irnmunoprecipitated with 3 tg of IRS-1 or IRf3 antibody ovemight at 4 °C. followed by
incubation with protein A sepharose for 2 h. Immunoprecipitated IRS-1 or 1R13 was
collected by centrifugation, washed 2 times with buffer A and once with phosphate
buffered saline containing PTPase and protease inhibitors. The immunoprecipitates were
submitted to 7.5% SDS-PAGE under reducing conditions, transferred to PVDF
membranes, and incubated with polyclonal p85 antibody (1:4.000) or PY99 (1:2.000).
Proteins were detected by a horse radish peroxidase-conjugated second antibody and
visualized with an ECL detection kit.
PTPase activity
Confluent, serum-starved HircA ceils were incubated with I mM of vanadium
compounds for 10 min. The ceils were lysed in buffer A without NaOV and equal
amounts of the clarified lysates were assayed for total PTPase activity as described
elsewhere [36]. Briefly, lysates adjusted to contain the sarne arnount of proteins were
added to PTPase assay buffer containing 40 mM NaOAc/HC1, pH 5.00, 1 mM
ethylenediamine tetraacetic acid, I mM DTT and 25 mM p-nitrophenyl phosphate.
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Phosphatase reaction was carried out for 10 min at room temperature and stopped by the
addition of 0.2 M NaOH. The amount of product (p-nitrophenol) produced was
measured by monitoring the increase in absorbance at 405 nm optical density. The
nonenzymatic hydrolysis of p-nitrophenol phosphate was corrected by measuring the
increase in absorbance at 405 nm in the absence of enzyme.
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3.4-RESULTS
Effect of different organic and inorganic vanadium compounds on PKB
phosphorylation
b evaluate the potency of different vanadium compounds on PKB phosphorylation,
CHO-HIR celis were treated with 1 mM of 2 OVC, VAC or BMOV or 3 inorganic
vanadium compounds VS. NaMV or NaOV. PKB phosphorylation was measured by
using a phospho-specific PKB antibody which detects only the phosphorylated and active
form of PKB. As shown in Figure 1, the OVC BMOV and VAC were more potent than
VS in enhancing PKB phosphorylation. In fact, the phosphorylation induced by VAC
was virtually equipotent to that elicited by 100 nM insulin. However, other vanadium
compounds or compounds of other metals as Cr and Co, failed to exert any effect on PKB
phosphorylation.
To further compare the relative abilities of the most active vanadium compounds VAC,
BMOV and VS on PKB phosphorylation, dose response analysis was performed. As
shown in figure 2A, VAC was more potent than either BMOV or VS in stimulating PKB
phosphorylation, and caused a robust increase at 100 !.iM concentration.
Effect of different concentrations of VAC, BMOV and VS on GSK-313
phosphorylation
Since PKB elicits its response through the phosphorylation of several downstream targets
such as GSK-313 [291, we investigated if vanadium compounds exerted any effect on the
phosphorylation of this substrate. To test this possibility, lysates prepared from ceils
stimulated with different concentrations of VAC or BMOV and VS for 10 min were
immunoblotted using phospho-specific antibodies for GSK-3f3 . As shown in figure
2B, all the vanadium compounds at the 2 concentrations increased the phosphorylation of
GSK-3f3. However, as was the case with PKB phosphorylation, VAC was the rnost
potent compound, and was several fold more efficient than BMOV or VS. At 100 iM,
9$
VAC was about 2 times more effective than BMOV and about 4 times stronger than VS
in enhancing GSK-3J3 phosphorylation.
Effect of Wortmannin on VAC-, BMOV- and VS-induced phosphorylation of PKB
and GSK-3f3
P13-K is an upstream regulator ofthe PKB signaling pathway in response to insulin [28,
29]. Therefore, by using Wortrnannin a phanTiacological P13-K inhibitor [37] we
investigated if P13-K plays a role in vanadium compound—induced PKB and GSK-313
phosphorylation. As shown in figure 3, Wortmaimin pretreatment resulted in alrnost
complete attenuation of insulin, as well as vanadium-induced PKB and GSK-3f3
phosphorylation.
Effect of VAC, BMOV and VS on PTPase activity and protein tyrosine
phosphorylation
Vanadium compounds are potent PTPase inhibitors [1. 27, 3$]. Therefore, we wished to
examine if the higher capacity of VAC and BMOV vs VS on PKB and GSK-33
phosphorylation is reflected in their ability to differentially inhibit PTPase activity. As
shown in figure 4A, treatment of HircA ceils overexpressing PTP lB with VAC or
BMOV resulted in 50% inhibition whereas VS caused only 20% inhibition of total
PTPase activity. Next, we exarnined if the higher potency of OVC to inhibit PTPase
activity conelated with their ability to increase the tyrosine phosphorylation of cellular
proteins. As shown in Figure 4B, treatment of CHO-HIR with lmM of different
vanadium cornpounds augmented the tyrosine phosphorylation of several proteins with
varying degrees. The molecular sizes of these proteins ranged from 60 to 200 KDa.
However, phosphorylation of protein was more robust with VAC than with either BMOV
orVS.
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Effect of VAC, BMOV and VS on IR and IRS-1 phosphorylation
Since the tyrosyl phosphorylation of 1R13 is an early step in the insulin signaling cascade.
we wished to deterrnine if vanadium cornpounds enhanced the tyrosine phosphorylation
of IRj3. As shown in F igure 5A. IRf3 immunoprecipitation from CHO-HIR treated with
lmM of VAC, BMOV. VS or 100 nM of insulin, followed by immunoblotting with
phosphotyrosine antibody, reveaied that both VAC and BMOV induced an increase in
tyrosyl phosphorylation of 1R13. However, under similar conditions, VS was ineffective
and failed to enhance 1R13 phosphorylation. We next assessed the effect of different
vanadium compounds on the tyrosine phosphorylation of IRS-1. As shown in Figure 5B,
insulin as weil as ail vanadium cornpounds enhanced IRS-1 tyrosine phosphorylation to
varying degrees. BMOV- and VAC-induced IRS-1 tyrosine phosphorylation was
identical to their effects on IRf3 phosphorylation. VS which was unable to cause any
detectable increase in IR3 tyrosine phosphorylation aiso enhanced IRS- 1
phosphorylation, however, this was several times lower than that elicited by BMOV or
VAC. Since P13-K activation requires the association ofits p$5Œ reguiatory subunit with
the tyrosyl phosphorylated form of IR$-1, we next investigated the degree of association
of p$5Œ with IRS-1 in ceils treated with various vanadium compounds. As shown in
Figure 5B, ail the agents tested enhanced the association of p85Œ with IRS-1. but insulin
induced the highest level of association between IRS-1 and p85Œ. which was followed by
VAC, BMOV and VS with decreasing order of potency. This degree of association is
consistent with the leveL of IRS-1 as well as PKB phosphorylation achieved in response
to insulin and vanadium compounds.
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3.5-DISCUSSION
In the current study, we have demonstrated that OVC are more potent, than inorganic
forms of vanadium in activating key components of the insulin signaling pathway. The
OVC VAC and BMOV were more efficient than VS in stimulating PKB activity which
was associated with an increase in GSK-313 phosphorylation. Our resuits also show that
Wortmannin, a P13-K inhibitor. decreased insulin- and vanadate-induced PKB and
GSK3-13 phosphorylation (Fig. 5) suggesting that P13-K is an upstrearn component in
vanadium-induced PKB and GSK-313 phosphorylation events. Although it is well-known
that OVC are more potent than inorganic vanadium saits in improving glucose
homeostasis in animal models of insulin resistance [18, 34, 35, 39, 40], the precise
mechanism of this effect is unknown. Since activation of the PKB signaling system is
believed to play a key role in mediating the metabolic responses of insulin [28]. to the
best of our knowledge. our data are the first to provide a molecular basis for the higher
efficacy of OVC in improving glucose homeostasis compared to inorganic vanadium
salts. More robust activation of PKB may also be responsible for several fold higher
glucose transport observed in adipocytes in response to VAC [41] as weÏl as the increased
GLUT-4 translocation in strepzotocin (STZ)-diabetic rat skeletal muscle in vivo [42].
GSK-3r3 has been suggested to play an important role in decreasing the activity of
glycogen synthase by catalyzing its serine phosphorylation [43] but PKB-induced
phosphorylation of GSK-3J3 renders it inactive and allows the full activation of glycogen
synthase [43]. Thus, the OVC-induced robust enhancernent of GSK-3f3 phosphorylation
observed in our study could serve as a potential rnecbanism for a more potent effect of
these compounds on glucose utilization and storage seen in BMOV- and VAC-treated
rodent models [18, 41].
GSK-3 î3 bas been implicated in regulating the gene expression of the key gluconeogenic
enzymes PEPCK and G6Pase [28, 29, 31]. Vanadium cornpounds have also been shown
to inhibit the heightened expression and/or activity of PEPCK and G6Pase in several
diabetic rat models [18-20, 33. 44. 45]. Thus. it is possible that a greater abillty of
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BMOV and VAC to induce GSK-3 phosphorylation may contribute to the normalization
of cxaggerated PEPCK and G6Pase expression in the STZ-diabetic rat liver [20].
Our data also indicated that treatrnent of intact celis with OVC inhibited the activity of
cellular PiPase more potently than VS. These data are in agreement with recent studies
in which 3MOV was reported to be a non-selective competitive inhibitor of several
PTPases in vitro [39, 40, 46]. PTPases play an important role in the regulation of insulin
signaling [47, 48], and it was shown recently that mice deficient in PTPIB. a cytoplasmic
PTPase. exhibit increased insulin sensitivity with resistance to weight gain, even when
put on a high-fat diet [49]. Moreover, several studies have documented an
overexpression of PTPases in diabetes (reviewed in [47]), and BMOV treatrnent inhibits
exaggerated PTP 13 activity in the skeletal muscle of Zucker fatty rats, a mode! of insu!in
resistance [46]. Since enhanced tyrosine phosphorylation caused by both protein tyrosine
kinase (PTK) activition and/or PTPase inhibition is primordial in triggering the insulin
signa!ing cascade, it is possible that more potent inhibition of PTPase by OVC
contributes to a heightened tyrosine phosphory!ation of IRf3 and IRS-1 by both VAC and
BMOV. In confirmation with our data BMOV was recently shown to enhance the
tyrosine phosphory!ation of IRf3 [39, 40]. In addition, the OVC were superior to VS in
augmenting the tyrosine phosphorylation of the IRS-1 and IRS-1/p85 association which
might provide a molecular basis for the high impact of these compounds in activating
PKB phosphory!ation.
In surnmary, our resu!ts demonstrate that. compared to VS. OVC are more potent
activators ofPKB and GSK-3j3 phosphorylation in a P13-K-dependent mairner. A greater
inhibitory effect of OVC on PTPases and increased protein tyrosine phosphory!ation
might serve as triggering mechanisms, leading to upregulation of the PKB signa!ing
pathway and eventually contributing to a greater potency of OVC in improving glucose
homeostasis.
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3.6-FIGURE LEGENDS
Figure 1: Vanadium compound-induced PKB phosphorylation in CHO-HIR celis
Confluent, serum-starved CHO-HIR ceils were incubated with 100 nM of insulin for 5
min or 1 mM of different vanadium compounds or cornpounds of other metals for 10
min. The ce!! !ysates were subjected to immunob!otting using phospho-specific (Ser
473)-PKB (upper immunob!ot) or total PKB antibody (lower irnmunob!ot) as described
in the Materials and Methods section. The resuits are representative of 3 independent
experirnents. VAC, vanadium (IV) oxo bis (acety!acetonate); VS. vanady! sulfate;
BMOV, vanadium (IV) oxo bis(malto!ato); Crdipic, chromium (III) bis(2,6-
pyridinecarboxyy!ate); NaMV, sodium metavanadate; NaOV. sodium orthovanadate;
Co2dipic, cobalt (II) bis(2,6-pyridinecarboxy!ate) heptahydrate.
Figure 2: VAC-, BMOV- and VS-induced PKB phosphory!ation is dose-dependent
in CHO-HIR ce!!s
Confluent, serurn-starved CHO-HIR ce!!s were incubated with the indicated
concentrations of VAC, BMOV or VS for 10 min. The cel!s were !ysed, and the lysates
were subjected to immunoblotting using phospho-specific (Ser 473)-PKB antibody
(upper immunob!ot in A), total PKB antibody (!ower immunoblot in A), phospho-specific
(5cr 9)-GSK-313 (upper immunoblot in B) and total GSK-313 antibody (!ower immuob!ot
in B). The resu!ts are representative of 3 independent experiments.
Figure 3: VAC-, BMOV- and VS-induced PKB and GSK-313 phosphory!ation is
dependent on P13-K activity
Confluent, serum-starved CHO-IR ce!!s were incubated in the presence or absence of
100 nM Wortmaimin for 30 mi fo!!owed by incubation with 100 nM of insu!in for 5
min or 1 mM of VAC, BMOV or VS for 10 min. The ceils were !ysed, and the lysates
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were subjected to immunoblotting, using phospho-specific (Ser 473)-PKB antibody
(upper immunoblot in A), total PKB antibody (lower immunoblot in A), phospho-specific
(Ser 9)-GSK-33 (upper immunoblot in B) and total GSK-313 antibody (lower immunoblot
in B). The resuits are representative of 3 independent experiments.
Figure 4: VAC and BMOV are more potent than VS in inhibiting PTPase activity
and in enhancing tyrosine phosphorylation
Confluent, serum-starved HircA (A) or CHO-HIR (B) celis were incubated with lrnM of
VAC, BMOV or VS for 10 min. The ceils were lysed, and the lysates were subjected to
measure PTPase activity as described in the Materials and Methods section (A) or to
immunoblotting, using antiphosphotyrosine antibody (PY99) (B). The resuits are
representative of 3 independent experiments.
Figure 5: VAC and BMOV are more potent than VS in enhancing the tyrosine
phosphorylation of 1R13. IRS-1 and IRS-1/p8’ association
Confluent, serum-starved CHO-HIR ceils were incubated with 100 nM insulin for 5 min
or with 1 mM of VAC. BMOV or VS for 10 min. The celis were lysed, and equal
arnounts of total protein from the clarified lysates were subjected to immunoprecipitation
(IP) with an anti-1R13 (A) or IRS-1 (B) antibody. The immunoprecipitates were
immunoblotted (lB) with the indicated antibodies. A representative immunoblot from 3
independent experiments is shown.
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4.7 -ABSTRACT
Vanadium (IV) oxo bis(maltolato) (BMOV). an organo-vanadium compound, is a potent
insulinornimetic agent and improves glucose homeostasis in various models of diabetes.
We have shown earlier that BMOV stimulates the phosphorylation of PKB which may
contribute as one of the mechanism for the insulinmimetic effect of this compound.
However, the upstream mechanism of BMOV-induced PKB phosphorylation remains
elusive. Therefore, in this study we have exarnined the upstream events leading to
BMOV-induced PKB phosphorylation in HepG2 celis. Since BMOV is an inhibitor of
Protein Tyrosine Phosphatases and through increased tyrosine phosphorylation may
activate various Protein tyrosine kinases (PTK), we have investigated the potential role of
different receptor or non receptor PTK in mediating BMOV-induced PKB
phosphorylation. Among several pharmacological inhibitors tested, only AG1024, a
selective inhibitor of IGf- 1 R-PTK almost completely blocked BMOV-stirnuÏated
phosphorylation of PKB. In contrast. AG1295 and AG147$. specific inhibitors of
PDGFR and EGfR respectively were unable to block the BMOV response. BMOV
induced PKB phosphorylation was associated with an increased tyrosine phosphorylation
of 1RJ3 subunit. IRS-1 and p8 subunit of P13-Kinase. However, this response xvas
independcnt of IR-PTK activity because in celis overexpressing a PTK-inactive fonri of
IR, insulin response was attenuated while BMOV remained intact. A role of PKC in
BMOV-induced response was also tested. Pharmacological inhibition with chelerythrine
a non-selective PKC inhibitor or rottlerin a PKC inhibitor as well as Chronic treatment
with PMA attenuated BMOV-induced PKB phosphorylation. In contrast. GÔ6976 and
RO 31-8220 PKCaJJ3 selective inhibitor failed to alter BMOV effect. Taken together,
these data suggest that IGF-IR and PKC are required to stimulate PKB phosphorylation
in response to BMOV in HepG2 cells.
117
4.2-INTRODUCTION
Vanadium is a transition metal and its compounds have been shown to exert insulin-like
properties both in vivo and in vitro systems (reviewed in (1 ;2)). Oral administration of
vanadium leads to improved insulin resistance and lowers hyperglycernia in rodent
models of diabetes mellitus as well as in lirnited studies with human subjects (l;3-5).
Vanadium mimics many physiological effects of insulin including stimulation of glucose
uptake, glycogen synthesis, and lipid synthesis in muscle, adipose, and hepatic tissues as
well as inhibition of gluconeogenesis in the liver and kidneys and lipolysis in fat celis
(1;2). In cultured ceils, vanadium activates several key components of insulin signaling
cascade implicated in mediating the physiological responses of insulin including the
tyrosine phosphorylation of the insulin receptor substrate (IRS-l) (6;7) and activation of
extracellular signal-regulated kinase (ERKI/2) (8-10) and phosphatidylinositol 3-kinase
(P13-K)/protein kinase B (PKB) signaling cascade (6-8:10-12).
PKB , also known as Akt. is a 57 kDa serine/threonine kinase which has been irnplicated
in the regulation of many physiological processes such as glucose transport. glycolysis,
protein synthesis. lipogenesis. glycogen synthesis. suppression of gluconeogenesis. ccli
survival, determination of ccli size and cell-cycie progression (reviewed in (13)). In rnost
cdl types, PKB is activated via a P13-K-dependent mechanism through dual
phosphorylation on serine 473 in the C-terminal regulatory region and threonine 30$
within the catalytic loop. Phosphorylation of PKB on Thr 308 is catalyzed by
phosphatidylinositol 3.4,5 -triphosphate (PIP3 )-dependent protein kinase 1 (PDK- 1), but
the kinase responsible for phosphorylation at Ser 473, the putative PDK-2, rernains
elusive (13;14). Activated PKB exerts its effect through the phosphorylation of several
downstream targets, such as glycogen synthase kinase-3 3 (GSK-313). forkhead
transcription factor (FKHR). Bd-2 related protein (BAD). 1kB Kinase . Mdm2. Caspase 9
and endothelial nitric-oxide synthase (eNOS) (13;14).
Recently, we have demonstrated that organo-vanadium compounds are more potent than
inorganic vanadium sa]ts in inhibiting the total PTPase activity and in increasing the total
11$
protein tyrosine phosphorylation which was associated with a robust activation of PKB
pathway (7). A much higher potency of organo-vanadium compounds, as compared to
inorganic vanadium saits, to enhance the phosphorylation of PKB and its downstream
substrates has been suggested as one of the mechanism to explain their greater
antidiabetic effects (15-17). We have also shown that vanadium (IV) oxo bis(maltolato)
(BMOV)-a well established antidiabetic and insulinmimetic (1$-22) organo-vanadium
compounds enhanced the tyrosine phosphorylation of the 3 -subunit of insulin receptor
(1R13) in Chinese hamster ovary celis overexpressing IR (CHO-IR) (7), suggesting an
involvement of IR-protein tyrosine kinase (PTK) activity in provoking BMOV-response.
However, a clear involvement of TR-PTK as an upstream inducer of vanadium action has
not been established and a role of both IR-PTK-dependent (23-26) and —independent
(6;1l;27-29) events have been suggested to contribute to the insulin-like effects of
vanadium. Therefore, in the present studies we have investigated a potential role of
receptor PTKs in BMOV-induced PKB phosphorylation in human hepatoma (HepG2)
celis.
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4.3-MATERIALS AND METHODS
Materials
Insulin was from Eh Lilly Co. (Indianapolis. IN). Vanadium (IV) oxo bis(rnaltolato)
(BMOV). was a kind gifi from Dr. Debbie Crans (Colorado State University. Fort
Collins, CO). PhorboÏ-12-myristate-13-acetate (PMA) was from Sigma Aldrich (St.
Louis,MO). HepG2 ceils (HB-$065) were obtained from Arnerican type culture
collection (Rockville, MD). Human IGF-1 was from Peprolech Inc. (New Jersey,
U.S.A.). Epidermal growth factor (EGf), platelet growth factor receptor (PDGF) and all
pharrnacological inhibitors were from Calbiochem (La Joua. CA). Polyclonal insulin
receptor-3 subunit antibody, polyclonal insulin growth factor type 1 receptor-3 subunit
antibody. monoclonal antiphosphotyrosine antibody (PY99). polyclonal phospho-GSK
3f3 (Ser9) antibody, polyclonal PKC6 and polyclonal GSK-313 antibody were purchased
from Sauta Cruz Biotech (Santa Cruz, CA). Polyclonal phospho-PKB (Ser473).
polyclonal PKB antibody and monoclonal phospho-inuhin growth factor type 1 receptor
(Tyr1131)/phospho-inuhin receptor (Tyr1146) receptor antibody were from cell signahing
(Beverly, MA). Polyclonal insuhin receptor substrate antibody and polyclonal p8
antibody were from Upstate (Lake placid. NY). Phospho-PKOE (Tyr311) antibody was
from Biosource (Camarillo, CA). Protein A sepharose beads and the enhanced
chemiluminescense (ECL) detection system kit was from Amersham Pharmacia Biotech
(Baie d’Urfé. Quebec. Canada). All cell culture materials were from Invitrogen Corp.
(Grand Island, NY).
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Methods
Ce!! culture
HepG2 celis were maintained in DMEM medium containing 10 % fetal bovine serum.
Chinese hamster ovary celis overexpressing either wild type human insulin receptor
(CHO-IR) or the PTK mutant form (CHO-1018). a gifi from Dr. Morris F. White (Joslin
Diabetes Center. Boston. MA). were maintained in HAM’s F-12 medium containing 10%
fetal bovine serum. They were grown to $0-90% confluence in 100-mm plates or 60 mm
plates at 37°C in a humidified atmosphere of 5% C02. Prior to the experiment, cells were
incubated in serum-free medium for 20 h (7;10).
Imrnuiiob!otting
Ceils subjected to various experimental treatments were lysed in buffer A (25 mM Tris
HC1, pH 7.5. 25 mM NaC1. 1 mM Na orthovanadate. 10 mM Na fluoride. 10 mM Na
pyrophosphate. 20 nM okadaic acid. 0.5 mM ethylenebis-(oxyethylenenitrilo) tetraacetic
acid (EGTA), 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 Ig/ml aprotinin, and 1%
Triton X-100, and the lysates were clarified by centrifugation to remove insoluble
material. The clarified cell lysates normalized to contain equal amounts of protein were
electrophoresed on 7.5 % or 10 % SDS-PAGE under reducing conditions, transfcrred to
PVDF membranes, and incubated with indicated antibody. Proteins were detected by a
horse radish peroxidase conjugated second antibody and visualized with an ECL
detection kit (7;10).
Immunoprecipitation
The clarified celi lysates. normalized to contain equal amounts ofprotein (500 fig), were
subjected to immunoprecipitation with 2 tg of various antibodies ovemight at 4°C,
followed by incubation with protein A sepharose for 2 h. Immunoprecipitated proteins
were collected by centrifugation, washed 2 times with buffer A and once with phosphate
buffered saline (PBS) containing PTPase and protease inhibitors. The
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immunoprecipitates were electrophoresed on 7.5% SDS-PAGE under reducing
conditions, transferred to PVDf membranes, and incubated with respective prirnary
antibodies. Proteins were detected by a horse radish peroxidase conjugated second
antibody and visualized with an ECL detection kit (7).
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44-RESULTS
Effect of BMOV on PKB and GSK-33 phosphorylation in HepG2 celis
Our previous studies have demonstrated that organovanadium cornpounds such as
BMOV are more potent activators of PKB pathway than inorganic vanadium cornpounds
in CHO-IR cells (7). Therefore, in the present studies. we have first evaluated whether
BMOV alters the activation of PKB and its downstream targets such as GSK-3f3 in
HepG2 celis which has been used as a model to investigate insulin action in liver (30).
Since increased phosphorylation in specific serine/threonine residues of both PKB and
GSK-3t3 is critical for their activation state. we have utilized phospho-specific antibodies
to monitor their activity. As shown in Fig. lA. treatrnent ofHepG2 ceils for 15 min with
escalating concentrations of BMOV en]rnnced PKB and GSK-313 phosphorylation in
dose-dependent manner. BMOV elicited a robust phosphorylation ofthese two kinases at
1 mM. Next, we assessed the tirne-dependence of 1 mM BMOV response, as shown in
Fig. 13, 1 mM BMOV enhanced the phosphorylation ofPKB and GSK-313 within 10 min
which reached maximum in 30 min.
Effect of BMOV on tyrosine phosphorylation of total protein, insulin receptor (IR),
IRS-1 and p85 in HepG2 celis
Since BMOV is a potent inhibitor of protein tyrosine phosphatases (PTPases), and an
increase in the tyrosyl phosphorylation of several key proteins such as IR3 and IRS-1 is
an early step in triggering the insulin signaling cascade, we wished to deterrnine the
effect of BMOV on tyrosine phosphorylation of the total proteins as well as on the
phosphorylation of IR. IRS-1 and regulatory subunit of P13-K (p85) in HepG2 celis. As
illustrated in Fig. 2A and 23, BMOV increased the tyrosine phosphorylation of several
proteins in a dose- and time-dependent fashion. The molecular size of these proteins
1
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ranged between 35 and to 200 kDa and the increase in phosphorylation by BMOV could
be detected within 10 min of treatment (Fig. 2B). b further analyze if sorne of these
proteins were IR and its targets, phosphotyrosylproteins immunoprecipitates from BMOV
treated celis were immunoblotted with antibodies to 1R. IRS-1 and p. As shown in
Fig. 2C. BMOV treatment resulted in a significant increase in the phosphorylation of
IRF3, IRS-1 and p8.
Role of IR-PTK on BMOV-induced PKB phsophorylation
BMOV-induced increased tyrsoine phosphorylation of IRt3 suggested a possible role of
IR-PTK in 3MOV-induced cffects on PKB phosphorylation. This possibility was probed
further by utilizing CHO celis that overexpress an inactive form ofIR-PTK (CHO-101$).
The inactivation of IR-PTK in these celis was achieved by the mutation oflysine 101$ to
alanine in the ATP-binding dornain ofthe IRf3 (31). As illustrated in Fig. 3, both insulin
and BMOV enhanced the phosphorylation of PKB in CHO-IR cells overexpressing a
nonrial IR. However, in CHO-l0l$ cetts overxpressing PTK-inactive IR, the insulin
induced phosphorylation of PKB was almost cornpletely attenuated, whereas the BMOV
evoked increase was not inhibited. These data suggested that in contrast to insulin,
BMOV-induced phosphorylation of PKB was independent of IR-PTK activity.
Effect of receptor tyrosine kinase inhibitors on 3MOV-induced PKB
A potential role of epidermal growth factor receptor (EGFR) transactivation in vanadyl
sulfate (VS)-induced signaling has been demonstrated (32:33) and insulin-like growth
factor type I receptor (IGf- I R) activation bas also suggested to play a role in vasoactive
peptide-induced signaling (34;35). Therefore, we wished to determine if IGF-1R, EGFR
or platelet growth factor receptor (PGDFR) were the putative PTKs mediating BMOV
induced PKB phosphorylation. As depicted in Fig. 4A. AG1024 a highly specific
inhibitor ofIGF-1R-PTK (36) prevented the phosphorylation ofPKB induced by BMOV
as well as IGF-1. In contrast. while AG 147$. an EGFR-PTK inhibitor (37), completely
blocked EGF-induced PKB phosphorylation, it failed to change the stirnulatory effect of
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BMOV on this event (F ig. 4B). Similarly, AG 1295. an inhibitor of PDGFR-PTK also
had no effect on PKB phosphorylation induced by BMOV (3$) (Fig. 4C). In fact, PKB
phosphorylation was not detected in HepG2 ceils in response to PDGF treatrnent
suggesting that PDGFR may not be expressed in these celis.
Effect of different doses ofAGlO24 on BMOV-induced signaling
Since BMOV-induced PKB phosphorylation was altered solely by AG1024, we analyzed
the effect of this inhibitor in more detail. As shown in Fig. 5A, treatment of ceils with
AGI 024 inhibited the phosphorylation of PKB and GSK-3 [3 in a dose-dependent fashion
with almost complete attenuation observed at 1 .tM. Since tyrosine phosphorylation of
IGF-1R [3-subunit (IGF-lRf3) is primordial in increasing its PTK activity. we investigated
the effect ofBMOV on the tyrosine phosphorylation ofTGF-1R[3. As shown in Fig. 5B,
tyrosine phosphorylation of IGF-1R[3 was increased by BMOV and pretreatment of cells
with AG1024 prior to stimulation with BMOV resulted in a significant reduction in this
response. IGF-IR[3 lias three critical tyrosines at positions 1131, 1135. and 1136 in the
kinase domain crucial to maintain its activity and to elicit all IGF-IR-dependent functions
(39). Therefore. by using a phospho-specific antibody. which recognizes
phosphorylation ofthe IGF-IRf3 at tyrosine 1131. we investigated the effect ofBMOV on
the phosphorylation of this site. As depicted in Fig. 5C. BMOV increased the
phosphorylation of IGF-1Rf3 on Tyr’ 131 and sirnilar to its effect on total tyrosine
posphorylation of IGF-1Rf3, AG1024 rnarkedly blocked this response (Fig. 5C).
Cumulatively, these results suggested that BMOV-induced PKB phosphorylation was
associated with an increased tyrosine phosphorylation of IGF-lRf3.
Effect of AG1024 on the phosphorylation ofIRS-1 and p85 induced by BMOV
Increased phosphorylation of IRS-1 and p8 regulatory subunit of P13-K are critical
intermediary steps to signal the activation of PKB signaling in response to IGF-1R
activation. Therefore. we next assessed if BMOV-enhanced tyrosine phosphorylation of
IRS-1 and p8) in HepG2 cells (Fig. 2C) was dependent on IGF-IR-PTK activity. The
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resuits shown in fig. 5D demonstrated that BMOV induced tyrosine phosphorylation of
both IRS-1 and p85 which was suppressed by AG1024.
Requirement of PKC6 in 8MOV-induced PKB phosphorylation
A potential role of PKC in mediating the responses of different stimuli such as PDGf
(40). EGF (41:42). Vascular Endothelial Growth Factor (VEGF) (43:44), Angiotensin 11
(45), and F1202 (46) have been suggested. Therefore, we sought to verify if PKC
dependent pathways were involved in BMOV-induced phosphorylation of PKB in
HepG2 ceils. PKCs are composed ofthree groups; the classical (cPKC) subtype (Œ, 131,
1311, and y) are activated by calcium, diacylglycerol (DAG), phosphatidylserine (PS) and
phorbol esters; the novel (nPKCs) subtype (& E. ri. and 0) are activated by DAG, PS.
phorbol esters and unsaturated fatty acids and the atypical (aPKCs) subtype ( and ?Jr)
are insensitive to DAG, but are activated by PS and phopshatidylinositides (reviewed in
(47)). The results shown in Fig. 6A dernonstrate that GÔ 6976 or RO 31-$220, selective
chemical inhibitors of cPKC and aPKC isoforrns respectively, failed to inhibit BMOV
induced phosphorylation of PKB whereas chelerythrine chloride an isoform-non-selective
inhibitor and rottlerin, a highly selective PKC inhibitor treatment significantly reduced
PKB phosphorylation induced by BMOV. Involvement of PKC was further confirrned
by downregulating the PKC activity in HepG2 celîs by 24h treatrnent with Phorbol-12-
myristate-13-acetate (PMA). As shown in Fig. 6B. PMA treated celis exhibited a
signiflcantly attenuated PKB phosphorylation in response to BMOV as compared to
untreated cells. Immunoblotting of parallel samples showed that PMA treatment
significantly reduced the amount of PKC protein in these cells whereas the total PKB
levels remained unaltered by this treatment (Fig. 6B).
Effect of BMOV on tyrosine phosphorylation of PKOE
Recent studies have identifled tyrosine phosphoryÏation as a potential mechanisrn through
which PKC activation is regulated (47). Therefore. we investigated the effect of
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BMOV on tyrosine phosphorylation of PKOE by immunoprecipitating PKC from lysates
of ceils treated with BMOV foÏlowed by irnrnunobÏot analysis with antiphosphotyrosine
antibody. As depicted in Fig. 7A. BMOV treatment of HepG2 ceils caused a significant
increase in the tyrosine phopshorylation of PKC& We also assessed the effect of BMOV
on the tyrosine phosphorylation of PKC at tyrosine 311 (Tyr311). This tyrosine residue
is flanked between the regulatory and catalytic domains and is critical for generating the
active form of PKOE in response to J-1202 and PMA (48-50). As shown in Fig. 7A,
BMOV induced the Tyr31’ phosphorylation of PKC& In addition, both total tyrosine and
Tyr311 phosphorylation of PKOE enhanced by BMOV was blocked by rottierin (Fig. 7B).
Taken together these data indicated that BMOV-induced phosphorylation of PKB is
associated with an activation of PKOE as judged by an increase in tyrosine
phosphorylation residues.
Effect of AG1024 on BMOV-induced tyrosine phosphorylation ofPKOE
Since PKOE has been shown to be tyrosine phosphorylated by various protein tyrosine
kinases, including IGF-1R (51), PDGFR (52;53), EGFR (54). IR (53) and Src family
kinases (49;53-55). we investigated if IGF-IR-PTK was responsible for triggering the
phosphorylation of PKC in response to BMOV. As shown in Fig. 8A. treatrnent of
HepG2 ceils with AGI 024 alrnost completely abolished BMOV-stirnulated total tyrosine
phosphorylation of PKC& In addition, AGI 024 also inhibited phosphorylation of PKOE
in Tyr31’ while AGI47$, an EGFR inhibitor, failed to alter the phosphorylation of PKC
on this site (Fig. 83). Since PKOE has been shown to be phosphorylated on Tyr3 in
response to various agonists including PMA. we wished to detennine if similar to
BMOV, PMA-induced effects are also dependent on JGF-1R-PTK. As shown in Fig. 8C,
in contrast to its inhibitory effect on PKC6 phosphorylation stimulated by BMOV,
AG1024 was unable to block the effect of PMA suggesting that IGF-1R is an upstrearn
regulator of PKOE phosphorylation in response to BMOV and not PMA.
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4.5-DISCUSSION
BMOV bas been shown to exert glucoregulatory effects in rnany rodent models of
diabetes (1$-22), however, the precise rnechanisrn through which this response is
rnediated remains largely unclear. We bave shown earlier that BMOV activates PKB (7).
a central player involved in carbobydrate rnetabolisrn (13). therefore. in this study we
have studied the upstream mechanism responsible for this response and demonstrated that
BMOV-enhanced phosphorylation of PKB in HepG2 ceÏÏs was associated with an
increased tyrosine phospborylation of the total celtular proteins, IR3, IGF-ÏRf3, IRS-1
and p85 subunit of PI3K. We bave also provided evidence that PTK activity of the IGf
I Rf3 is responsible for BMOV-induced activation of the PKB pathways. Tbis conclusion
is based on the use of highly selective inhibitors of IGF-IR. EGFR and PDGFR-PTKs
which showed tbat only the inhibition of IGF-IR-PTK by AG1024 blocked BMOV
induced PKB phosphorylation. Our resuits showing that BMOV treatment increased the
total tyrosyl phosphorylation as well as tyr1131 phospborylation of IGf-1R13 which was
specifically inhibited by AG 1024 suggested that the PTK activity of IGf- 1 R13 was indeed
being stimulated in response to BMOV. A role of IGF-lRf3 in Angiotensin II and H202
(56:57) induced ERKI/2 phosphorylation. and in Angiotensin II and purinergic receptor
P2Y12-induced P13-KIPKB signaling pathway bas been reported earlier (35:58).
Transactivation of other growth factor receptor PTKs bas also been suggested to play
critical interrnediary role in response to agonists coupled to G-protein receptors (GPCR)
(reviewed in (59)). However, the data presented here are the first to demonstrate that
BMOV, a non GPCR-agent also signais through IGF-IR-PTK transactivation to activate
PKB.
IR and IGF-lR show a higli degree of homology and share several signaling features
(reviewed in (60)) and despite having a higher 1C50 for IGF-1R-PTK, AG1O24 can also
inhibit IR-PTK activity at high concentrations (36). Further, our results showing that
BMOV treatrnent increased the tyrosine phosphorylation ofIR rnight argue for a role of
IR-PIK in BMOV-induced responses. However. our observations tbat in CHO-10l$
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ceils insulin response was attenuated while BMOV effect was intact suggested an IR
PTK-independent rnechanism of BMOV action. Earlier studies using inorganic
vanadium compounds have also documented Yack of a role of IR-PTK in inducing the
vanadium response (27:61). In addition. several investigators have also reported that the
insulin-like effects of vanadium were flot associated with an increase in the tyrosine
phosphorylation of IR3 in many systems (6; 11:27-29). Thus,despite the fact that sorne
studies have dernonstarted an increase in IR tyrosine phosphorylation in vivo in response
to vanadium treatment in diabetic animal models (1 8;62), our data support the notion that
IGF- 1 R-PTK activation by BMOV may serve as an altemate rnechanism to mediate the
insulin-like effect of this compound.
PKC is a serine/threonine kinase, that plays a key role in many physiological responses
as growth regulation (63:64), tissue rernodeling (65;66), migration (67) and
transformation (51). In response to insulin, PKOE and PKCO, two novel PKC isoforms.
have been shown to convey insulin signal toward glucose transport (62:69), glycogcn
synthesis (70). and cell proliferation (71). In contrast. several studies have reported that
PKC may down-regulate insulin signaling in response to high glucose concentrations
(72) and other stimuli (73). Therefore, it appears that novel PKC isoforrns may both
mediate insulin stimulatory effects on glucose metabolism and inhibit insulin intracellular
signals. Our data showing that PKB phosphorylation was blocked by chelerythrine and
rottierin and flot by GÔ 6976 or RO 31-$220 suggested a role of PKC in BMOV action.
Rottierin has been extensively used as a selective inhibitor of PKC, however recent
reports have suggested that it may have additionaL non- PKC6 dependent-responses
(74;75). Therefore, we directly tested the effect of BMOV on PKC activation by
assessing increase in its tyrosine phosphorylation status and have shown that both, the
total tyrosine phosphorylation as well as the phosphorylation oftyr311, were enhanced by
BMOV treatment of HepG2 ceils. This is consistent with previous reports where
pervanadate was shown to enhance the tyrosine phosphorylation and activation of PKC
(49:55). Furthermore. our resuits showing that in ceils chronically treated with PMA. the
attenuated response of BMOV on PKB phosphorylation was associated with a decreased
expression of PKC6 provided additional support for a role of this isoform of PKC in
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BMOV action. b the best of our luowledge. our data are the first to demonstrate an
involvement of PKC in vanadiurn-mediated PKB activation response. This is consistent
with previous reports where an involvement of PKCs in mediating PKB activation was
documented (43;76). In contrast however, a negative regulatory role of PKC in PKB
activation has also been suggested (77;7$). Because PKC expression and its action have
been suggested to be tissue-specific (79). it is possible that PKC may elicit different
responses depending on ceil type. The attenuation of BMOV-induced PKCS
phosphorylation by AG1024 observed in our studies indicates that IGf-IR may be an
upstrearn mediator of this event. A requirement of PKC in IGf-1R- induced signaling
has also been described (51 ;8O;$1). However, the precise rnechanisrn and interrnediary
steps responsible for PKC-rnediated PKB activation in response to BMOV remains to be
explored.
In surnmary. our studies have provided experirnental evidence for a role of 10f-1 R-PTK
in BMOV-induced activation of PKB signaling pathway in HepG2 ceils. We have also
demonstrated that PKC6 activation plays an intermediary role to transduce IOF-1R
signaling leading to PKB phosphorylation in response to BMOV. These data provide
nove! insight into the cellular rnechanism of BMOV action.
1—,
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4.6-FIGURE LEGENDS
Figure 1: BMOV-indnced PKB and GSK-3fl phospltorylatioit is tirne- and dose
dependent in HepG2 celis
Confluent, serum-starved HepG2 ceils were incubated with different concentrations of
BMOV for 15 min (A) or witli 1 mM BMOV for the indicated time periods (B). The ceils
were lysed and the lysates were subjected to immunoblotting using phospho-specific (Ser
473)-PKB antibodies (upper immunoblot in A and B) and phospho-specific (Ser 9)-GSK-
33 antibodies (lower immunoblot in A and B). The resuits are representative of 3
independent experiments.
Figure 2: 3MO V- enhanced tyrosine pitosphorylation oftotatproteins and ofIRJi
IRS-1 and p85
Confluent, serum-starved HepG2 celis were incubated with different concentrations of
BMOV for 15 min (A) or with 1 mM BMOV for the indicated time periodes (B). The
ceils were lysed. and the lysates were subjected to immunoblotting, using
antiphosphotyrosine antibodies (PY99) (A and B). In (C). ceils treated without or with
I mM of BMOV for 15 min were lysed and equal arnounts of total protein from the
clarified lysates were subjected to immunoprecipitation (IP) with antiphosphotyrosine
antibodies (PY99). The immunoprecipitates were immunoblotted (lB) with an anti-IRt3 -
IRS-l or p8 antibodies. A representative immunoblot from 3 independent experiments is
shown.
Figure 3: BMOV-btduced PKB phospitorylation is independent on IR-PTK activity
in CHO celis
1—,
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Confluent, serum-starved CHO-IR and Cl-10-101$ celis were incubated in the absence or
presence of 0.1 nM insulin (Ins) or with 1 mM of BMOV for 15 min. The ceils were
lysed and the lysates were subjected to immunoblotting using phospho-specific (Ser
473)-PKB antibodies. The resuits are representative of 3 independent experiments.
Figure 4: 3MO V-indticed PKB phosphorytation is inhibited by AGi 024 but not by
AG1478 orAGl29S
Confluent, serum-starved HepG2 celis were pretreated without (-) or with (+) 10 jiM of
AG1024 (A), AG147$ (B) or AG1295 (C) for 30 min followed by stimulation with lmM
ofBMOV for 15 min. 10 ng/rnL ofIGF-1 or lOnM ofEGF or 10 ng/mL PDGF for 10
min. The ceils were lysed and the lysates were subjected to immunoblotting using
phospho-specific (Ser 473)-PKB antibodies. The resuits are representative of 3
independent experirnents.
Figure 5: AG1024 decreased 3MO V-indiiced PKB phosphorylation in a
dose dependent manner and reduced the tyrosilte pitospitorylation ofIGf-iR IRS-i
and p85 subunit ofP13-K
Confluent, serum-starved HepG2 celis were pretreated without (-) or with (+) different
doses of AG1024 (A) or 1tM (B. C and D) for 30 min followed by stimulation with
lmM of BMOV for 15 min. The cells were Iysed, and equal amounts of total protein
from the clarified lysates were subjected to immunoblotting using phospho-specific (Ser
473)-PKB antibodies and phospho-specific (Ser 9)-GSK-313 antibodies (A) or phospho
IGf-IR (Tyr131)/phospho-IR (Tyr”46) (C) or to immunoprecipitation (IP) with
antiphosphotyrosine antibodies (PY99) followed by immunoblotting with the indicated
antibodies (B and D). The phosphorylation level of protein showed in A and C were
quantitated by densitometric scanning using NTH ImageJ software and expressed as fold
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increase over control ceils (time = 0). A representative immunoblot from 3 independent
experirnents is shown.
Figure 6: chelerythine chloride, rottierin and !ong-term PM4 pretreatrneitt
bihibits 3MoV-induced PKB phosphorylation
Confluent, serum-starved HepG2 celis were pretreated without (-)or with (+) 5 jiM of
chelerythine chloride, GÔ 6976. RO 31-$220 or rottierin for 30 min (A) or with 100 nM
ofPMA for 24hr (A) followed by stimulation with lrnM ofBMOV for 15 min. The ceils
were lysed and the lysates were subjected to immunoblotting using phospho-specific (Ser
473)-PKB antibodies (upper immunoblot in A and B) or total PKC antibodies (lower
immunoblot in B). The resuits are representative of 3 independent experirnents.
Figure 7: rottlerin decreased BMO V-induced total tyrosine phosphorylation
and Tyrosine31’ ofPKCc5
Confluent, serum-starved HepG2 ceils were pretreated with or without 5 p.M of rottierin
for 30 min followed by stimulation in the absence or presence of lmM of BMOV for 15
min. The celis were lysed, and equal amounts of total protein from the clarified lysates
were subjected to immunoprecipitation (IP) with total PKOE antibodies followed by
immunoblotting with antiphosphotyrosine antihodies (PY99) or phospho-specific (Tyr
31 1) - PKC antibodies. A representative immunoblot from 3 independent experiments
is shown.
Figure 8: AG 1024 decreased BMOV but not —PM4 induced tyrosine
phosphoiylation ofPKC on Tyrosine31’
Confluent, serum-starved HepG2 cells were pretreated with or without 10 j.tM ofAGlO24
or AG 147$ (B) for 30 min followed by stimulation with lmM of BMOV or lOOnM of
PMA for 15 min. The cells were lysed, and equal amounts of total protein from the
clarified lysates were subjected to immunoprecipitation (IP) with total PKC antibodies
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followed by immunoblotting with antiphosphotyrosine antibodies (PY99) (A) or were
immunoblotted using phospho-specific (Tyr 311) - PKC antibodies (B and C). A
representative immunoblot from 3 independent experiments is shown.
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5.7 -ABSTRACT
Hydrogen peroxide (H202) mirnics many physiological responses of insulin, and increased
H202 generation via the Nox-4 subunit of NAD(P)H oxidase was rccently demonstrated to
serve as a critical early step in the insulin signaling pathway. Exogenously-added H202 has
also been shown to activate several key components of the insulin signaling cascade.
H202-induced signaling responses have been found to be associated with the activation of
receptor and non-receptor protein tyrosine kinases (PTK), including the insulin receptor
(IR)-13 subunit. Therefore, in the present studies on Chinese hamster ovary ceils
overexpressing wild type IR-PTK (CHO-IR) or a PTK-inactive fonri of IR (CHO-Ï018).
we investigated whether IR-PTK plays a role in H202-induced signaling events. Treatrnent
of CHO-IR ceils with H202 increased the phosphorylation of extracellular signal-reguiated
kinases 1 and 2 (ERKI/2), protein kinase B (PKB) and glycogen synthase kinase-3 beta
while enhancing tyrosine phosphorylation of the IR-13 subunit and the p85 subunit of
phosphatidylinositol 3-kinase (PI3K). Compared to CHO-IR ceils. the stimulatory effect of
IT202 on ERK1/2 and PKB was partially reduced in CHO-1O18 celis. However,
pharmacological inhibition of Src family PTK by 4-amino-5-(4-chlorophenyl)-7-(t-
butyl)pyrazolo[3.4-dlpyramidine (PP-2) alrnost completeiy blocked H202-stimulated
phosphorylation of the p85 subunit of PI3K. ERK 1/2 and PKB. Moreover. 1-1202 but flot
insulin induced Tyr-4 1$ phosphorylation of Src which was also suppressed by PP-2. Taken
together, these data suggest that both IR-PTK and Src family PTKs contribute to 1-1202-
induced signaling in CHO-IR celis aibeit IR-PTK has a less dominant foie in this process.
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5.2- INTRODUCTION
Reactive oxygen species have been suggested to serve as mediators of the action of several
growth factors. cytokines and insulin (5.13.20,21.23.32). Insulin is the major hormone
involved in glucose homeostasis. and its effect is initiated by binding to its receptor on cell
membranes. The insulin receptor (IR) is a heterodimeric (u, 132) protein, and insulin
binding to the IR-Œ subunit resuits in conformational changes, leading to enhanced intrinsic
protein tyrosine kinase (PTK) activity of the 13 subunit by multi-site tyrosine
phosphorylation. Once activated, IR-PTK can phosphorylate several cytosolic IR
substrates such as IRSs and Shc. which serve as docking sites for Src homology 2 (SH-2)
domain-containing signaling molecules (37). triggering the activation of 2 key signaling
pathways. In I pathway, the association of IRS-1 with Grb-2-SOS complex resuits in
activation of the Ras, Raf, MEK and extracellular signal-regulated kinase (ERK) pathway
(36,38). Activated ERK1/2 phosphorylates and activates a downstream ribosomal protein
kinase, p9O. Both ERK1/2 and p90t can be translocated to the nucleus where they
phosphorylate transcription factors. and contribute the mitogenic and growlh-promoting
effects of insulin (36.37). The second pathway that radiates from the IRS complex upon
insulin stimulation involves phosphatidylinositol 3-kinase (PI3K) activation (36,38). PI3K
phosphorylates phosphatidylinositol (PI) lipids at position 3 of the inositol ring, and
generates 3-phosphorylated forms of PI, such as phosphatidylinositol 3, 4, and 5 (30),
which are implicated in the activation of phospholipid-dependent kinase and related
serine/threonine protein kinases. These activated kinases in turn are responsible for the
phosphorylation and stimulation of several downstrearn signaling protein kinases, such as
protein kinase B (PKB) (also known as Akt). glycogen synthase kinase 3 (GSK-3), 70s6k
(11), and protein kinase C-zeta (PKC) (10). Activation of these protein serine/threonine
kinases has been demonstrated to mediate the metabolic effects of insulin at the level of
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glucose transport. glucose transporter (GLUT-4) transiocation, glycogen and protein
synthesis (36).
Recent studies have demonstrated that insulin stimulation of celis generates an hydrogen
peroxide (1-1202) burst whicli enhances the tyrosine phosphorylation of IR and IRS-1 (23).
An important role for the NAD(P)H oxidase catalytic subunit homolgue Nox-4 in
enhancing 11202 production in response to insulin lias been suggested recently (22). In
addition, exogenously-added 11202 has been shown to mirnic rnany physiological effects of
insulin, including glucose transport (15), glycogen synthesis (17), lipogenesis (24),
lipolysis (19) and phosphoenolpyruvate carboxykinase (PEPCK) gene expression (33).
11202 lias also been found to increase tyrosine phosphorylation ofthe IR-J3 subunit (15.16).
and activation of the ERKY/2 and PI3K/PKB signaling pathways in several ceil types
(3.4,6.8,18.31.34.35). A potential role for epidermal growth factor (EGf) receptor
transactivation (12.28,39) and the src farnily of PTK in H202-induced signaling has been
postulated (1,2,12). However, despite the ability of H202 to enhance IR-PTK activity and
IR-{3 subunit phosphorylation, the possible involvement of IR-PTK in H202-induced
responses lias flot been characterized. Therefore. in the present studies. we investigated the
possible requirernent of IR-PTK in H202-induced phosphorylation of the ERK1 /2 and PKB
pathways.
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5.3-MATERIALS AND METHODS
Materials
Insulin was obtained from the Eh Lilly Co. (Indianapolis, IN). H202 from the Sigma
Chernicals Co. (St. Louis. MO). and IRS-1 and p8’ antibodies from Upstate Biotechnology
(Lake Placid, NY). Phospho-specific and total antibodies. against p44/p42 and GSK-313.
antiphosphotyrosine antibody (PY99), and IR antibody were purchased from Santa Cruz
Biotech (Santa Cruz, CA). Phospho-specific and total PKB antibodies were procured from
New England BioLabs (Beverly. MA), and phospho-specific c-Src antibody from
Biosource (Camarillo. CA). Protein A sepharose beads and enhanced chemiluminescence
(ECL) detection kits were from Arnersham Pharmacia Biotech (Baie d’Urfé, Quebec,
Canada).
Methods
Gel! ctiltttre
Chinese hamster ovary ceils overexpressing either wild type human insulin receptor (CHO
IR) or the PTK mutant form (CHO-1018), a gifi from Dr. Morris F. White (Joslin Diabetes
Center, Boston, MA). were maintained in HAM’s F-12 medium containing 10% fetal
bovine serum. Ihey were grown to confluence in 1 00-mm plates and incubated in serum
free F-12 medium for 16 h prior to the experiment (26).
Ce!! lysis aiid immunoblotting
Cells subjected to various experimental treatrnents were washed twice with ice-cold
phosphate-buffered saline and lysed in buffer A (25 mM Tris-HC1. pH 7.5, 25 mM NaCÏ.
1 mM Na orthovanadate. 10 mM Na fluoride. 10 mM Na pyrophosphate, 20 nM okadaic
acid, 0.5 mM ethylenebis-(oxyethylenenitrilo)-tetraacetic acid, 1 mM phenylmethylsulfonyl
fluoride, 10 g/rn1 aprotinin, and 1% Triton X-100). The lysates were clarifled by
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centrifugation to remove insoluble material. The clarified lysates, normalized to contain
equal amounts of protein, were subj ected to 12% sodium dodecyl sulfate-polyacrylarnide
gel electrophoresis (SDS-PAGE) under reducing conditions, transfened to PVDF
membranes, and incubated with respective prirnary antibodies, followed by incubation with
a horse radish peroxidase-conjugated second antibody. The antigen-antibody complex was
visualized with an ECL detection kit. The immunoblots were quantified by densitometric
scanning with NIH ImageJ software (27).
Immirnoprecipitation
The clarified celi lysates, normalized to contain equal amounts of protein (500 fig), were
imrnunoprecipitated overnight with I ig of PY99 antibody at 4°C, followed by incubation
with protein A sepharose for an additional 2 h. Immunoprecipitated phosphotyrosine
proteins were collected by centrifugation, washed twice with buffer A and once with
phosphate-buffered saline. The phosphotyrosine protein immunoprecipitates underwent
7.5% SDS-PAGE under reducing conditions. transferred to PVDF membranes, and
incubated with respective primary antibodies. Proteins were detected by a horse radish
peroxidase-conjugated second antibody and visualized with an ECL detection kit (27).
PI3K assay
The clarified cell lysates were subjected to immunoprecipitation with 2 tg ofp85’ antibody
for 2 h at 4°C, followed by incubation with protein A sepharose for an additional 2 h. The
immunoprecipitates were washed before PI3K assay, as described earlier (26). The
phosphorylated lipid products were extracted and separated by ascending thin layer
chromatography (26). Radioactivity in the spots conesponding to P13-phosphate was
quantified by Phosphorlmager (Molecular Dynamics, Sunnyvale, CA).
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5.4-RESU LTS
Effect of H202 on ERK1/2, PKB and GSK-3t3 phosphorylation in CHO-IR ceils
We first evaluated whether H202 alters the activation of ERK 1/2, PK3 and its downstream
targets in CHO-IR ceils. Since increased phosphorylation in specific serine/threonine
residues of these motecules is associated with their activation, their activity was measured
by using phospho-specific antibodies. As shown in Figure lA, treatment of IR
overexpressing celis for 5 min with escalating concentrations of H202 induced ERK 1/2,
PKB and GSK-33 phosphorylation. H202-increased ERK 1/2 phosphorylation at
concentrations as low as 10 jiM with maximal effect at 100 j.tM. whereas higher
concentrations 500 !IM to 1 mM. were required to elicit robust PKB phosphorylation.
Next, we assessed the time-dependence of the 14202 response. As seen in f igure 13. 1 mM
H202 rapidly enhanced the phosphorylation ofERK 1/2, PKB and GSK-3j3. The increase,
which declined slowly, occurred within 5 min to almost basal levels within 60 min of F1202
treatment.
Effect of 11202 on ERK1/2 and PKB phosphorylation in IR-PTK-deficient celis
To examine the role of IR-PTK in H70-,-induced effects on ERK 1/2 and PKB
phosphorylation, we studied CHO- 101$ celis that overexpress an inactive form of IR-PTK.
The inactive form of IR was generated by the mutation of lysine 1018 to alanine in the
ATP-binding domain of the IR-f3 subunit. This mutation resuits in the loss of ATP-binding
activity and, thus, PTK function (7). As illustrated in Figure 2, both insulin and 1{202
enhanced the phosphorylation of ERK 1/2 and PKB in CHO-IR celis overexpressing a
normal IR. However, in CHO-l01$ celis, the insulin-induced phosphorylation of both
ERK 1/2 and PKB was almost cornpletely attenuated, whereas the H202-evoked increase
was partially blocked in this ccli type. These data suggested that, compared to insulin,
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H202-induced phosphorylation of ERK 1/2 and PKB is exerted in part through IR-PTK
activity.
Effect of 11202 on IR, IRS-1 and p85 tyrosine phosphorylation
Since the insulin effects on ERK 1/2 and PKB are mediated through the enhanced tyrosine
phosphorylation of IR and IRS-1, we next explored, if sirnilarly to insulin, H202 increases
the tyrosine phosphorylation ofIR and IRS-1. As shown in Figure 3, both insulin and I12O2
augrnented tyrosine phosphorylation of the IR-3 subunit, but tyrosine phosphorylation of
the IR-13 subunit induced by H202 was significantly lower than that observed with insulin.
Furtherrnore, whereas insulin enhanced the tyrosine phosphorylation of IRS-1, a sirnilar
effect of H202 on IRS-1 tyrosine phosphorylation was not detected in CHO-IR ceils (Fig.
3). In contrast, both insulin and H202 treatment resulted in enhanced tyrosine
phosphorylation ofthe p85 subunit ofPI3K.
Requirement of c-Src in 11202-induced ERK 1/2 and PKB phsophorylation
The resuits with CHO-1O1$ ceils indicated that H202 effect on ERK 1/2 and PKB
phosphorylation required additional signais besides IR-PTK. Since potential involvement
of the Src family of PTKs in H202-induced signaling bas been proposed in other ccii types,
we investigated iL in CHO ceils also, Src-PTK was responsible for triggering the
phosphorylation of various signaling components. We utilized PP-2 (4-arnino-5-(4-
chlorophenyl)-7-(t-butyl)pyrazolo [3 ,4-dJpyrimidine), a selective inhibitor of Src-PTK, and
PP-3 (4-amino-7-phenylpyrazoi [3,4-d] pyrirnidine), an inactive analogue of PP-2, to
examine the contribution of Src in H202-induced increased pbosphoryiation events. As
depicted in Figure 4, treatment of celis with PP-2 almost cornpieteiy suppressed H202-
stimulated phosphorylation of both ERJ( 1/2 and PKB. Since PP-2 is a potent and specific
inhibitor of c-Src activity, and its ability to suppress H202-induced responses suggested a
role of Src in this process, we directly assessed if I-1202 would enhance Src activity in
CHO-IR cells. This was achieved by evaiuating the increase in Tyr-41 $ phosphoryiation in
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the activation ioop. As shown in figure 4, H202 treatment enhanced the Tyr-41$
phosphorylation of Src, which was almost completely blocked in PP-2-pretreated ceils.
Effect ofPP-2 on IR and p85 lyrosine phosphorylatïon and ofwortmannin on ERK 1/2
and PKB phosphorylation induced by H202
To determine if c-Src is an upstrearn mediator of IR and p85 tyrosine phosphorylation, we
evaluated the effect of PP-2 on H202-induced phosphorylation of these signaling
components. As illustrated in figure SA, PP-2 treatrnent failed to block tyrosine
phosphorylation of the IR-13 subunit whereas it cornpletely attenuated the tyrosine
phosphorylation of the p85 regulatory subunit of PI3K. Next, we examined if p85
phosphorylation by H202 was associated with an increase in the PI3K activity of CHO-IR
celis. As seen in Figure 5B. H202 treatrnent enhanced PI3K activity which was sensitive to
inhibition by wortrnannin, a specific PI3K inhibitor. Furthermore, both ERK 1/2 and PKB
phosphorylation induced by J-1202 were almost completely attenuated by wortmannin
pretreatrnent of celis.
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5.5-DISCUSSIONS
In this study, we have shown that exogenously-added T-1202 enhanced the phosphorylation
ofERK 1/2 and PKB signaling pathways in CHO-IR ceils. The increased phosphorylation
of ERK 1/2 and PKB was associated with heightened tyrosine phosphorylation of the IR-f3
subunit and p85 subunit of P13 K. We have also provided evidence that PTK activity of the
IR-13 subunit is partially responsible for H202-induced activation ofthe ERK 1/2 and PKB
pathways. This contention is based on the resuits with the CH0 ceils that overexpress a
PTK-inactive form of IR. Although earlier studies have demonstrated a stirnulatory effect
of H202 on tyrosine phosphorylation of the IR-j3 subunit in adipocytes, no atternpts have
been made to determine the contribution of TR-PTK to H202-inducing signaling events.
Thus, to the best of our knowledge, this work provides the first evidence in support of the
involvement of IR-PTK in H202-induced phosphorylation of ERK 1/2 and PKB.
H202 has recently emerged as an important redox molecule for the action of several growth
factors, cytokines and insulin (5,13,20,21,23,32). Sorne ofthe effects ofH2O2 on signaling
events have been shown to be rnediated by transactivation of EGF receptor PTK and the
Src family of PTKs in several celi types (1,2,12,28,39). In CHO-TR celis FT202 also
enhanced Src activity, as judged by the increased phosphorylation of Tyr-41 8 in the
activation ioop of Src. The participation of Src in H202-induced signaling in CHO celis
was evaluated by using PP-2, a highly specific inhibitor of Src PTK activity. PP-2 almost
completely attenuated the H202-induced increase of phosphorylation of ERK 1/2, PKB and
the p85 subunit of P13 K. This is in contrast to the partial inhibition elicited in PTK-deflcient
cells where the H202-induced effect was blocked by only 20-30% (Fig. 2). An important
role of Src PTK in insulin-induced activation of PKC was demonstrated recently in
primary cultures of skeletal myotubes (29). In these studies, insulin stimulated Src PTK
activity which was blocked by PP-2 (29). Moreover, PP-2 also inhibited insulin-induced
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IR-f3 tyrosine phosphorylation as well as glucose uptake in these myotubes. In the case of
CHO-IR ceils, however, neither insulin - nor H202-induced IR-f3 subunit phosphorylation
was blocked by PP-2. Furthermore PP-2 was ineffective in inhibiting the increased
phosphorylation of ERK 1/2 and PKB induced by insulin (data not shown), whereas it
completely blocked the H202-evoked effect in these celis (Fig. 4), which suggested that
Src-PTK-dependent pathways in CHO-IR celis mediate the II2O2 response and not that of
insulin. Furtherrnore, in contrast to insulin. H202 treatment did not enhance IRS-1 tyrosine
phosphorylation but increased tyrosine phosphorylation of the p85 subunit of PI3K which
was sensitive to inhibition by PP-2. Src farnily PTK-catalyzed Tyr-6$$ phosphorylation of
p85 was recently shown to activate PI3K in COS celis (9). The fact that H202 induced PI3K
activation in these cells, and wortmaimin. a specific inhibitor of PI3K, blocked H202-
evoked activation of ERK 1/2 and PKB in these celis suggests that PI3K may be an
upstream intermediate in H202 signaling events.
Recent studies have shown that insulin-induced generation of H202 via NAD(P)H oxidase
activation serves as a trigger to initiate insulin signaling (22). In these experiments,
ablation of Nox-4, one of the subunits of NAD(P)H oxidase complex, resulted in
diminished F1202 production, associated with decreased tyrosine phosphorylation of IR- and
IRS-1 (22). The data indicated that endogenously-generated F1202 in response to I12O2 is
able to enhance IRS-1 phosphorylation in 3T3-L1 adipocytes (22), whereas the resuits with
CHO-IR ceils demonstrated that exogenous F1202 fails to modify IRS-1 phosphorylation
(fig. 3). Thus, it appears that the intracellular upstrearn targets of endogenously generated
and exogenously-added F1202 may be different.
The precise rnechanism by which H202 induces tyrosine phosphorylation of substrate
proteins remains obscure; however, its ability to inhibit the activities of rnany protein
tyrosine phosphatases (PTPases), such as PTPIB (12), and SHP-2 (25), bas been suggested
as a potential mechanisrn. PTPase inhibition by H202 is accomplished by oxidation of
catalytically-essential cysteine residue in the active site of PTPase (14); this inhibition
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shifis the equilibrium of the phosphorylation-dephosphorylation cycle, resulting in
increased tyrosyl phosphorylation of substrate proteins, such as Src, the IR-13 subunit and
the p85 subunit of PI3K. These tyrosyl-phosphorylated proteins prornote the assernbly of
signaling molecules responsible for activating various components of the mitogen-activated
protein kinase and PI3K signaling pathways.
In summary, our studies have demonstrated that H202-induced activation of ERK 1/2 and
PKB is associated with enhanced tyrosine phosphorylation of the IR-f3 subunit, the p85
subunit of PI3K and c-$rc in CHO-IR cells. We have also provided evidence of the
involvernent of both IR-PTK- and Src-PTK-dependent upstrearn rnechanisrns as mediators
ofthe F1202 response.
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5.6-FIGURE LEGENDS
Figure 1: H202-induced ERK1/2, PKB and GSK-3fl phospitorylation is tinte- and
dose-depeitdent in CHO-IR ceils
Confluent, serum-starved CHO-IR were incubated with different concentrations of H202
for 5 min (A) or with 1 mM H202 for the indicated time periodes (B). The celis were lysed
and the lysates were subjected to immunoblotting using phospho-specific (Tyr-204)-
ERK1/2 antibodies (upper immunoblot in A and B), phospho-specific (Ser 473)-PKB
antibodies (middle immunoblot in A and B) and phospho-specific (Ser 9)-GSK-3J3
antibodies (lower immunoblot in A and B). The resuits are representative of 3 independent
experiments.
Figure 2: H202-induced ERK 1/2 and PKB phosphorylation is partially dependent
on IR-PTK activity in (‘HO ceits
Confluent, serurn-starved CHO-IR and CHO-1018 celis were incubated in the absence or
presence of 0.1 nM insulin (Ins) (A) or with different concentrations of H202 (B) for 5 min.
The celis were lysed and the lysates were subjected to immunoblotting using phospho
specific (Tyr-204)-ERK1/2 antibodies (upper immunoblot in A and B) and phospho
specific (Ser 473)-PKB antibodies (lower immunoblot in A and B). The resuits are
representative of 3 independent experiments.
Figure 3: H202-induced tyrosine pitosphorylation of IR and p85 but ,,ot IRS-1 in
CHO-IR ceils
Confluent, serurn-starved CHO-IR ceils were incubated with 100 nM insulin (Ins) or with
1 mM 11202 for 5 min. The ceils were lysed, and equal amounts of total protein from the
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clarified lysates were subjected to immunoprecipitation with an antiphosphotyrosine
(PY99) antibody. The immunoprecipitates were immunoblotted with the indicated
antibodies. A representative immunoblot from 3 independent experiments is shown.
Figure 4: H202-induced ERK1/2 and PKB phosphorylation is tota!ly dependent on
Src-PTK activity in CHO-IR celis
Confluent, serum-starved CHO-IR celis were pretreated with or without 10 tM PP-2 or its
inactive analogue PP-3 for 30 mm, followed by incubation with 1 mM H202 or 100 nM
insulin (Ins) for 5 min. The celis were lysed and the lysates were subjected to
immunoblotting using phospho-specific (Tyr-204)-ERK 1/2 antibodies (upper
immunoblot), phospho-specific (Ser 473)-PKB antibodies (rniddle immunoblot) and
phospho-specific (Tyr-418)-Src antibodies (lower immunoblot). The results are
representative of 3 independent experiments.
Figure 5: H202-induced p85 pliospiiorylation and E1?K 1/2 and PKB phosphorylation
are dependent on Src-PTK aiid PI3K, respectively
Confluent, serum-starved CHO-IR cells were pretreated with 10 jiM PP-2 or its inactive
analogue PP-3 (A) or 100 nM wortmairnin (W) (B and C) for 30 mm, followed by
incubation with 1 mM H202 for 5 min. In (A). the cells were lysed, and equal amounts of
total protein from the clarified lysates were subjected to immunoprecipitation with
antiphosphotyrosine (PY99) antibody. The immunoprecipitates were immunoblotted with
IR antibodies (upper immunoblot) and p85 antibodies (lower immunoblot). In (B), the cells
were lysed, and the celi lysates were subjected to immunoprecipitation using p85Œ
antibodies. PI3K activity was measured in p8 immunoprecipitates with
phosphatidylinositol (PIP) as substrate, and [y-32P] ATP as phosphoryl group donor. The
anows mark the position of P13-P. In (C), the cells were lysed and the lysates were
subjected to immunoblotting using phospho-specific (Tyr-204)-ERK1/2 antibodies (upper
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immunoblot) and phospho-specific (Ser 473)-PKB antibodies (lower immunoblot). The
resuits are representative of 3 independent experirnents.
Abbreviations
CHO-IR, Chinese hamster ovary ceils overexpressing insulin receptor; ECL, enhanced
chemiluminescence; EGF, epidermal growth factor; ERK, extracellular signal-regulated
kinases; GSK, glycogen synthase kinase; H202, hydrogen peroxide; IR, insulin receptor;
IRS-1, insulin receptor substrate-1; PAGE, polyacrylamide gel electrophoresis; PI3K,
phosphatidylinositol 3-kinase; PKB, protein kinase B; PKŒ, protein kinase C-zeta; PTK,
protein tyrosine kinase; PTPases, protein tyrosine phosphatases; SDS, sodium dodecyl
sulfate; PP-2, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3 ,4-d]pyrimidine; PP-3, 4-
amino-7-phenylpyrazol [3 ,4-d]pyrirnidine; PY99, antiphosphotyrosine antibody.
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CHAPTER 6
GENERAL DISCUSSION
Vanadium was first demonstrated to have insulin-like effect properties in vitro in 1979 (34)
in adipocytes and hepatocytes and in vivo in 1985 (19). Since then, these findings were
followed up by several groups who confirmed and extended them to animal models of type
1 and type 2 diabetes mellitus as well as in humans (6$;240). The ability of vanadium
cornpounds to stimulate glucose uptake, glycogen and lipid synthesis in muscle, adipose
and hepatic tissues and to inhibit gluconeogenesis in the liver and kidney as well as
lipolysis in fat celis contribute as a potential mechanisrn for their anti-diabetic insulin-like
effects. At the cellular level, we have shown earlier that vanadium salts, sucb as VS and
NaOV mimic insulin and activate several key elements of the insulin signal transduction
pathway, such as the tyrosine phosphorylation of IRS-1, including P13-K, PKB and
Ras/MAPK.
6.1 POTENTIAL MECHANISM 0F VS AS INSULIN-ENHANCER AGENT
In sorne of in vivo studies, the glucose-lowering effect of vanadium was shown to be
dependent on the presence of endogenous insulin suggesting that vanadium does not act
completely independently in vivo, but augments tissue sensitivity to low levels of plasma
insulin (289). Moreover. in cell system, vanadate bas been shown to enhance insulin
induced effects. For example, in isolated cardiomyocytes from obese Zucker rats, VS in
combination with insulin potentiates insulin-induced glucose transport (290). In
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adipocytes, sodium orthovanadate bas also been reported to enhance and prolong insulin
stimulated activation ofIR and lipogenesis (291). In addition, in combination with insulin,
vanadium compounds prolong IR and IRS-1 phosphorylation in 32D mouse myeloid
progenitor ceils (292). However, the precise signaling steps by whicb vanadate enhances
and/or prolongs insulin action remains poorly characterized. Since insulin mediates its
physiological effects through P13-K and ERK1/2 pathways. therefore. in the studies
presented in chapter 2 (293). we investigated if vanadiurn-induced effects on insulin action
are correlated with an enhancement or prolongation in the activation state of ERK1/2 and
P13-K signaling system. Thus, treatment of CHO-HIR celis with VS prior to insulin
resulted in a sustained phosphoprylation of ERK1/2 and activity (293). Under these
conditions, VS treatment had no effect on a dual-specificity protein phosphatase MKP-1
which is capable to dephosphorylate ERK1/2. In addition to ERK1/2 pathway; these
studies have demonstrated that VS also prolonged the insulin-stimulated activation of P13-
K (293). Since P13-K activation requires association between P13-K via its p8 subunits
and phosporylated-IRS- 1, ouf results demonstrated that sustained P13-K activation by
insulin in VS-pretreated celis was due to prolonged association ofp8with IRS-1. Since
vanadate-induced ERKI/2 activation is inhibited by P13-K inhibitors and thus suggest an
upstream role of P13-K in the activation of ERK1/2 (87:247;248), we conclude that
prolongation of insulin-stimulated ERK1/2 phosphorylation could be the result of sustained
activation of PI3-K activity. Furthermore, we demonstrated in this study that the insulin
enhancer role of VS on ERKÏ/2 and P13-K activation was independent of any alteration on
the degree of the insulin-induced tyrosine phosphorylation of IR3 and IRS-1. Since
vanadium salts are potent inhibitors ofPTPases, it is possible that VS prolongs the duration
of insulin-induced ERK1/2 and P13-K activation through the inhibition of the
dephosphorylation of specific tyrosines in IR or IRS-1 or other proteins acting upstream of
P13-K in the insulin signaling pathway. One consequence of this effect could be the
sustained association of IRS-1 with p85 and P13-K activation. This data is confinned by
recent studies in which VS added to insulin-treated 3T3-L1 adipocytes did not alter the
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effect of insulin on stimulating IR or IRS-1 tyrosine phosphorylation while VS enhanced
insulin-induced glycogen synthesis (294). In contrast, vanadate was found to augment
insulin-stimulated IR-PTK activity in rat adipocytes (291) and insulin-increased tyrosine
phosphorylation of the insulin receptor and IRS-1 in cardiornyocytes (249) and in 32D
mouse myeloid progenitor cells (292). The reason of these discrepant resuits is not clear
but it could be due to the difference in the properties of celi unes used as well as the
concentration and time of exposure with vanadium used in each of these studies. Taken
together, our studies were the first to provide a molecular basis of the insulin-enhancer
action of VS which could be reflected by prolongation and enhancing in the insulin
increased ERK1/2 and P13-K activation responses. Since insulin signaling pathway is not
precisely elucidated, we can not rule out that VS could enhance insulin action through
additional putative mechanisms. Therefore, further work is needed to define the precise
mechanism by which VS potentiates insulin-induced signaling pathways.
6.2 MECHANISM 0F ACTION 0F ORGANO-VANADIUM COMPOUNDS
Since relatively higher doses of inorganic vanadium compounds were needed to elicit a
significant hypoglycemic response in diabetic models, it was feit, therefore, that the use of
vanadium compounds with increased lipophilicity might lower the effective doses of
vanadium needed to ameliorate hyperglycemia by improving gastrointestinal absorption.
Therefore, several organo-vanadium cornpounds (OVC) were synthesized by conjugating
vanadium element to organic ligand. These compounds were shown to be more potent than
inorganic compounds in lowering hyperglycemia and improving insulin resistance in rodent
models of diabetes mellitus (12-15;17;21;4$;57). OVC was also more potent than
inorganic vanadium in stimulating glucose transport (295), glycogen synthesis (296) as
welÏ as lipogenesis (297) in isolated cells. However, the molecular mechanism responsible
for the stronger insulinmimetic effect of OVC over inorganic cornpounds remains poorly
defined. Since our previous studies have found that inorganic vanadium compounds
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activate several key components ofthe insulin signaling cascade including P13-K, PKB and
ERK1/2, we have examined here the possibility that the insulinmimetic and antidiabetic
actions of OVC could be attributed to their ability to enhance the phosphorylation of PKB
and its downstream target GSK-3f3. Our resuits demonstrated that treatment of CHO-HIR
by VAC or BMOV, two OVC, increased PKB and GSK-3f3 phosphorylation to a higher
level than that detected in response to VS (298). As discussed above, P13-K bas been
shown to be an upstream regulator of the PKB signaling pathway in response to insulin or
inorganic vanadium compounds (90). Therefore, we investigated if OVC also activates
PKB phosphorylation through P13-K activity by using Wortmaimin as a pharmacological
P13-K inhibitor. We found that PKB and GSK-313 phosphorylation induced by OVC was
completely blocked by wortmaimin suggesting that OVC also increased PKB
phosphorylation through P13-K. PKB pathway bas been primordially irnplicated in the
regulation of carbohydrate metabolism in response to insulin, therefore we have speculated
that a more robust activation of PKB by OVC may explain their higher potency on
increasing glucose transport in adipocytes (295), GLUT-4 transiocation in diabetic rat
skeletal muscle ($0) as well as glucose utilization and storage (13;295;296). In addition, an
important role of GSK-3 13 in the regulation of PEPCK and G6Pases bas been shown (197)
and vanadium compounds have been reported to inhibit the heightened expression and/or
activity of PEPCK and G6Pase in several diabetic rat models (13;9$;104-109;299), thus it
could be possible that a greater potency of BMOV and VAC to induce GSK-313
phosphorylation may contribute to the correction of high PEPCK and G6Pase expression
level in the diabetic rat liver.
Since vanadium compounds are potent protein tyrosine phosphatase (PTPase) inhibitors
(236), the capacity of VAC, BMOV and VS on the inhibition of PIPase was also
measured. Interestingly, the OVC were stronger inhibitors of PTPase activity than VS
(29$). Furthermore, the higher PiPase inhibitory potential of the OVC was associated with
more robust tyrosine phosphorylation of several proteins, including the IRf3 and IRS- 1. In
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addition, OVC exerted high efficiency in complexing IRS-1 and p85 than VS. Since IRS
1/p85Œ association is an important step leading to activate P13-K, this data provide a
molecular basis for the high impact of the OVC in activating PKB phosphorylation.
Among the two OVC tested in our studies (29$), VAC has been shown to be more effective
than BMOV or VS in increasing insulin signaling system. These observations are
compatible with the idea that an upregulation of P13-K!PKB signaling may be responsible
for a potent effect of VAC in improving hyperglycernia and impaired hepatic
gluconeogensis and glycolysis of diabetic rats (13) as well as in increasing glucose
transport and lipogenesis in adipocytes (295;297). Our resuits on OVC-induced signaling
have recently been confirmed by Mustafi et al. who demonstrated that VAC is more potent
than VS in increasing PKB and GSK-3f3 phosphorylation in 3T3-L1 adipocytes in presence
or absence ofinsulin (296).
In summary, the present findings indicate that. as compared to VS. OVC are more potent
activators of PKB and GSK-313 phosphorylation. This response can be due to the higher
PTPase inhibitory potential of OVC resulting in an increased phosphorylation of key
tyrosine-phosphorylated substrates responsible to trigger the mechanism leading to
upregulation of the PKB signaling pathway and eventually contributing to a greater potency
of OVC in improving glucose homeostasis.
6.3 MECHANISM 0F BMOV-INDUCED PKB PHOSPHORYLATION
BMOV is the most studied OVC and its insulin-like and antidiabetic properties of BMOV
are well documented as discussed in chapter 1 and 3. However, the cellular mechanism of
its insulin-mimetic effect is largely unclear. In CHO-HIR cells, BMOV was shown to be a
potent activator of PKB and it was suggested that this might serve as a potential mechanisrn
for the insulinrnimetic and antidiabetic effect of this OVC (29$). We have also
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demonstrated that BMOV induced the tyrosine phosphorylation of IRf3 and its substrat IRS
Ï and increased the association between IRS-1 and p85 subunit ofPI3-K. Since IRS-l, P13-
K and PKB are downstream targets of rnany receptors-PTKs: we attempted to identify the
putative PTKs responsible for BMOV-induced effects on the activation of these signaling
intermediates in human hepatoma (HepG2) celis (Chapter 4). The first finding in these
studies was that BMOV, similarly to its effects on CHO-IR (298) activated PKB and GSK
313 phosphorylation as well as tyrosine phosphorylation of many proteins including 1R13,
IRS-1 and p subunit of P13-K in HepG2 ceils (Chapter 4). b investigate if IR is an
upstrearn PTK in mediating BMOV-induced phosphorylation ofPKB, we used two types of
CR0 ceils. the one overexpressing a normal IR (CH0-IR) and the other, overexpressing
PTK-inactive form of IR (CHO-1018). While insulin failed to activate PKB
phosphorylation in CHO-1018. BMOV increased PKB phosphorylation to same level in
both ccli unes. These data suggested that IR-PTK is not implicated in the phosphorylation
of PKB in response to BMOV. To examine the involvernent of other receptor-PTKs in the
BMOV response. we have utilized a series of well characterized and widely used inhibitors
of PTKs. Among these, AG1024. an IGF-1R13-PTK specific inhibitor (300), biocked the
phosphorylation of PKB by BMOV. In contrast, AG1478 and AG1295, inhibitors of
EGfR and PDGFR respectively, failed to change the activation of PKB in response to
BMOV. These data suggested that IGF-1R13 might play a role in BMOV action and
allowed us to examine in more detail the implication of the IGF- I R-PTK in this event. We
found that BMOV increased the tyrosine phosphorylation of IGf- I R13 and this cffect was
inhibited by AG1024. In addition, AG1024 aiso suppressed the tyrosine phosphorylation
of IRS-1 and p85 subunit of P13-K further supporting the invoivement of IGF-1R13 in
BMOV-induced PKB activation. Severai earlier studies have shown that IR-PTK is not
involved in mediating the effect of inorganic vanadium saits (238:301) and an increase in
the tyrosine phosphorylation of 1R13 in vanadium-mediated insulin-like effects was also flot
observed by several investigators (90:101:238). these studies have identified IGF-IR-PTK
as an upstream regulator ofPKB in response ofBMOV.
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In addition, these studies have also demonstrated that BMOV-induced PK3
phosphorylation was decreased by Rottlerin, a PKOE inhibitor, suggesting a role for this
PKC isoform in BMOV signaling towards PKB (Chapter 4). Since PKOE activity is
associated with increase in its tyrosine phosphorylation, we investigated the effect of
BMOV on the phosphorylation of total tyrosine and tyr3 11 of PKC& As speculated
BMOV increased both total tyrosine as well as tyr3 11 phosphorylation. This effect was
blocked by AG1024 pretreatrnent of HepG2 ceils indicating that IGF-IR signais through
PKC to activate PKB in resoponse to BMOV.
In sumrnary, our studies show that BMOV-induced activation of PKB signaling pathway in
HepG2 requires IGF-1R-PTK activity of and is independent ofIR, PDGFR and EGFR. In
addition, PKC appears to mediate PKB activation in response to BMOV with evidence of
an involvement of IGF-1 R as an upstrearn modulator of PKOE action in this response.
6.4 INVOLVEMENT 0F INSULIN RECEPTOR (IR)- AND C-SRC-PTK(S) IN THE
MECHANISM 0F ACTION 0F H202
Insulin has been shown to mediate its cellular signalling and action through reactive oxygen
species (ROS) generation such as F1202. Nox-4, a homologue catalytic subunit of NADPH
oxidase has been reported to be implicated in insulin-stirnulated H202 production.
Furthermore, treatment of cells with H202 lias been dernonstrated to mimic several
physiological effects of insulin including stimulation of glucose transport, glycogen
synthesis, lipogenesis as well as inhibition of lipolysis and PEPCK gene expression (302).
In addition, H202 has also been found to mediate its insulin-like cffects through activation
ofkey insulin signalling components such as 1R13, P13-KJPKB and ERK1/2. Furthermore,
an involvement of ROS in vanadium-induced responses has also been demonstrated (273-
275;277), and it was suggested that ROS generation by vanadium may serve as a potential
rnechanism for insulin-mimetic effects ofthese compounds.
1 O
I
Both H202 and vanadium have been sbown to inhibit the activities of different PiPases
which negatively regulates many PTKs including IR-PTK. Althougb the role of IR-PTK in
mediating vanadium-induced cellular events bas been extensively studied
(42;$7;90 101; 11 7;23 7;23 $ 303),tbe requirement of IR-PTK in H202—induced signalling
bas flot been characterized. Therefore. we investigated if IR-PTK was involved in H202-
evoked the activation of PKB and ERKI/2 pathways (304). We observed that H202
increased the phosphorylation of ERKI/2 and PKB in CHO-IR which was associated with
an increased in the tyrosine phosphorylation ofIRf3 and p85usubunit ofPI3-K. By using the
CHO-1018 celis that over express inactive form of IR. we found that H202-induced
ERK1/2 and PKB was partially reduced while it was intact in CHO celis with an active IR
PTK whicb suggested that IR-PTK contributes partially in increasing the phosphorylation
of PKB and ERKY/2. In contrast, the inhibition of the non receptor PTK c-Src by PP2, a
pharmacological inhibitor of c-Src. suppressed cornpletely H202-stirnulated ERK 1/2 and
PKB activation, whicb suggested that c-Src activity bas a more dominant role than IR in
mediating the J-1702 responses. Consequently. we investigated the effect of PP2 on other
components of insulin signalling pathway in response to H202. We demonstrated that c-Src
inhibition by PP2 completely suppressed H202-induced tyrosine pbosphorylation of pS5Œ
whereas it failed to decrease its effect on lRf3 phosphorylation suggesting that c-Src exerted
its effect upstream of 85a but downstream of IR. Cumulatively, these data suggested that
the activity ofboth IR as well as c-Src is required to maintain full activation ofERKI/2 and
PKB by H202.
Based on evidence that vanadium compounds induced the activation of PKB and ERKÏ/2
pathway in IR-PTK-independent manner (Chapter 4 and (301)) while FJ202 required at least
partially an active IR-PTK to induce this events, we suggest that vanadium compounds and
H202 exert insulin-like effects tbrough different rnechanism.
Conclusion and Perspectives
Overail, the work presented in this thesis (fig. 10) dernonstrates that vanadium-induced a
prolonged interaction between IRS-1 and p85 resulting in a sustained activation of ERKI/2
and P13-K could contribute as a potential rnechanism of VS as an enhancer of insulin
action. A more potent inhibition of protein tyrosine phosphatases (PTPases) by organo
vanadium compounds (OVC). resulting in a robust protein tyrosine phosphorylation of
many proteins. including key components of insulin signaling pathway, as well as strong
activation of P13-K/PKB, may be responsible for a higher efficacy of tbe OVC versus
inorganic vanadium saits as insulin-mimetic and antidiabetic agents. Furtber elaboration of
tbe mechanisrn of action of BMOV. an OVC. bas identified IGf-IR-PTK as an upstream
mediator in the signaling events leading to PKB phosphorylation by BMOV. Finally. we
bave demonstrated that J-1,02, another insulin-mimetic compound whicb is also generated in
response to vanadium, induced PKB phosphorylation through both IR- and c-Src-PTK
dependent pathway.
I believe that the resuits presented in this thesis have uncovered the mechanism(s) by which
inorganic and organic vanadium cornpounds elicit their insulin-enhancing and -mimetic
responses at the molecular level. hie discovery that IGf-IR serves as a mediator of
BMOV action is intriguing but requires further confirmation using IGF- 1 R deficient mice
celis. Moreover. since many phosphotyrosylated proteins are detected in OVC-treated ceils
it will be important to identify the proteins by using proteomics approaches. Identification
of these proteins will help to discover additional altemate new molecules involved in
insulin action and glucose homeostasis.
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Figure 10: A model summarizing mechanism of insulin-enhancing and mimetic of
vanadium compounds
The work presented in this thesis has demonstrated that a prolonged interaction of IRS
1/p85 in response to vanadyl sulfate (VS) resulted in a sustained activation of ERK1/2/P13-
K which might play an important role in enhancing the insulin action. We have also
demonstrated that as compared to inorganic vanadium saits, the organo-vanadium
compounds (OVC) are more potent inhibitors of protein tyrosine phospatases (PTPases)
and strong activators of P13-K/PKB signaling and thus may be responsible for a higher
efficacy of OVC in regulating glucose homeostasis in diabetic models. An important role
of IGF- 1 R activation as an upstream PTK to evoke BMOV-induced PKB phosphorylation
was also identified in these studies. Finally, we have also established that H202 another
insulin-mimetic agent which is also generated by vanadium utilized IR and c-Src-PTK to
initiate the P13-KIPKB and ERKÏ/2 activation. (Abbreviations are defined in the list of
abbreviations)
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IAnnexe
Figure I : Effect of diphenyliodonium chloride (DPI) on VAc-, BMOV- and VS
induced PKB phosphorylation in CHO-IR and HepG2 celis
‘- Figure II: Potential rnechanism of Vanadium-evoked ROS generation
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Figure I: Effect of diphenyliodonium chloride (DPI) on VAC-, BMOV- and VS
induced PKB phosphorylation in CHO-IR and HepG2 celis
Confluent, serum-starved CHO-IR ceils or HepG2 celis were incubated in the presence or
absence of 10tM DPI for 30 mm, followed by incubation with 1 mM of VAC, BMOV or
VS for 10 min. The celis were lysed, and the lysates were subjected to immunoblotting,
using phospho-specffic (Ser 473)-PKB antibody or total PKB antibody.
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of mitogen-activated protein kinases ERK 1/2
ami phosphatidylinositol 3-kinase by vanadyl sulfate, a protein
tyrosine phosphatase inhibitor
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Vanadium saits such as vanadyl sulfate (VS), potent inhibitors of protein tyrosine phosphatases, have been shown to mimic,
augment, and prolong insulin’s action. However, the molecular mechanism of responses to these saits is flot clear. In the present
studies, we examined if VS-induced effects on insulin action are associated with enhancement or augmentation in the activation state
ofkey components ofthe insulin signaling pathway. Treatment of insulin receptor-overexpressing ceils with insulin or VS resulted in
a time-dependent transient increase in phosphorylation and activation of extracellular signaÏ-regulated kinases I and 2 (ERK 1/2)that peaked at about 5 mm, then declined rapidly to about baseline within 30 min. However, when the ceils were treated with VSbefore stimulation with insulin, sustained ERK 1/2 phosphorylation and activation were observed well beyond 60 min. VS treatment
also prolongcd the insulin-stimulated activation of phosphatidylinositol 3-kinase (P13-K), which was associated with sustaincdinteraction between insulin receptor substrate-1 (IRS-1) and the p8 subunit ofphosphatidylinositol 3-kinase (P13-K) in response toinsulin. These data indicate that prolongation of insulin-stimulated FRK 1/2 and P13-K activation by VS is due to a more stable
complex formation of [RS-l with the p8 subunit which may, in turn, be responsible for its ability to enhance and extend thebiological effects of insulin.
© 2003 Elsevier Inc. Alt rights reserved.
Keviuords: Insuiin; Vanadium; Insulino-mimesis; Phosphatidyiinositoi 3-kinase; Mitogen-activated protein kinases; Protein tyrosine phosphatases
Insulin is the primary hormone involved in glucose
homeostasis. and an absolute or relative lack of its se
cretion or action leads to aberrant glucose metabolism
and diabetes. Insulin action is triggered by binding to its
receptor on the ceil membrane of target tissues. Insulin
binding to the Œ-subunit of the insulin receptor (IR) re
suits in conformational changes that activate intrinsic
protein tyrosine kinase (PTK) activity of the Ç3-subunit
by its autophosphorylation in multiple tyrosine residues
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[1.2]. Once activated, the IR can phosphorylate several
cytosolic insulin receptor substrates (IRSs) in tyrosine
residues. which function as docking proteins for src
homology 2 domain-containing signaling proteins
(reviewed in [31). These proteins include growth factor
receptor binder 2 (Grh-2)-rnammalian son of sevenless
(SOS) complex [4], with Grb-2 being growth factor
binding protein. SOS being a guanine nucleotide
exchange factor for guanosine triphosphate (GTP)
binding protein, and the 85-kDa regulatory subunit of
phosphatidylinositol 3-kinase (P13-K), a lipid and pro
tein kinase [5].
The IRS-associated complex initiates two signaling
pathways. In one pathway. binding of the Grb-2-SOS
complex to IRS-l leads to p2lras stimulation by GTP
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icading with subsequent activation cf Raf, mitogen-ac
tivated protein kinase kinase (MEK), and two isozymic
forms cf mitogen-activated protein kinase (MAPK),
44maPk (extraceliular signal-regulated kinase-l, ERK-1)
and p42maPk (ERK 2) [2,4]. Activated MAPK phos
phorylates and activates a downstream ribosomal pro
tein kinase, p90r [61.
Another pathway that radiates from the IRS com
piex upon insulin stimulation involves P13-K activation
[2]. P13-K phosphorylates phosphatidylinositol lipids at
the 3 position of the inositol ring and generates 3-
phosphorylated forms cf PI such as phosphatidylinosi
toi 3, 4, 5 (PIP3) [7], which are involved in the activation
of PIP3-dependent kinase (PDK) and related serine!
threonine protein kinases responsible for the plies
phorylation and stimulation of several downstream
signaling protein kinases such as protein kinase B(PKB), p7056k [8], protein kinase-zeta [9]. and gluco
corticoid-inducible kinase [10]. Activation cf these
serine!threonine protein kinases has been implicated in
many of the physiclogicai responses cf insulin at the
level cf glucose transport, glycogen synthesis, and
prctein synthesis [11—17].
Enhanced tyrosine phosphoryiaticn cf IR and IRSs is
critical for the initiation of insulin signaling, whereas
tyrosine dephosphorylation cf IR and its substrates can
attenuate and terminate insulin’s action (reviewed in
[18,19]). IR and IRS-1 dephosphcrylaticn is cataiyzed in
vitro by several protein tyrosine phosphatases (PTPases)
that consist cf cytoplasmic and transmembrane recep
tor-type PTPases [19]. A possible role cf PTPases in
insulin action and in the pathogenesis cf diabetes has
been postulated on the basis of studies showing that
vanadium-based or other small molecule inhibitors cf
PlPases can improve glucose homeostasis in rodent
models cf type I and II diabetes mellitus and in a small
number cf type 2 diabetic human subjects [20—23]. In
this regard, it is notewcrthy that the expression level of
PTPases lias been shown te be impaired in rodent
models cf type 1 and type 2 diabetes mellitus as well as
in human subjects [24- 27]. Further support for the in
volvernent of PTPase in insulin’s action cornes from
recent studies demonstrating that reduction cf the
PTPase PTP-IB, by using antisense oligonucleotides,
normalizes blcod glucose and imprcves insulin sensi
tivity in diabetic mice [281. In addition, the ability cf
vanadium salts, potent PTPase inhibitors, in lowering
hyperglycemia and improving insulin sensitivity in ani
mal models cf diabetes mellitus and in human subjects
[20.22,29] bas generated interest in expicring tlie
mclecutar mechanisms cf vanadium action.
We have shown earlier that vanadium saits, such as
sodium orthovanadate and vanadyl sulfate (VS), mimic
insulin and activate several key comporients, such as
P13-K and ras/MAPK, cf the insulin sigitaling pathway
[15,30—32]. Sodium orthovanadate lias aise been
reported to enhance and prolong insulin-stimulated
activation cf IR-PTK and lipogenesis in rat adipocytes
[33]. Hcwever, the precise signaling steps responsible for
these responses to vanadium remain pccrly character
ized. Therefore, in the present studies, we investigated if
the vanadiurn-induced eftects on insulin action are as
scciated with an enhancement or augmentation in the
activation state of ERK 1/2 and P13-K-twc key eiements
of the insulin signaling pathway.
Materials and methods
Iviateriats
Chinese hamster ovary ceils overexpressing human
insulin receptor (CHO-HIR celis) were a gift from Dr.
Morris f. White (Joslin Diabetes Center. Boston, MA).
Insulin was obtained from Eh Lilly (Indianapolis, IN),
VS was from Aldrich Chemical (Milwaukee. WI). and
polyclonal ERK-2 antibcdy. mcnoclonal antiphosp
hotyrosine antibody (4Gb), IR, and IRS-1 antibodies
were from Upstate Biotechnologv (Lake Placid, NY).
Phcspho-specific p44/p42 antibody was from New En-
gland BioLabs (Beverly, MA), prctein A—Sepharcse
beads were from Pharmacia Biotecli (Mississauga, Ont.,
Canada), and the enhanced chemiluminescense (ECL)
detecticn system kit was from Amersham—Pharmacia
Bictech (Baie d’Urfé, Que., Canada). MAPK phcspha
tase-1 (MKP-1) and p antibodies were purcliased from
Santa Cruz Biotech (Santa Cruz, CA). Silica gel-60
plates were obtained from Merck (Raliway, NI).
Methods
Ccli culture
Ceils were maintained in HAM’s F-12 medium ccn
taining 10% fetal bovine serum. They were grcwn to
confluence in 100 mm plates and incubated iii serum-free
F-12 medium fer 16h prior te the experiment [15].
ERK activit]’
ERK catalytic activity was measured as described
earlier [31]. Briefiy. ceils subjected to various experi
mental treatments were lysed in buffer A (25 mM Tris—
HC1, pH 7.5, 25mM NaCI. 1 mM Na ortliovanadate.
lOmM Na fluoride, lOmM Na pyrophosphate, 2OnM
okadaic acid, 0.5 mM ethylenebis-(cxyethylenenitrilc)
tetraacetic acid (EGTA). b mM phenylmethylsulfcnyl
flucride, 10Lg!rn1 aprotinin, and 1% Triton X-100, and
the lysates were clarified by centrifugation te remove
insoluble material. The clarified lysates. normalized te
contain equal amounts cf prctein (100 tg), were incu
bated for 4h at 4°C with 5ig ERK-2 antibcdy pre
adsorbed to protein A—Sepharose beads. The immune
ccmplex was collected by centriftigation, foilowed by
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washing three times with buffer A and once with buffer B
(20 mM Hepes (N-(2-hydroxyethyl) piperazine-N’-2-
ethanesulfonic acid), pH 7.4, lOmM MgCI2, 1 mM di
thiothreitol (DIT), and 10 mM 3-g1ycerophosphate).
and 40 .d of kinase buffer (25 mM Tris—HCI, pH 7.4,
10 mM MgCI2. 2 mM MnCI2, 1 mM DIT, I 1iM
staurosporine, 0.5mM EGTA, and 10t1 myehn basic
protein (MBP) (1 mg/ml)) was added. The reaction was
initiated by adding 51.tl of 1 mM adenosine 5-triphos-
phate (ATP)2 containing 0.5cCi [‘y-3P]ATP (specific
activity 3,000CiJmmol: Amersham). After l2min at
30°C, the reaction was stopped by spotting an aliquot
of the supernatant on P-81 filter paper. which was
washed in 0.5°/ phosphoric acid and cotmted for ra
dioactivity [301.
P13-K assav
The clarified celi lysates were subjected to immuno
precipitation with 2 .tg pS5Œ antibody for 2 h at 4 °C.
followed by incubation with protein A—Sepharose for an
additional 2 h. The immunoprecipitates were washed
and subjected to P13-K assay. as described earlier [15].
The phosphorylated Iipid products were extracted and
separated by ascending thin layer chromatography [15].
The radioactivity in the spots corresponding to P13-
phosphate was quantified by Phosphorlmager (Molec
ular Dynamics, Sunnyvale, CA).
lininunoprecipitalion
The clarified ceil lysates, normalized to contain equal
amounts of protein (500 fig), were subjected to immu
noprecipitation with 1 jtg IRS-1 antibody for 2h at 4°C.
followed by incubation with protein A—Sepharose for an
additional 2h. Immunoprecipitated IRS-1 vas collected
by centrifugation and washed two tirnes with buffer A
and once with phosphate-buffered saline. The IRS-1
immunoprecipitates were electrophoresed on 7.5% so
dium dodecyl sulfate—polyacrylamide gel electrophoresis
(SDS—PAGE) under reducing conditions, transferred to
PVDF membranes. and incubated with polyclonal p85°
antibody (1:4000) or a polyclonal IRS-1 antibody
(1:2000). Proteins were detected by a horseradish per-
2 Abbreviations used: ATP. adenosine 5-triphosphate; CHO-HIR.
Chinese hamster ovary ceils overexpressing human insulin receptor:
DPI. diphenylene iodonium; DIT. dithiothreitol: ECL. enhanced
chemiluminescence; EGTA, ethylenebis-(oxyethylenenitrilo)-tetraace
tic acid; ERK, extracellular signal-regulated kinases; Grb, growth
factor receptor binder; GTP. guanosme triphosphate: Hepes, N-(2-
hydroxyethyl)piperazine-N’-2-ethanesulfonic acid: IR, insulin receptor:
IRS- 1, insulin receptor substrate- 1; MAPK, mitogen-activated protein
kinase: MBP, myclin basic protein; MEK, MAPK kinase: MKP-l.
MAPK phosphatase-l; PAGE, polyacrylamide gel electrophoresis:
P13-K, phosphatidylinositol 3-kinase: PIK, protein tyrosine kinase;
PTPases, protein tyrosine phosphatases; ROS, reactive oxygen species:
SDS. sodium dodecyl sulfate; SOS. mammahan son of scvenless: VS.
vanadyl sulfate.
oxidase-conjugated second antibody and visualized with
an ECL detection kit [32].
Immiinoblotting
The clarified celi lysates normalized to contain equal
amounts of protein were electrophoresed on 12% SDS—
PAGE under reducing conditions, transferred to PVDf
membranes, and incubated with monoclonal anti
phosphotyrosine antibody (1:1000), a polyclonal phos
pho-specific p441p42 ERK 1/2 antibody (1:2000), a
polyclonal ERK 1/2 antibody (1:8000) or a polyclonal
MKP-I antibody (1:500), followed by incubation with a
horseradish peroxidase-conjugated second antibody.
The antigen—antibody complex was visualized with an
ECL detection kit. The immunoblots were quantified by
densitometric scanning using NIH Irnagel software [32].
IR ami IRS-] tyrosine phospiiorylation
The clarified lysates, normalized to contain equal
amounts of protein. were pre-cleared with protein A—
Sepharose for 30 min and incubated with either IR or
IRS-1 antibody for 4h at 4°C. Immunoprecipitates were
collected w’ith protein A—Sepharose and washed 3 times
with 5OmM Hepes buffer, pH 7.5, containing 0.1%
Triton X-100 and 0.1% SDS. and two times with the
above buffer without SDS. The immunoprecipitate vas
solubilized by boiling in 2x sample buffer for lOmin,
electrophoresed on 10% SDS—polyacrylamide gels, and
immunoblotted with antiphosphotyrosine antibody
(1:1000) [151. The blots were visualized with an ECL
detection system [32].
Resuits and discussion
FfJct of VS on insu/in-stimulated ERK 1/2 activation
E.RK 1/2 activation constitutes a key step in the in
sulin signaling pathway [2], we first examined if VS can
prolong the ellèct of insulin on this signaling compo
nent. Therefore. insulin receptor over-expressing CHO
HIR ceils were used in these studies, and the activation
status of ERK 1/2 was assessed with a phospho-specific
antibody of ERK 1/2. This antibody reacts with only
phosphorylated (Thr202 and Tyr204) and activated
forms of ERK 1/2.
As shown in Fig. lA. treatment of CHO-HIR celis
with 100 nM insulin resulted in transient activation of
ERK 1/2. asjudged by enhanced phosphorylation. ERK
1/2 phosphorylation vas rapid peaking at Srnin and
declining to just above baseline at 15 mm, with almost
complete dephosphorylation in 2h. A similar transient
increase in ERK 1/2 phosphorylation was seen in CHO
HIR ceils stimulated with 100 !.LM VS, except that the
intetisity of phosphorylation was slightly Iower than in
insulin-stimulated celis, and a second phase ofenhanced
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fig. 1. VS delays Éhe dephosphorylalion ofERK I and ERK 2 in insulin-stimulated ceils. Confluent. sertim-starved CHO-HIR celis were incubated
with lOOnM insulin (A), 1009M VS (B) or 1001.sM VS for I5min followcd by lOOnM insulin (C) for the indicated times. The cells were lyscd andlysates were subjected to immunobtotting using phospho-specific (1hr202/Tyr204)-ERK 1/2 antibodies (upper immunoblot) or total ERK 1/2 (lowerimmunoblot). The arrows indicate the position of phosphorvlated. p-ERK 1/2 or total ERK 1)2. The bottom panel shows the densitometricquantification of phospho-FRK 1/2 bands. The results are representative of thrce independent experiments and are expressed as a percentage of the
maximum.
phosphorylation was detected at 2 h (Fig. lB). However.
when the celis were pretreated with 100 1tM VS for
15 min prior to stimulation with 100 nM insulin, a rise in
ERK 1/2 phesphorylation vas evident as early as 1 min
after the addition of insulin, with a peak at 2min
(Fig. 1C), In these ceils, the level of ERK 1/2 phos
phorylation declined slightly at 15 min. but was restored
te just below peak levels at the 30- te 120-min time
points (Fig. 1C). It is noteworthy that at ail the time
points tested, the magnitude cf ERK 1/2 phosphoryla
tien was significantly more robust than that observed
with either insulin (Fig. lA) or VS alone (Fig. lB). The
reason for this biphasic response remains unexplained at
this moment and would require additional work. As
shown in the bottom panel cf the immunoblots, none of
the experimental conditions altered the total amount of
ERK 1/2.
In contrast te CHO-HIR ceils. the effect cf vanadate
on ERK 1/2 phosphorylatien and activation in rat
adipocytes was net transient but remained sustained for
up to 20 min [34]. In these studies however, no attempts
were made te investigate if at later time points this re
sponse was modified [34]. Furthermore, vanadate did
net exert any enhancing effect on insulin-stimulated
ERK 1/2 activation in adipecytes during the 20 min time
period cf the study [34]. The reason fer these discrep
ancies is net clear but it may be possible that vanadium
exerts a celi-type specific response.
Te determine if the pattern cf ERK 1/2 phosphory
latien ebserved in the experiments described above
correlated with the catalytic phesphekinase activity ef
ERKs, lysates prepared from ceils stimulated fer the
sanie time periods with insulin. VS and VS followed by
insulin were assayed using MBP as exegeneus substrate
[30]. As seen in Fig. 2, similar to the effect on ERK 1/2
phospherylation, ERK 1/2 catalytic activity in respense
te insulin, VS as well as VS plus instilin (VS followed by
insulin treatment) peaked at 5 min. then declined te just
abeve baseline in insttlin- and VS-stimulated ceils
(Fig. 2A and B). It is netewerthy that in VS-stimulated
celis. there was a graduai recovery after 60 min which
reached about 80% cf peak stimulation at 2h (Fig. 2B).
This recevery cf ERK 1/2 activation correlated with the
second phase cf enhanced ERK 1/2 phespherylatien in
response te VS (Fig. lB). Thus, in contrast te insulin,
VS exhibited a second phase cf ERK 1/2 phespheryla
tien and activation. The reason for this second phase cf
activation is net clear but may be attributed te the
generatien cf peroxevanadium due te the production cf
reactive oxygen species (ROS). Vanadyl is known te
react spontaneously with oxygen te generate superoxide
anion (O). a ROS [35] leading te the formation cf
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Fig. 2. VS prolongs the duration of insulin-induced ERK 1/2 activation. Confluent, serum-starved CHO-HIR celis were incubated with 100nMinsulin (A), 100 tM VS (B) or 100 0M VS for 15 min followed by t00nM insulin (C) for the indicated times. The celis were lysed and lvsates were
analyzed for the phosphokinase activity of ERKs using MBP as exogenous substrate. Parallel samples were analyzed by immunoblotting ta de-termine the total amount of ERK 112 and a representative blot is shown in the bottom panel. The resuits are mcans± SE from three separate experiments and are expressed as a percentage of the maximum.
peroxovanadyl complexes [36]. We have tested a po
tential role of ROS generation in VS action by utilizing
diphenylene iodonium (DPI), an inhibitor of NADPH
oxidase and ROS scavenger. Pretreatment of celis with
DPI prior to stimulation with VS and insulin was found
to attenuate ERK 1)2 phosphorylation (data not
shown). Recent studies have demonstrated that ROS
generation plays a critical role in activation of the in
sulin signaling pathway [37]. Therefore. it is possible
that increased ROS generation after long incubation
with VS might be responsible for the second phase of
ERK 1/2 phosphorylation.
In VS + insulin-treated celis, the decline in ERK 1/2
catalytic activity was minimal (about lO%), and this le
vel of activation (about 80—90% of the peak value) was
sustained for up to 2h of incubation (Fig. 2C). On the
other hand, the level of ERK 1/2 activation in celfs
stimulated with insulin only declined after 15 min and
remained at about baseline (f ig. 2A). Thus, pretreat
ment of celis with VS prolonged the duration of ERK
1/2 activation in response to insulin.
Effect of insulin on MKF-1 expression
MKP-l is a dual specificity phosphatase which dep
hosphorylates MAPK at both the tyrosine and threo
une residues necessary for ERK 1/2 activation of
[38,39]. Stimulation of fibroblasts overexpressing the
human insulin receptor by insulin has been shown to
increase MKP-1 mRNA and protein levels, resulting in
the attenuation of MAPK activity [40,41]. Therefore, we
investigated if VS was exerting its effect by altering
MKP-1 expression in CHO-HIR celis. As shown in
Fig. 3A, MKP-1 protein expression was detectable even
in unstirnulated ceils, and this level of expression was
not changed significantly by insulin treatment up to
60 min. A similar pattern of MKP-1 protein expression
was detected in cells treated with VS followed by insulin
(Fig. 3B). It thus appears that alteration in MKP-l ex
pression may not contribute to the observed effects of
VS on sustained ERK 1/2 phosphorylation in CHO
HIR cells by insulin. Since MKP-1 expression in re
sponse to insutin is transcriptionally regulated f40]. we
sought to determine if blocking MKP-1 transcription by
actinomycin-D, an inhibitor of RNA synthesis, would
modify the ERK 1/2 phosphorylation pattern in
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Fig. 3, MKP-1 levels are flot modified by insulin or vs plus insulin.
Confluent, serum-starved CHO-HIR cells were incubated with tOOnM
insulin (A) or 100 pM VS for 15 min followed by 100 nM insulin (B) for
the indicated times. The ceils were lysed and the lysates were subjected
to immunoblotting using MKP-1 antibody. A representative immu
noblot from three independent experiments is shown.
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response to either insulin alone or VS plus insulin. Ac
tinomycin-D pretreatment, however, did not affect the
time course of ERK 1/2 phosphorylation (data flot
shown). A similar result was observed with cyclohexi
mide, a protein synthesis inhibitor (data flot shown).
These resuits suggest that the rapid decline in ERK 1/2
phosphorylation by insulin was flot transcriptionally or
translationally regulated. In addition, our earlier studies
demonstrated that the effect of VS on ERK 1/2 phos
phorylation was mediated by activation of MEK. which
is an upstream kinase responsible for phosphorylating
the threonine and tyrosine residues of ERK 1/2 [321.
Thus, it appears that in CHO-HIR ceils. the outcome of
VS on ERK 1/2 phosphorylation and activation is
achieved by enhanced MEK phosphorylation and flot
by inhibiting its dephosphorylation by MKP-1. This
notion is supported by the studies in which VS or
vanadate was found to enhance MEK activation in
CHO-HIR cells [321 and MEK phosphorylation in rat
adipocytes [34].
Ejjèct of VS on insulin-stirnutated P13-K activation
We have shown earlier that VS-induced stimulation
of ERK 1/2 phosphorylation and activation is flot due
to decreased ERK 1/2 dephosphorylation, but is medi
ated by sequential stimulation of elements upstream of
the ERK 1/2 activation cascade [321. VS or vanadate has
also been found to stimulate P13-K activity in CHO
HIR celis [321 and in adipocytes [34,42,43] and the use of
P13-K inhibitors has indicated that P13-K is an up
stream regulator of the ERK 1/2 activation cascade in
these ceils [32]. We, therefore, investigated if prolonga
tion of insulin-stimulated ERK 1/2 activation by VS is
associated with sustained activation of P13-K activity.
P13-K activity in celis treated for various tirne periods
with insulin, VS and VS followed by insulin was mea
sured in p85 immunoprecipitates from cell lysates [32].
As shown in fig. 4A, insulin-stimulated P13-K activity
in a time-dependent manner. P13-K activation peaked
within I min ofexposure ofcelts to insulin and gradually
declined to just above baseline at 30 min. This low level
of activity was maintained for up to 120 min. A similar
pattern of P13-K activation in response to VS was ob
served except that the peak was detected only after 5 min
of treatrnent of celis with VS and was slightly Iess robust
as compared to insulin alone (Fig. 4B). Furthermore,
VS-induced activation of P13-K was biphasic. declining
to just above baseline at 30 min but showing reactivation
at 60 and 120 min of incubation (Fig. 43). It should be
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Fig. 4 VS prolongs the duration of insulin-induced activation of phosphatidylinositol 3-kinase (P13-K). Confluent. serum-starved CHO-H1R cells
were incubated with 100 nM insulin (A), 100 9M VS (B) or 100 9M •VS for 15 min followed by 100 nM insulin (C) for the indicated times. The ceils
were lysed and the ccli lysates were subjected to immunoprecipitation using pt5’ antibodies. P13-K activity was measured in p8’ immunoprecipitates
with phosphatidylinositol (PI) as substrate and [y-32P]ATP as phosphoryl group donor. The arrow marks the position ofPl3-P. ParaHel samples were
analyzed by immunoblotting to determine the total amount of p85 and a representative blot is shown in the middle panel. Tise resuits are repre
sentative of three separate experiments and are expressed as a percentage of the maximum.
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noted that the biphasic impact of VS on P13-K activa
tion was similar to its effect on ERK 1/2 phosphoryla
tion and activation (Figs. 13 and 23). In contrast to the
transient action of insulin, and the biphasic outcome of
VS. analysis of P13-K activity in celis treated with VS
prior to stimulation with insulin revealed that VS pre
treatment prolonged the duration of insulin action and
resulted in sustained P13-K activation (Fig. 4C). The
prolongation of insulin-stimulated P13-K activation by
VS (Fig. 4C) correlated well with the effect of VS on
insulin-induced ERK 1/2 phosphorylation and activa
tion (figs. IC and 2C). However, one notable difference
was that despite a sustained activation of P13-K ob
served in VS plus insulin-treated cells. ERK 1/2 phos
phorylation still declined slightly at 15 min (Fig. lC).
The precise reason for this decline is flot clear but may
be attributed to its rapid dephosphorylation by ERK
1/2-specific PTPases other than MKP-l. Alternatively a
potential role of a P13-K-independent pathway in this
response may be suggested however. it should be noted
that pharmacological inhibition of P13-K activity lias
been shown to completely abrogate ERK 1/2 activation
and phosphorylation induced by insulin and VS [32.34].
Ejj’ect of VS on insztlin—induced association of p8 it’ith
IRS-]
Since P13-K activation requires association of its pt5Œ
regulatory subunit with IRS-l. we next determined if the
sustained P13-K activation by insulin in VS-pretreated
cetis was due to a prolonged association of p8 with
IRS-1. As shown in Fig. 5A, insulin induced an increase
in the association of IRS-l with p855 within Smin of
treatment, which peaked at 15 min and then decreased
to almost basal levels within 60 min. Similar to insulin.
treatment of celis witli VS alone resulted in complex
formation between p85 and IRS-1 which peaked at
5min (Fig. 53). However, as compared to insulin trea
ted celis, in VS treated cells. the magnitude 0f p85/IRS-1
association was tess and, a biphasic effect was observed,
i.e., a slight decline in p$Sa/IRS_l association at 15 min
followed by an enhancement in pSSŒ binding to IRS-1 at
30 and 60 min (Fig. 53). On the other hand, in celis
pretreated with VS, insulin-induced association of p85
with IRS-l was sustained for up to 60 min (Fig. 5C).
Thus, it is possible that the pssa/IRS1 complex is more
stable in the presence of VS and contributes to prolon
gation of P13-K activity by insulin (Fig. 4C).
Effect of VS on insuhn—stimulated ivrosine phosphoryla—
tion of IR and IRS-]
Since the insulin response is mediated through en
hancement in the tytosine phosphorylation of IR and
IRS-l [2,7], we examined the effect of VS on insulin
stimulated tyrosine phosphorylation of IR and IRS-1.
Insulin treatment of cells resulted in a rapid increase in
phosphotyrosine content of IR (Fig. 6A) and IRS-l
1 joie fun’
Fig. 5. vs prolongs the duration ofinsulin-induced binding ofp85 [o IRS-l. Confluent. serum-starved CHO-HIR cells were incubated with lO0nM
insulin alone (A), 100 )IfvI VS (B) or 100 aM VS for 15 min followed by lOOnM insulin (C) for [lie indicated times, The ceils were lysed and equal
amounts of clarified lysates were subjected to immunoprecipitation using IRS-1 antibodies. IRS-) immunoprecipitates (1P) were immunoblotted (lB)
with either anti- p55 (upper panel) (1:4000) or with IRS-1 antibody (middle panel) (1:1000). The bottom panel shows the densitometric quantification
ofp55 hound to IRS-1. Vhs results are representative of three independent experiments and are expressed as fold increase over control (Omin) which
was arbitrarily set at 1.0.
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(Fig. 6C). Maximum IR and IRS-l phosphorylation was
detected within 1 min of insulin stimulation and this
level did flot change significantly (Fig. 6) for up to
120 min. It is interesting that the decline in ERK 1/2 and
P13-K activation observed in insulin-stimulated ceils at
15 min (Figs. lA, 2A and 4A) was not associated with a
similar decrease in the tyrosine phosphorylation of ei
ther IR or IRS-1 (Fig. 6). In fact, at this time point, the
global tyrosine phosphorylation of IR or IRS-1 was
almost the same as that occurring at 1 min after insulin
stimulation. Thus, it appears that enhanced tyrosine
phosphorylation of IR and IRS-1 is critical for initiating
the insulin signal, but may flot have a significant mie in
regulating the duration of the response. Since VS pre
treatment of celis pfior to stimulation with insulin failed
to alter the global tyrosine phosphorylation status of IR(Fig. 63) or IRS-1 (Fig. 6D) while prolonging the du-
ration of insulin-induced ERK 1/2 and P13-K activa
tion, it is possible that VS exerts these effects by
inhibiting the dephosphorylation of specific phospho
tyrosines in IR or IRS-1 or other proteins acting up
stream of P13-K in the instilin signaling pathway. One
consequence of this eftct is the sustained association of
IRS-1 with the pt subunit and P13-K activation. In
contrast to the work presented here, vanadate was found
to augment insulin-stimulated IR-PTK activity in rat
adipocytes [33]. The reason for this discrepancy is flot
clear but it is possible that IR overexpressing ceils me
spond differently than normal adipocytes. Further work
is needed to define the precise mechanism by which VS
modifies insulin-induced signaling pathways.
In summary, an important finding of the present study
is that VS. a PTPase inhibitor and insulinomimetic agent.
increased the magnitude and duration of insulin-stimu
lated ERK 1/2 and P13-K activation. This effect otVS on
insulin response was associated with an enhanced inter
action of IRS-1 with the p85a subunit of P13-K which
appeared to be responsible for a sustained activation of
P13-K. Since P13-K activation bas been implicated in in
sulin-induced activation of glucose transport and lipo
genesis, the resuits of the present investigation provide a
mechanistic basis for the observed augmentation of in-
sulin-induced lipogenesis [33] and glucose transport [44]
by vanadate. Taken together, the present work provides
first evidence suggesting that prolonged activation of
ERK 1/2 and P13-K, key components of the insulin sig
naling pathway, contributes to the molecular mechanism
of the insulin-enhancing effect of this vanadium.
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Organo-vanadium compounds (OVC) have been shown to be more effective than inorganic vanadium compounds in ametiorating glucose homeostasis and insulin resistance in rodent models of diabetes mellitus. However. the precise molecular mechanism ofOVC emciency rcmains poor[y defined. Since inorganic vanadium compounds have been found to activate several key components
ofthe insulin signaling cascade, such as protein kinase B (PKB), the objective of the present study was to investigate if stimulation ofPKB and its downstream target glycogen synthase kinase-3 (GSK-3), are responsible for the more potent insulinomimetic effects ofOVC. Among several vanadium compounds tested, vanadium (1V) oxo bis (acetylacetonate) and vanadium (IV) oxo bis(maltolato)
markedly induced the phosphorylation ofPKB as weIl as GSK-3)3 compared to vanadyl sulfate (VS), an inorganic vanadium salts inChinese hamster ovary cells overexpressing the insulin receptor (IR). furthermore, the OVC were stronger inhibitors ofprotein tyro
sine phosphatase (PTPase) activity than VS. The higher PTPase inhibitory potential of the OVC was associated with more robusttyrosine phosphorylation of several cellular proteins, inctuding the IRL3 subunit and insulin receptor substrate-I (IRS-1). In addition,greater IRS-1/p55 interaction was elicited by the OVC than by VS. These data indicate that the higher PTPase inhibitory potential ofOVC translates into greater phosphorylation of PKB and GSK-3, which. in turn. may contribute to a more potent effect of OVC onglucose homeostasis.
© 2005 Elsevier Inc. Alt rights reserved.
Keywards: Diabetes; Insulin; Vanadium: Protein kinase B: Pratem tyrosine phosphatase
Compounds of the trace elernent vanadium have been
demonstrated to exert a variety of insulin-like effects in
in vitro and in vivo systems [1]. including their ability to
improve glucose homeostasis and insulin resistance in
animal models of diabetes mellitus [l—3]. In addition,
several reports have documented vanadium therapy
induced improvements in liver and muscle insulin sensi
tivity in a number of type II diabetic human subjects
[4—8]. Vanadium compounds have also been shown to
Correspondingauthor. Fax: +15144127152.
E-mail address: (A.K. Srivastava).
stimulate glucose uptake [9—11], glycogen synthesis
[9.12—15], and lipid synthesis [16.17] in muscle, adipose,
and hepatic tissues. They inhibit gluconeogenesis, the
activities of the gluconeogenic enzymes phosphoenol
pyruvate carboxykinase (PEPCK) and glucose-6-phos-
phatase (G6Pase) in the liver and kidneys [9,18—20]
as well as lipolysis [17.21] in fat celis. At the cellular
level, vanadium activates key elements of the insulin
signaling system: tyrosine phosphorylation of insulin
receptor substrate-I tIRS-1) [22] and activation ofpath
ways sucli as extracellular signaf-regulated kinase
(ERKÏ/2) [23,24], phosphatidylinositol 3-kinase (P13-K)
0003-9861/8 - sec front matter © 2005 Elsevier Inc. AIl tights reserved.
doi: 10.101 61j.abb.2005.06.008
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[22,25], and protein kinase B (PKB)1 [23,26]. These effects
are believed to be secondary to its ability to inhibit pro
tein tyrosine phosphatase (PTPase) activity [27].
PKB plays a critical role in insulin-induced glucose
transport, glycogen synthesis, proliferation. and ccli sur
vival [28]. It is phosphorylated on serine 473 and threo
fine 30$ residues by P13-K-dependent kinase [28,29]
resulting in its full activation. Activated PKB phosphor
ylates several downstream targets, such as glycogen syn
thase kinase-3 3 (GSK-33) and forkhead transcription
factor (FKHR). GSK-3 is phosphorylated by PKB on
serine 9, and this phosphorylation leads to the inhibition
of its catalytic activity [30]. GSK-3f3 plays an important
role in the regulation of glycogen synthesis and regulates
gluconeogenesis by altering the gene expression of
PEPCK and G6Pase [31]. Vanadium treatment has been
found to decrease the heightened expression and/or
activity ofPEPCK and G6Pase in isolated ceils as well as
in diabetic rats [18—20,32,33]. Recent studies have
revealed that in comparison to inorganic vanadium com
pounds, such as vanadyl sulfate (VS). sodium metavana
date (NaMV), and sodium orthovanadate (NaOV),
organo-vanadium complexes (OVC) of vanadium such
as vanadium (IV) oxo bis (acetylacetonate) (VAC) and
vanadium (1V) 0x0 bis(maltolato) (BMOV) are more
potent in lowering blood glucose in rodent models of
diabetes mellitus [18,34,35]. However, the molecular
mechanism responsible for the stronger insulinomimetic
effect of OVC over inorganic vanadium saits remains
unknown. Therefore, the aim ofthe present study was to
investigate if the insulinomirnetic and antidiabetic
actions of OVC could be attributed to their abiiity to
enhance PKB and GSK-313 phosphorylation.
Materials and mcthods
Maieriols
Chinese hamster ovary cells overexpressing human
insulin receptor (CHO-HIR ceils) were a generous gift
Abbreviations used. PKB. protein kinase B: BMO’, vanadium (IV)
oxo bis(maholato); Crdipic, chromium (III) bis(2,6-pyridinecarboxy-
late); Co2dipic, cobalt (II) bis(2,6-pyridinecarboxylate) heptahydrate:
CHO-HIR, Chinese hamster ovary ceils overexpressing human insulin
receptor; ECL. enhanced chemiluminescence: fKHR, forkhead tran
scription factor; GSK-3, glycogen synthase kinase-3; G6Pase. glucose
6-phosphatase; HircA, rat 1 flbroblast overexpressing human insulin
receptor and PTPIB; IR, insulin receptor; IRS-1, insulin receptor sub
strate-1; NaMV, sodium metavanadate; NaOV, sodium orthovana
date: OVC, organo-vanadium compounds: PEPCK,
phosphoenolpyruvate carboxykinase: Pt3-K, phosphatidvlinositol 3-
kinase; PTK, protein tyrosine kinase; PTPase. protein tyrosine phos
phatase; PTPIB, protein tyrosine phosphatase-IB; PY99, monoclonal
antiphosplsotyrosine antibody; SDS—PAGE, sodium dodecyl sulfate—
polyacrylamide gel electrophoresis; SIZ, streptozotocin; VAC. vanadi
um (IV) oxo bis (acetylacetonate); VS. vanadyl sulfate.
from Dr. Morris F. White (Joslin Diabetes Center. Bos
ton, MA). Insulin was from Lii Lilly (Indianapolis, IN),
VS. NaOV, and NaMV were from Aldrich Chemical
(Mifwaukee, WI), and the OVC were kindly donated by
Dr. Debbie Crans (Colorado State University, Fort Col
lins, CO). Polyclonal insulin receptor f3 (IRf3) subunit anti
body, monoclonal antiphosphotyrosine antibody (PY99),
polycional phospho-GSK-3f3 (5cr9) antibody. and poly
clonai GSK-3f3 antibody were purchased from Santa Cruz
Biotech (Santa Cruz. CA). Polyclonal phospho-PKB
(Ser473) and polyclonal PKB antibody were from Ccli Sig
nahng (Beveriy, MA). Polyclonal IRS-1 antibody and
polyclonai p8 antibody were from Upstate Biotechnol
ogy (Lake Placid, NY). The enhanced chemiluminescence
(ECL) detection system kit was from Amersham Pharma
cia Biotech (Baie d’Urfé, Quebec, Canada).
Methods
Ceil culture
CHO-HIR cells were maintained in Ham’s F-12
medium containing 10% fetal bovine serum, and rat I
fibroblast overexpressing HIR and protein tyrosine
phosphatase lB (PTP1B) cells (HircA) were maintained
in DMEM—F-i2 medium containing l0% fetal bovine
serum. The ceils were grown to confluence in 60-mm
plates and incubated in serum-free medium for 16h
prior to the experiment [23].
Inumuzoblo tring
Cells subjected to various experimental treatments
were lysed in buflèr A (25 mM Tris—HCI, pH 7.5, 25mM
NaC1, imM NaOV, lOmM Na fluoride, iOmM Na
pyrophosphate, 20 nM okadaic acid. 0.5 mM ethylenebis
(oxyethylenenitrilo) tetraacetic acid. 1 mM phenylmethyl
sulfonyl fluoride, l0tg/ml aprotinin, and 1% Triton
X-100), with the lysates being clarified by centrifugation
to remove insoluble material. The clarifled ccli lysates
normalized to contain equal amounts of protein were
subjected to 7.5 or 10% sodium dodecyl sulfate—polyaciyl
amide gel electrophoresis (SDS—PAGE) under reducing
conditions, transferred to PVDF membranes, and md
bated with the indicated antibodies. Proteins were
detected by a horseradish peroxidase-conjugated second
antibody and visualized with an ECL detection kit [23].
Immun oprecip irai ion
The cÏarified ccli lysates, normalized to contain equal
amounts of protein (500 g). were imtnunoprecipitated
with 31g of IRS-1 or IRf3 antibody overnight at 4°C, fol
lowed by incubation with protein A—Sepharose for 2h.
Immunoprecipitated IRS-i or IRf3 vas collected by cen
trifugation, washed two times with buflèr A and once with
phosphate-buffered saline containing PTPase and prote
ase inhibitors. The immunoprecipitates were submitted to
7.5% SDS--PAGE under reducing conditions. transferred
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to PVDF membranes. and incubated with polyclonal p
antibody (1:4000) or PY99 (1:2000). Proteins were
detected by a horseradish peroxidase-conjugated second
antibody and visualized with an ECL detection kit.
PTFase activity
Confluent, serum-starved HircA ceils were incubated
with I mM of vanadium compounds for 10 min. The celis
were lysed in buffer A without NaOV and equal amounts
of the clarifled lysates were assayed for total PTPase activ
ity as described elsewhere [36]. Briefly, lysates adjusted to
contain the same amount of proteins were added to
PTPase assay buffer containing 40 mM NaOAcIHC1, pH
5.00, 1 mM ethylenediammetetraacetic acid, 1 mM DIT,
and 25mM p-nitrophenyl phosphate. Phosphatase reac
tion was carried out for 10 min at room temperature and
stopped by the addition of 0.2M NaOH. The amount of
product (p-nitrophenol) produced was measured by moni
toring the increase in absorbance at 405 nm optical den
sity. The non-enzymatic hydrolysis of p-nitrophenol
phosphate was corrected by measuring the increase in
absorbance at 405 nm in the absence of enzyme.
Resuits
fJfect of different organic aizd inorganic vanadium
compounds on PKB phosphon’laiion
b evaluate the potency of diflèrent vanadium com
pounds on PKB phosphorylation, CHO-HIR ceils were
treated with I mM of two OVC, VAC or BMOV or three
inorganic vanadium compounds VS. NaMV or NaOV.
PKB phosphorviation was measured by using a phospho
specific PKB antibody which detects only the phosphory
lated and active form of PKB. As shown in Fig. 1, the
OVC BMOV and VAC were more potent than VS in
enhancing PKB phosphorylation. In fact, the phosphory
lation induced by VAC was virtually equipotent to that
elicited by lOOnM insulin. However, other vanadium
compounds or compounds of other metals such as Cr and
Co failed to exert any effect on PKB phosphorylation.
b further compare the relative abilities of the most
active vanadium compounds VAC. BMOV. and VS on
PKB phosphorviation. dose—response analysis was per
forrned. As shown in Fig. 2A, VAC was more potent than
either BMOV or VS in stimulating PKB phosphorylation
and caused a robust increase at 100 iM concentration.
Effect of dtffi?renl concentrcttions oJ VAC, BMOV, and
VS on GSK-3fl phosphorylation
Since PKB elicits its response through the phosphory
lation ofseveral downstream targets such as GSK-33 [29],
we investigated if vanadium compounds exerted any effect
on the phosphorylation of this substrate. To test this pos
I — — I <— p-PKB
< PKB
Fig. 1. Vanadium compound-induced PKB phosphorylation in CHO
HIR ceils. Confluent, serum-starved CHO-HIR ceils were incubatcd
with 100 nM of insu! in for 5 min or I mM of different vanadium com
pounds or compounds of other metals for 10 min. The ce!! lysates were
subjected to immunoblotting using phospho-specific (Ser 473)-PKB
(upper immunoblot) or total PKB antibody (lower immunoblot) as
described in Materials and methods. The resuits are representative of
three independent experiments. VAC. vanadium (1V) 0x0 bis (acetyl
acetonate): VS. vanadvl sulfate; BMOV. vanadium (IV) oxo
bis(ma!tolato); Crdipic, chromium (III) bis(2.6-pyridinecarboxyy!ate):
NaMV, sodium metavanadate; NaOV, sodium orthovanadatc; Co2di-
pic, cobalt (II) bis(2,6-pyridinecarboxy!atc) heptahydrate.
VAC BMOV VS
0 100 1,000 100 1,000 100 1,000 (j1Vl)
A j
- .4— p-PKB
— — .
—. —
PKB
t ] 4— p-GSK-3f3
4—GSK-3
Fig. 2. VAC-, BMOV-, and VS-induced PKB phosphorylation is dose
dependent in CHO-HIR cells. Confluent, serum-starved CHO-HIR
cefis were incubated with the indicated concentrations of VAC.
BMOV or VS for 10 min. Ihe cells wcre lysed and the lysates were sub
jected to immunoblotting using phospho-specific (Ser 473)-PKB anti
body (tipper immunoblot in A), total PKB antibody (!ower
immunoblot in A). phospho-specific (5cr 9)-GSK-33 (upper immuno
blot in B) and total GSK-313 antibody (lower immunoblot in B). The
results are representative of three independent experiments.
sibility. lysates prepared from celis stimuiated with diflèr
ent concentrations of VAC or BMOV and VS for 10 min
were immunoblotted using phospho-specific antibodies
for GSK-39. As shown in Fig. 2B, ail the vanadium
compounds at the two concentrations increased the phos
phorylation of GSK-3. However. as was the case with
PKB phosphorylation, VAC was the most potent com
pound and was severai fold more efficient than BMOV or
VS. At 100 iM, VAC was about two times more effective
thon BMOV and about four times stronger than VS in
enhancing GSK-3j3 phosphorylation.
Ejfect of Wortmannin on VA C-, BMO V-, and V$-inditced
p/iosphori’lation of PKB cmd GSK-3/3
P13-K is an upstream regulator of the PKB signahng
pathway in response to insulin [28.29]. Iherefore, by
,F /
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using Wortmannin as a pharmacological P13-K inhibi
tor [37] we investigated if P13-K plays a role in vana
dium compound-induced PKB and GSK-313
phosphorylation. As shown in f ig. 3, Wortmannin pre
treatment resulted in almost complete attenuation of
insulin. as well as vanadium-induced PKB and GSK-313
phosphorylation.
Effeci of VA C, BMO V, ami VS on PTPase actieity ami
protein tyrosine phosphorylation
Vanadium compounds are potent PTPase inhibitors
[1,27,38]. Therefore, we wished to examine if the higher
capacity of VAC and BMOV vs VS on PKB and GSK-3f3
phosphorylation is reflected in their ability to differen
tially inhibit PTPase activity. As shown in Fig. 4A, treat
ment offlircA ceils overexpressing PTP1B with VAC or
BMOV resulted in 50% inhibition, whereas VS caused
only 20% inhibition of total PTPase activity. Next. we
examined if the higher potency ofOVC to inhibit PiPase
activity correlated with their ability to increase the tyro
sine phosphorylation of cellular proteins. As shown in
Fig. 4B, treatrnent of CHO-HIR with 1 mM of different
vanadium compounds augmented the tyrosine phosphor
ylation of several proteins with varying degrees. The
molecular sizes of these proteins ranged from 60 to
200 kDa. However, phosphorylation of protein was more
robust with VAC than with either BMOV or VS.
Effect of VA C, BMO V and VS on IRfi and IRS-1
phosphorylation
Since the tyrosyl phosphorylation of 1R13 is an early
step in the insulin signaling cascade, we wished to deter
mine if vanadium compounds enhanced the tyrosine
phosphorylation of 1RJ3. As shown in Fig. 5A, IR3
immunoprecipitation from CHO-HIR treated with
1 mM of VAC, BMOV. and VS or lOOnM of insulin.
ii ii F
Fig. 4. VAC and BMOV are more potent than VS in inhibiting VfPase
activity and in enhandng tyrosine phosphotyIation. Confluent. serum
starved HircA (A) or CHO-HIR (B) ceils were incubated with I mM of
VAC, BMOV or VS for 10 min. The celis were lysed and the lysates were
subjected to measure PTPase activity as described in Matenals and meth
ods (A) or to immunoblotting. using antiphosphotyrosine untibody (PY99)
(B). lise resuits are representative of three independent experiments.
followed by immunoblotting with phosphotyrosine anti
body, revealed that both VAC and BMOV induced an
increase in tyrosyl phosphorylation of IR. However,
—
— —
— +- PKB
—
‘.
4—GSK-3J3
Fig. 3. VAC-. BMOV-. and VS-induced PKB and GSK-3fl phospisorylation is dependent on P13-K activits. Confluent, serumstarved CHO-IR ceils
were incubated in the presence or absence of iOOnM Wortmannin for 3flmin, followed by incubation with IOOnM oC insuhn for 5min or I mM of
VAC, BMOV or VS for 10 min. Tite ceils were iysed and the lysates were subjected to immunoblotting, using pisospho-specific (Ser 473)-PKB anti
body (upper immunoblot in A), total PKB antibody (Iower immunoblot in (A)), phosplso.spcciflc (Ser 9)-GSK-3p (upper immunoblot in (B)), and
total GSK-3f3 antibody (Iower immunoblot in (B)). The resuits are representative of three independent experinsents.
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Fig. 5. VAC and BMOV are mote potent than VS in enhancing the tyrosine phosphorylation of 1R13. IRS-1. and IRS-1/p85 association. Confluent.
sensm-starved CHO-HIR celis were incubated with 100 nM insulin for 5 min or with 1 mM of VAC, BMOV or VS for 10 min. The ceils were Iysed and
equal amounts of total protein from the clarified lysates were subjected to immunoprecipitation (IP) with an anti-IRl (A) or IRS-1 (B) antibody. Theimmunoprecipitates were immunoblotted (lB) with the indicated antibodies. A representative immunoblot from three independent experiments is shown.
under similar conditions, VS was ineffective and failed to
enhance IRE3 phosphorylation. We next assessed the
effect of diffcrent vanadium cornpounds on the tyrosine
phosphorylation of IRS-I. As shown in fig. 5B, insulin
as weIi as ail vanadium compounds enhanced IRS-f
tyrosine phosphorylation to varying degrees. BMOV
and VAC-induced IRS-t tyrosine phosphorylation was
identical to their effects on lRp phosphorylation. VS
which was unable to cause any detectable increase in
1R3 tyrosine phosphorylation aiso enhanced IRS-1
phosphorylation, however, this was several times lower
than that elicited by BMOV or VAC. Since P13-K acti
vation requires the association of its p8 regulatory sub
unit with the tyrosyl phosphoryiated form of IRS-1, we
next investigated the degree of association of p8 with
IRS-i in cdils treated with various vanadium com
pounds. As shown in Fig. 5B. ail the agents tested
enhanced the association of p8° with IRS-i, but insulin
induced the highest level of association between IRS-I
and p8. which was foflowed by VAC, BMOV, and VS
with decreasrng order of potency. This degree of associa
tion is consistent with the levei of IRS-1 as weil as PKB
phosphoryiation achieved in response to insulin and
vanaditim compounds.
Discussion
In the current study, we have demonstrated that OVC
are more potent than inorganic forms of vanadium in
activating key components of the insulin signaling path
n way. The OVC VAC and BMOV were more efficientthan VS in stimulating PKB activity which was associ
ated with an increase in GSK-313 phosphorylation. Our
resuits also show that VVortmannin, a P13-K inhibitor,
decreased insulin- and vanadate-induced PKB and
GSK3-13 phosphorylation (Fig. 5). suggesting that P13-K
is an upstream component in vanadium-induced PKB
and GSK-3f3 phosphorylation events. Aithough it is weli
known that OVC are more potent than inorganic vana
dium saits in improving giucose homeostasis in animai
models of insulin resistance [18.34,35,39,40], the precise
mechanism of this effect is unknown. Since activation of
the PKB signaling system is believed to play a key foie in
mediating the metabohc responses of insulin [28], to the
best of our knowledge, our data are the first to provide a
moiecular basis for the higher efficacy of OVC in
improving glucose homeostasis compared to inorganic
vanadium salts. More robust activation of PKB may
also be responsible for several fold higher glucose trans
port observed in adipocytes in response to VAC [41] as
weli as the increased GLUT-4 transiocation in strepto
zotocin (STZ)-diabetic rat skeietal muscle in vivo [42].
GSK-33 has been suggested to play an important role in
decreasing the activity of glycogen synthase by catalyz
ing its serine phosphorylation [43] but PKB-induced
phosphorylation of GSK-3!3 renders it inactive and
ailows the full activation ofgiycogen synthase [43J. Thus,
the OVC-induced robust enhancement ofGSK-313 phos
phorylation observed in our study could serve as a
potential mechanism for a more potent effect of these
compounds on glucose utilization and storage seen in
BMOV- and VAC-trcated rodent modeis [18.41].
GSK-3t3 has been impiicated in reguiating the gene
expression of the key gluconeogenic enzymes PEPCK
and G6Pase [28.29.31]. Vanadium compounds have aiso
been shown to inhibit the heightened expression and/or
activity of PEPCK and G6Pase in several diabetic rat
B
iR
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LP:IRS-l I IB:IRS-1
IP: IRS4 I tBtp
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models [18—20.33,44.45]. Thus, it is possible that a
greater ability of BMOV and VAC to induce GSK-3J3
phosphorylation may contribute to the normalization of
exaggerated PEPCK and G6Pase expression in the STZ
diabetic rat liver [20].
Our data also indicated that treatment of intact ceils
with OVC inhibited the activity of cellular PTPase more
potently than VS. These data are in agreement with
recent studies in which BMOV was reported to be a non
selective competitive inhibitor of several PlPases in vitro
[39,40.46]. PlPases play an important role in the regula
tion of insulin signaling [47,48], and it was shown
recently that mice deficient in PTPIB, a cytoplasmic
PTPase, exhibit increased insulin sensitivity with resis
tance to weight gain, even when put on a higli-fat diet
[491 Moreover, several studies have documented an
overexpression of PlPases in diabetes (reviewed in [47J).
and BMOV treatment inhibits exaggerated PTP1B activ
ity in the skeÏetal muscle of Zucker fatty rats, a model of
insulin resistance [461. Since enhanced tyrosine phos
phorylation caused by both protein tyrosine kinase
(PTK) activation and/or PTPase inhibition is primordial
in triggering the insulin signaling cascade, it is possible
that more potent inhibition of PTPase by OVC contrib
utes to a heightened tyrosine phosphorylation of IR
and IRS-1 by both VAC and BMOV. In confirmation
with our data BMOV was recently shown to enhance the
tyrosine phosphorylation of IR3 [39.40]. In addition, the
OVC were superior to VS in augmenting the tyrosine
phosphorylation of the IRS-1 and tRS-1/p8 associa
tion which might provide a molecular basis for the high
impact of these compounds in activating PKB phos
phorylation.
In summary, our results demonstrate that, compared
to VS. OVC are more potent activators of PKB and
GSK-313 phosphorylation in a P13-K-dependent man
ner. A greater rnhibitory effect of OVC on PTPases and
increased protein tyrosine phosphorylation might serve
as triggering mechanisms, leading to upregulation of
the PKB signaling pathway and eventually contribut
ing to a greater potency of OVC in improving glucose
h om eo stasi s.
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ABsTn.cr: Vanadium(IV) oxo-bis(maltolato) (BMOV), an organovanadium compound, is a potent
insulinomimetic agent and improves glucose horneostasis in various models of diabetes. We have shown
previously that BMOV stimulates the phosphorylation of PKB which may contribute as one of the
mechanisms for the insulinomimetic effect of this compound. However, the upstream mechanism of BMOV
induced PKB phosphorylation remains elusive. Therefore, in this study, we examine the upstream events
leading to BMOV-induced PKB phosphoiylation in HepG2 celis. Since BMOV is an inhibitor ofprotein
tyrosine phosphatases and through enhanced tyrosine phosphorylation may activate various protein tyrosine
kinases (PTK), we have investigated the potential role of different receptor or nonreceptor PTK in mediating
BMOV-induced PKE phosphorylation. Among several pharmacological inhibitors that were tested, only
AG1024, a selective inhibitor of IGF-lR-PTK, almost cornpletely blocked BMOV-stimulated phospho
rylation ofPKB. In contrast, AG1295 and AG1478, specific inhibitors ofPDGFR and EGFR, respectively,
were unable to block the BMOV response. Moreover, efficient reduction of the level of IGF-1R protein
expression by antisense oligonucleotides (ASO) attenuated BMOV-induced PKB phosphorylation. BMOV
induced PKB phosphoiylation was associated with an increased level of tyrosine phosphorylation of the
IRj3 subunit, IGF-1R]3 subunit, IRS-l, and p85° subunit of P13-kinase. However, this response was
independent ofIR-PTK activity because in celis overexpressing a PTK-inactive form ofIR, insulin response
was attenuated while the effect of BMOV remained intact. A role of PKC in 3MOV-induced response
was also tested. Pharmacological inhibition with chelerythrine, a nonselective PKC inhibitor, or rottlerin,
a PKCÔ inhibitor, as well as chronic treatment with PMA attenuated BMOV-induced PKB phosphotylation.
In contrast, GO6976 and R03 l-$220 PKCŒ//3 selective inhibitors failed to alter the BMOV effect. Taken
together, these data suggest that IGf-1R and PKCÔ are required to stimulate PKB phosphorylation in
response to BMOV in HepG2 celis and provide new insights into the molecular mechanism by which this
31 compound exerts its insulinomimetic effects.
32 Vanadium is a transition metal, and its compounds have
33 been shown to exert insulin-like properties in both in vivo
34 and in vitro systems (reviewed in ref 1). Oral administration
35 of vanadium leads to improved insulin resistance and lowers
36 the incidence ofhyperglycemia in rodent models ofdiabetes
37 mellitus as well as in limited studies with human subjects
38 (reviewed in ref 1). Vanadium mimics rnany physiotogical
39 effects of insulin, including stimulation of glucose uptake,
40 glycogen synthesis, and tipid synthesis in muscle, adipose,
41 and hepatic tissues as well as inhibition of gluconeogenesis
42 in the liver and kidneys and lipolysis in fat ceils (I). In
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cultured celis, vanadium activates several keys components
of the insulin signaling cascade implicated in mediating the
physiological responses of insulin, including the tyrosine
phosphoiylation ofthe insulin receptor substrate (IRS—1)’ (2,
3) and activation of extracellular signal-regulated kinase
(ERK1/2) (4) and the phosphatidylinositol 3-kinase (P13-
K)/protein kinase B (PKB) signaling cascade (2—4).
PKB, also known as Akt, is a 57 kDa serine/threonine
kinase which has been implicated in the regulation ofmany
physiological processes such as glucose transport, glycolysis,
Abbreviations: BMOV, vanadiurn(IV) oxo-bis(maltolato); CHO
HIR, Chinese hamster ovary cclls overexpressing human insulin
receptor; ECL, enhanced chemiluminescence; EGFR, epidermal growth
factor receptor; GSK-3, glycogen synthase kinase-3; IGF-IR, insulin
like growth factor type 1 receptor; IR, insulin receptor; IRS-1, insulin
receptor substrate-1; PDGFR, platelet-derived growth factor receptor;
P13-K, phosphatidylinositol 3-kinase; PKB, protein kinase B; PKCÔ,
protein kinase Cô; PMA, phorbol-l2-myristate-13-acetate; PTK, protein
tyrosine kinase; PTPase, protein tyrosine phosphatase; PY99, mono
clonal antiphosphotyrosine antibody; SDS—PAGE, sodium dodecyl
sulfate—polyacrylamide gel electrophoresis; VS, vanadyl sulfate.
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53 protein synthesis, lipogenesis, glycogen synthesis, suppres
54 sion of gluconeogenesis, ceil survival, determination of ceil
55 size, and celi-cycle progression (reviewed in ref 5). In most
56 ccli types, PKB is activated via a P13-K-dependent mecha
57 nism through dual phosphorylation of serine 473 in the
58 C-terminal regulatory region and threonine 308 within the
59 catalytic loop. Phosphorylation of PKB at Thr 308 is
60 catalyzed by phosphatidylinositol 3,4,5-triphosphate (PIP3)-
61 dependent protein kinase 1 (PDK-l), but the kinase respon
62 sible for phosphorylation at Ser 473, the putative PDK-2,
63 remains elusive (5, 6). Activated PKB exerts its effect
64 through the phosphorylation of several downstream targets,
65 such as glycogen synthase kinase-3 3 (GSK-33), forkhead
66 transcription factor (FKHR), Bcl-2-associated death promoter
67 (BAD), 1kB kinase, Mdm2, caspase 9, and endothelial nitric
68 oxide synthase (eNOS) (reviewed in refs 5 and 6).
69 Recently, we have demonstrated that organovanadium
70 compounds are more potent than inorganic vanadium salts
71 in inhibiting the total protein tyrosine phosphatase (PTPase)
72 activity and in increasing the level of total protein tyrosine
73 phospho:ylation which was associated with a robust activa-
74 tion of the PKB pathway (3). A much higher potency of
75 organovanadium compounds, compared to that of inorganic
76 vanadium salts, in enhancing the phosphoiylation of PKB
77 and its downstream substrates has been suggested as one of
78 the mechanism to explain their greater antidiabetic effects
79 (7—9). We have also shown that vanadium(IV) oxo-bis
80 (maltolato) (BMOV), a well-established antidiabetic and
81 insulinmimetic organovanadium compound (10—13), en-
82 hanced the tyrosine phosphorylation of the fi-subunit of the
83 insulin receptor (IRfl) in Chinese hamster ovary cells
84 overexpressing IR (CHO-IR) (3), suggesting the involvement
85 of IR-protein tyrosine kinase (PTK) activity in provoking
86 the BMOV response. However, the clear involvement of W-
87 PTK as an upstream inducer of vanadium action has not been
88 established, and a role ofboth IR-PTK-dependent (14—16)
89 and -independent (2, 17—20) events has been suggested to
90 contribute to the insulin-like effects of vanadium. Therefore,
91 in these studies, we have investigated a potential role of
92 receptor PTKs in BMOV-induced PKB phosphorylation in
93 human hepatoma (HepG2) celis.
94 MATERIALS AND METHODS
Materials
Insulin was from Eh Lilly Co. (Indianapolis, IN). Vana
dium(IV) oxo-bis(maltolato) (BMOV) was a kind gifi from
D. Crans (Colorado State University, Fort Collins, CO).
Phorbol- 1 2-myristate- 1 3-acetate (PMA) and luciferase/lu
ciferin were from Sigma Aldrich (St. Louis, MO). HepG2
cells (HB-8065) were obtained from American Type Culture
Collection (Rockville, MD). Human IGF-1 was from Pep
roTech Inc. Epidermal growth factor (EGF), platelet growth
factor receptor (PDGF), and ah phanTiacological inhibitors
were from Calbiochem (La Jolla, CA). Polyclonal insulin
receptor-/3 subunit antibody, polyclonal insulin-hike growth
factor type I receptor-fl subunit antibody, monoclonal
antiphosphotyrosine antibody (PY99), polyclonal phospho
GSK-3/3 (Scr°) antibody, polyclonal PKCÔ antibody, and
polyclonal GSK-3fl antibody were purchased from Santa
Cruz Biotech (Santa Cruz, CA). Polyclonal phospho-PKB
(Ser473), polyclonal PKB, and monoclonal phospho-insulin
like growth factor type I receptor (Tyr’131)/phospho-insulin
receptor (Tyr’ 146) antibodies were from CeIl Signaling
(Beverly, MA). Polyclonal insulin receptor substrate and
polyclonal p85 antibodies were from Upstate (Lake Placid,
NY). Phospho-PKCÔ (Tyr 311) antibody and phospho
insulin-hike growth factor type I receptor (Tyr 1131/1135/
I I36)/phospho-insulin receptor (Tyr 1158/1162/1163) were
from Biosource (Camarillo, CA). Protein A-Sepharose beads
and the enhanced chemiluminescense (ECL) detection system
kit were from Amersham Pharmacia Biotech (Baie d’Urfé,
PQ). Lipofectamine and all cdl culture materials were from
Invitrogen Corp. (Grand Island, NY).
Methods 125
CeIl Culture. HepG2 cells wcre maintained in DMEM
containing 10% fetal bovine serum. Chinese hamster ovary
ceils overexpressing either wild-type human insulin receptor
(CHO-IR) or the PTK mutant form (CHO- 1018), a gifi from
M. F. White (Boston Children’s Hospital, Boston, MA), were
maintained in HAM’s F-12 medium containing 10% fetal
bovine scrum. They were grown to 80—90% confluence in
100 mm plates or 60 mm plates at 37 °C in a humidified
atmosphere of 5% C02. Prior to the experiment, cells were
incubated in semm-free medium for 20 h (3).
Transfection with Oligonucleotides. HepG2 cells were
cultured in a cohlagen-coated Petri dish ovemight. The
following day, cells were transfected with either IGF-1R
antisense oligonucheotides (CGGCTTCTCCTCCATGGTCC)
or scrambled oligonucieotides (TCTTCCGCGACTTGCTC
CGC) using hipofectamine according to the manufacturer’s
instructions. Forty-eight hours after post-transfection, cehis
were semm staiwed ovemight followed by stimulation with
BMOV. Incubation was terminated by quickly washing the
celis in cold PBS. Phosphorothioate oligonucleotides (21)
were synthesized by Invitrogen Corp.
Immunoblotting. Ceils subjected to various experimental
treatmcnts were lysed in buffer A [25 mM Tris-HC1 (pH
7.5), 25 mM NaCI, 1 mM sodium orthovanadate, 10 mM
sodium fluoride, 10 mM sodium pyrophosphate, 20 nM
okadaic acid, 0.5 mM ethylenebis(oxyethylenenitrilo)
tetraacetic acid (EGTA), 1 mM phenylmethanesulfonyl
fluoride (PMSF), 10ug/mL aprotinin, and 1% Triton X-1001,
and the lysates were ciarified by centriffigation to remove
insoluble materiai. The clarified cdl lysates normalized to
contain equal amounts of protein were electrophoresed via
7.5 or 10% SDS—PAGE under reducing conditions, trans
ferred to PVDF membranes, and incubated with the indicated
antibody. Proteins were detected by a horseradish peroxidase
conjugated second antibody and visuahized with an ECL
detection kit (3). In some cases, cells were directhy iysed in
sampie buffer containing /3-mercaptoethanol followed by
Western blot analysis. The immunobhots were quantified by
densitometric scanning using NIH ImageJ.
hnonmopreciitation. The clarified cdl lysates, normahized
to contain equal amounts ofprotein (500 jtg), were subjected
to immunoprecipitation with 2 tg of various antibodies
ovemight at 4 °C, followed by incubation with protein
A-Sepharose for 2 h. Immunoprecipitated proteins were
collected by centriffigation and washed two times with buffer
A and once with phosphate-buffered saline (PBS) containing
PTPase and protcase inhibitors. The immunoprecipitates were
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electrophoresed via 7.5% SDS—PAGE under reducing
conditions, transferred to PVDF membranes, and incubated
with the respective primary antibodies. Proteins were detected
with a horseradish peroxidase-conjugated second antibody
and visualized with an ECL detection kit (3).
Measurement ofthe Leuel oflntracellular A T?. The ATP
levels was measured according to the procedure described
previousty (22) with mïnor modifications. HepG2 celis
cultured in six-well plates were treated with increasing
concentrations ofrottlerin for 30 min. The celis were washed
twice with cold PBS and lysed in a 0.1 M NaOH/0.5 mM
EDTA mixture. Ceil tysates were incubated at 60 oc for 20
min and frozen at —20 °C. The ATP levels was measured
by adding 10 uL of the lysates to 50 L of the luciferin!
luciferase assay mix and measuring the light output for 15 s
in a luminometer (Tumer Designs). A standard curve was
also constmcted by using serial dilutions of ATP (from 10
nM to 1 tM).
Statistics. Statistical analysis was performed by one-way,
repeated measures analysis of variance (ANOVA), followed
by a Newman-Keuls post-test. AIl data are reported as means
± the standard error. The dïfferences between means were
considered significant when P < 0.05.
EJjct of3MO Von PKB and GSK-3/3 Phosphoiylation in
HepG2 CelIs. Our previous studies have demonstrated that
organovanadium compounds such as BMOV are more potent
activators of the PKB pathway than inorganic vanadium
compounds in CHO-IR cells (3). Therefore, in these studies,
we have first evaluated whether BMOV alters the activation
of PKB and its downstream targets such as GSK-3/3 in
HepG2 cells which has been used as a model to investigate
insulin action in liver (23). Since enhanced phosphorylation
ofspecific serine/threonine residues ofboth PKB and GSK
3j3 is critical for their activation state, we have utilized
phospho-specific antibodies to monitor their activity. As
shown in Figure lA, treatment ofRepG2 ceils for 15 min
with escalating concentrations ofBMOV enhanced PKB and
GSK-3/3 phosphorylation in a dose-dependent manner.
BMOV elicited a robust phosphorylation ofthese two kinases
at 1 mM. Next, we assessed the time dependence of the 1
mM BMOV response; as shown in Figure 13, 1 mM BMOV
enhanced the phosphorylation of PKB and GSK-3t3 within
10 min which reached a maximum in 30 min.
EJJèct of BMOV on Tyrosine Phosptioiylation of Total
Protein, Insiitin Receptor (IR), IRS-], and p in HepG2
Cetls. Since BMOV is a potent inhibitor ofPTPases, and an
increase in the level of tyrosyl phosphorylation of several
key proteins such as W and IRS-1 is an early step in
triggering the insulin signaling cascade, we determined the
effect of BMOV on tyrosine phosphorylation of the total
proteins as well as on the phosphorylation of 1Rj3, IRS-1,
and p85, the regulatory subunit ofPI3-K in HepG2 ceils. As
illustrated in panels A and B of Figure 2, BMOV enhanced
the tyrosine phosphorylation of several proteins in a dose
and time-dependent fashion. The molecular size of these
proteins ranged between 35 and 200 kDa, and the increase
in the level of phosphorylation caused by BMOV could be
detected within 10 min oftreatment (Figure 2B). To further
analyze if some of these proteins were IR and its phospho
B
— — — — E— PKB
- .— —. == i,-GSK-3P
= z GSK-33
BMOVtndn) I) 5 10 15 0 60 120
— — •——
— — — — — — ‘a.- PKB
::E zp-GSK-3
::1;: . = :*: :=GSK-3p
FIGuRE 1: BMOV-induced PKB and GSK-313 phosphorylation is
time- and dose-dependent in HepG2 celis. Confluent, semm-starved
HepG2 ceils were incubated with different concentrations ofBMOV
for 15 min (A) or with I mM BMOV for the indicated time periods
(B). The celis were lysed, and the lysates were subjected to
immunoblotting using phospho-specific (Ser 473) PKB antibodies
(top immunoblot in panels A and B) and phospho-specific (Ser 9)
GSK-3/3 antibodies (bottom immunoblot in panels A and B). The
resuits are representative of three independent experiments.
tyrosyl-protein substrates, immunoprecipitates from BMOV- 233
treated celis were immunoblotted with antibodies to IR, IRS- 234
1, and p85. As shown in figure 2C, BMOV treatment resutted 235
in a significant increase in the level of phosphorylation of 236
1R3, IRS-1, and p85. To ftirther confiml the identity ofthese 237
proteins, 1R43 or IRS-1 was immunoprecipitated from the 238
lysates of the ceils stimulated with or without BMOV 239
followed by immunoblotting with anti-phosphotyrosine 240
antibodies. As shown in Figure 2D, a similar enhancement 241
of IRfl and IRS-1 tyrosine phosphorylation was observed 242
under these conditions. 243
Rote ofIR-PTK on 3MO V-Induced PKB Phosphotytation. 244
BMOV-induced enhanced tyrosine phosphorylation of IR/3 245
suggested a possible role of IR-PTK in BMOV-induced 246
effects on PKB phosphorylation. This possibility was probed 217
further by utitizing CR0 ceils that overexpress an inactive 248
form of IR-PTK (CHO-lOl 8). The inactivation of IR-PTK 249
in these ceils was achieved by the mutation of lysine 101$ 250
to alanine in the ATP-binding domain of IR (24). As 251
illustrated in f igure 3, both insulin and BMOV enhanced 252
the phosphoiylation ofPKB in CHO-IR ceils overexpressing 253
a normal IR. However, in CHO- 101$ celis overexpressing 254
PTK-inactive IR, the level ofinsulin-induced phosphorylation 255
of PKB was significantly reduced, whereas the BMOV- 256
evoked increase was flot affected. These data suggested that 257
in contrast to insulin, BMOV-induced phosphorylation of 258
PKB was independent of IR-PTK activity. 259
EJject ofReceptor Tyrosine Kinase Inhibitors on 3MO V- 2GO
Induced PKB. A potential role of epidermal growth factor 261
receptor (EGFR) transactivation in vanadyt sulfate (VS)- 262
induced signating has been demonstrated (25, 26), and 263
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264 insuhn-hke growth factor type I receptor (IGF-1R) activation
265 has also been thought to play a role in vasoactive peptide
266 induced signaling (27, 28). Therefore, we determined if IGF
267 1R, EGfR, or platelet growth factor receptor (PGDfR) was
268 the putative PTK mediating BMOV-induced PKB phospho
269 rylation. As depicted in Figure 4A, AG1024, a highly specific
270 inhibitor ofIGF-IR-PTK (29), prevented the phosphoiylation
271 of PKB induced by BMOV as weii as IGF-1. In contrast,
272 while AG1478, an EGFR-PTK inhibitor (30), completely
273 blocked EGF-induced PKB phosphorylation, it failed to
274 change the stimulatory effect ofBMOV on this event (Figure
275 4B). Similarly, AG1295, an inhibitor ofPDGFR-PTK (31),
276 aiso had no effect on PKB phosphoiylation induced by
277 BMOV (Figure 4C). In fact, PKB phosphorylation was flot
detected in HepG2 ceils in response to PDGF treatment, 278
suggesting that PDGFR may be expressed at extremeIy low 279
levels in these cells (32). 280
Effect of DUfrrent Doses ofAGlO24 on 3MO V-Induced 281
Signaling. Since BMOV-induced PKB phosphorylation was 282
altered solely by AG1024, we analyzed the effect of this 283
inhibitor in more detail. As shown in f igure SA, treatment 284
ofceiis with AG1024 inhibited the phosphoryiation ofPKB 285
and GSK-3/3 in a dose-dependent fashion with almost 286
complete attenuation observed at 1 tM. Since tyrosine 287
phosphorylation of IGF-1R -subunit (IGf-1R) is primor- 288
diai in increasing its PTK activity, we investigated the effect 289
ofBMOV on the tyrosine phosphorylation ofIGF-1R13. As 290
shown in Figure 5B, the level of tyrosine phosphotylation 291
A BMOV
\:S \çÇ
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105 —
50 —‘
B
flMOV (nd.n O 10 1 30 60 120
MW (kDa)
250 —,
160 —‘
105—÷ .
35 —,.
œ œ
____
—
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FIGuRE 2: BMOV-enhanced tyrosine phosphotylation of total proteins and oflR/3, IRS-l, and p85. Confluent, serum-starved HepG2 celis
were incubated with different concentrations ofBMOV for 15 min (A) or with 1 mlvi BMOV for the indicated time periodes (B). The ceils
were iysed, and the lysates werc subjected ta immunoblotting, using antiphosphotyrosine antibodies (PY99) (A and B). The blots shown
in panels A and B were also probed with total PKB antibodies to control for equal loading. In panels C and D, cells treated without or with
1 mM BMOV for 15 min were lysed, and equal amounts of total protein from the clarified lysates were subjected ta immunoprecipitation
(IP) with antiphosphotyrosine antibodies (PY99) (C) or with anti-IRj3 or -IRS-l antibodies (D). The immunoprecipitates were immunoblotted
(lB) with anti-IR3, -IRS-l, or -p85 antibodies (C) or with antiphosphotyrosine antibodies (PY99) (D). A representative immunoblot from
three independent experiments is shown.
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FIGuRE 3: BMOV-induced PKB phosphorylation is independent
ofIR-PTK activity in CHO celis. Confluent, senim-starved CHO
IR and CHO- 1018 cells were incubated in the absence or presence
oC 0.1 nM insulin (Ins) or with 1 mlvi BMOV for 15 min. The
celis were lysed, and the lysates were subjected to immunoblotting
using phospho-specific (Ser 473) PKB antibodies. The phospho
tylation level of PKB was quantified by densitometric scanning
using NIH ImageJ and expressed as the fold increase over control
ceils. Values are means ± the standard error of at least three
independent experiments. The asterisk indicates P < 0.001 vs CHO
IR ceils stimulated with insulin (Ins).
292 of IGf-1 /3 was increased by BMOV and pretreatment of
293 cells with AG 1024 prior to stimulation with BMOV resulted
294 in a significant reduction in this response. IGf-lRj3 has three
295 criticai tyrosines at positions 1131, 1135, and 1136 in the
296 kinase domain crucial for maintaining its activity and for
297 eliciting ail IGF-IR-dependent functions (33). Therefore, by
298 using two phospho-specific antibodies, one which recognizes
299 phosphorylation of IGF- 1 Rj3 at Tyr 1131, Tyr 1135, and Tyr
300 1136 Tyr 1131, we investigated the effect ofBMOV on the
301 phosphorylation of these sites. As depicted in Figure 5C,
302 BMOV increased the ievel of phosphorylation of IGF-1R/3
303 on ail three sites. Furthennore, like its effect on the total
304 tyrosine phosphoiylation of IGF-1R/3, AG1O24 markedly
305 biocked this response (Figure 5C). These resuits suggested
Bis(maltolato)oxovanadium(IV)-Induced PKB Phosphoiylation E
that BMOV-induced PKB phosphorylation was associated
with an increased level of tyrosine phosphorylation of IGF
lR/3.
Effect ofAGIO24 on the Phosphoiylation oJIRS-1 and
p Induced by BMOV Increased levels ofphosphorylation
of IRS-1 and p85 reguiatory subunit of P13-K are criticai
intermediaiy steps to signal the activation ofPKB signaling
in response to IGF-1R activation. Therefore, we next assessed
if BMOV-enhanced tyrosine phosphoiylation of IRS- 1 and
p85 in HepG2 ceils (Figure 2C) was dependent on IGF-1R-
PTK activity. The resuits shown in Figure 5D demonstrate
that BMOV induced tyrosine phosphorylation ofboth IRS-l
and p85 which was significantiy attenuated by AG1024.
Effect ofIGF-IR/3 Antisense Oligonucleotides (ASO) on
3MO V-Indcued PKB Phosphoiytation. To ftirther confirm
the rote ofIGF-1R in BMOV-induced PKB phosphorylation,
we utilized IGF-IR/3-specific antisense oligonucleotides
(ASO) which reduced the level of expression of IGF-IR/3
(2]). Transfection ofHepG2 ceils was carried out with either
scrarnbled (5CR) or increasing doses ofIGF-lRj3 ASO. ASO
treatrnent dose-dependently decreased the level ofIGF-1R/3
expression (Figure 6A). When IGF-IR/3 ASO or SCR-treated
celis were incubated with BMOV, the enhanced PKB
phosphorylation was significantly diminished in the 10f-
lR/3 ASO-treated group and flot in the SCR group (Figure
6B). These data provide additional evidence to support a
potential rote of IGF-1R in mediating the BMOV response.
Requfrernent ofPKCÔ in 3MO V-Induced PKB Phospho
tylation. A potential role ofPKC in mediating the responses
of different stimuli such as PDGF (34), EGF (35, 36),
vascular endothelial growth factor (VEGF) (37, 38), angio
tensin 11(39), and H202 (40) has been suggested. Therefore.
we sought to verif’y if PKC-dependent pathways were
invoived in BMOV-induced phosphorylation of PKB in
HepG2 celis. PKCs are composed ofthree groups. Members
of the classical (cPKC) subtype (a, /31, /311, and y) are
activated by calcium, diacylglycerol (DAG), phosphati
dylserine (PS), and phorbol esters; members ofthe the novel
(nPKCs) subtype (ô, E, i, and 0) are activated by DAG, PS,
phorbol esters, and unsaturated fatty acids, and members of
the atypicat (aPKCs) subtype ( and Et) are insensitive to
DAG but are activated by PS and phosphatidylinositides
‘
— ‘Ub imw
- KB
FIGURE 4; BMOV-induced PKB phosphorylation is inhibited by AG1024 but flot by AG147$ or AG1295. Confluent, serum-starved HepG2
celis were pretreated without (—) or with (+) 10 /3M AG1O24 (A), AG1478 (B), or AG1295 (C) for 30 min followed by stimulation with
I mM BMOV for 15 min or 10 ng/mL IGF-l, 10 nM EGF, or 10 ng/mL PDGF for 10 min. The cells were lysed, and the lysates were
subjected to immunoblotting using phospho-specific (Ser 473) PKB antibodies. The results are representative of three independent experiments.
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FIGURE 5: AG1024 decreased the level of BMOV-induced PKB phosphorylation in a dose-dependent manner and reduced the level of
tyrosine phosphorylation ofIGF-1R/3, IRS-l, and p subunit ofPI3-K. Confluent, senim-starved HepG2 cells were pretreated without t—)
or with (+) different doses ofAGlO24 (A) or I /M AG1024 (B—D) for 30 min followed by stimulation with 1 mM BMOV for 15 min.
The celis were lysed, and equal amounts of total protein from the clarified lysates were subjected to immunoblotting using phospho
specific (Ser 473)-PKB antibodies and phospho-specific (Ser 9)-GSK-3fl antibodies (A) or phospho-IGF-1R (Tyr°31013511136)/phospho-IR
(Tyrssms2hI 63) and phospho-IGF- I R (Tyr’ ‘ )/phospho-IR (Tyr’ 146) (C) or to immunoprecipitation (IP) with antiphosphotyrosine antibodies
(PY99) followed by immunoblotting with the indicated antibodies (B and D). The phosphorylation levels 0f the protein shown in panels A
and D were quantified by densitometric scanning using NIH ImageJ software and expressed as fold increase over control cells. Values are
means + the standard error ofat least three independent experiments. One asterisk indicates P < 0.001 vs BMOV alone, and two asterisks
indicate P < 0.01 vs BMOV alone.
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fIGURE 7: Chelerythine chloride, rottierin, and long-term PMA
pretreatment inhibits BMOV-induced PKB phosphorylation. Con
fluent, senim-starved HepG2 cells were pretreated without t—) or
with (+) 5 tM cheleiythine chloride, G06976, R03 1-8220, or
rottierin for 30 min (A) or with 100 nM PMA for 24 h (B) followed
by stimulation with I mM BMOV for 15 min. The ceils were lysed,
and the lysates were subjected to immunoblotting using phospho
specific (Ser 473) PKB antibodies (top immunoblot in panels A
and B) or total PKCI antibodies (bottom immunoblot in panel B).
The results are representative of three independent experiments.
decrease in ATP levels was contributing to its inhibitory
effect on BMOV-stimulated PKB phosphoiylation. It was
found that up to 10 1tM rottierin was unable to lower the
ATP levels in these ceils (data flot shown), suggesting that
ATP depletion was flot responsible for attenuating the
BMOV effect in HepG2 cells.
Effect of 3MO V on Tyi-osine Phosphoiytation ofPKCÔ.
Recent studies have identified tyrosine phosphorylation as
a potential rnechanism through which PKCÔ activation is
regulated (41). Therefore, we investigated the effect of
BMOV on tyrosine phosphorylation of PKCÔ by immuno
precipitating PKCÔ from lysates ofcells treated with BMOV
foltowed by immunoblot analysis with antiphosphotyrosine
antibody. As depicted in Figure 8, BMOV treatment of
HepG2 celts caused a significant increase in the level of
tyrosine phosphorylation of PKCÔ. We also assessed the
effect of BMOV on the tyrosine phosphorytation of PKCÔ
at tyrosine 311 (Tyr 311). This tyrosine residue is flanked
by the regulatory and catalytic domains and is criticat for
generating the active form of PKCÔ in response to II2O:
and PMA (43, 44). As shown in Figure 8A, BMOV induced
the Tyr 311 phosphoiylation ofPKCÔ. In addition, both total
tyrosine and Tyr 311 phosphorylation of PKCÔ enhanced
by BMOV were btocked by rottlerin (figure 8B). Taken
together, these data indicated that BMOV-induced phospho
rylation ofPK3 is associated with an activation ofPKCÔ as
judged by an increase in the level ofphosphorytation ofkey
tyrosine residues in its catalytic domain.
Ejfrct ofAGlO24 on 3MO V-Induced Tyrosine Phospho
iylation of PKCÔ. Since PKCÔ has been shown to be
tyrosine-phosphorylated by various protein tyrosine kinases,
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FIGuRE 6: IGf-1R/3 ASO decreased BMOV-induced PKB phos
phorylation. HepG2 ceils were transfected with 25. 100, and 200
nM antisense oligonucleotides (ASO) to IGF-tR or 200 nM
scrambled oligonucleotides (SCR) (A) or with 100 mM ASO to
IGF-tR/3 or 100 nM SCR (B). Unstimulated (A) orcells stimulated
in the absence (—) or presence (+) ofBMOV (B) were lysed. and
the lysates were subjected to immunoblotting using total IGF-lR3
antibodies (A) or phospho-specific (Ser 473)-PKB antibodies (B).
Blot shown in top panel of (B) was reprobed for total PKB for
equal loading and is shown in bottom. The resuits are representative
ofthree independent experiments. The immunoblots were quantified
by densitometric scanning using NIH ImageJ software. Values are
means ± the standard error of at least three independent experi
ments. One asterisk indicates P < 0.001 and vs scrambled.
348 (reviewed in ref 41). The resuits shown in figure 7A
349 demonstrate that G06976 and R03 J-8220, selective chemi
350 cal inhibitors of cPKC and aPKC isoforms, respectively,
351 failed to inhibit BMOV-induced phosphorylation of PKB,
352 whereas chelerythrine chloride, an isoform-nonselective
asa inhibitor, and rottlerin, a highly selective PKCÔ inhibitor,
354 treatment signiflcantly reduced the level of PKB phospho
355 rylation induced by BMOV. The involvement of PKC was
356 further confirmed by downregulating the PKC activity in
357 HepG2 celis by a 24h treatment with phorbol-l2-myristate-
358 1 3-acetate (PMA). As shown in Figure 7B, PMA-treated ceils
359 exhibited significantly attenuated PKB phosphoiylation in
360 tesponse to BMOV as compared to untreated ceils. Immu
361 noblotting of paraLlel samples showed that PMA treatment
362 significantly reduced the amount of PKC protein in these
363 celts, whereas the total PKB levets remained unattered after
364 this treatment (Figure 7B). Rottierin bas been suggested to
365 exert inhibitory effects through depletion ofATP levels (22,
366 42); in view of this, we determined if the rottlerin-induced
367
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FIGuRE 8: Rottlerin decreased the level of 3MOV-induced total
tyrosine phosphoiylation at tyrosine 311 of PKCÔ. Confluent,
serum-starved HepG2 ceils were pretreated with or without 5 ttM
rottlerin for 30 min followed by stimulation in the absence or
presence of I mM BMOV for 15 min. The celis were lysed, and
equal amounts of total protein from the cÏarified lysates were
subjected to immunoprecipitation (IP) with total PKCà antibodies
followed by immunoblotting with antiphosphotyrosine antibodies
(PY99) or phospho-specific (Tyr 311) PKC5 antibodies. A repre
sentative immunoblot from three independent experiments is shown.
39$ including IGF-IR (45, 46), we investigated if IGF-1R-PTK
399 was responsible for triggering the phosphorylation ofPKCÔ
400 in response to BMOV. As shown in Figure 9A, treatment of
401 HepG2 ceils with AG1024 almost comptetely abotished
402 BMOV-stimutated total tyrosine phosphorylation ofPKC ô.
403 In addition, AG1024 also inhibited phosphorylatïon ofPKCô
404 at Tyr 311 while AG1478, an EGFR inhibitor, failed to alter
405 the phosphorylation ofPKC6 at this site (Figure 9B). Since
406 PKCÔ bas been shown to be phosphorylated at Tyr 311 in
407 response to various agonists, including PMA, we deterrnined
40$ if like those of BMOV, PMA-induced effects are also
409 dependent on IGF-1R-PTK. As shown in f igure 9C, in
410 contrast to its inhibitory effect on PKC6 phosphorylation
411 stimulated by BMOV, AG1024 was unable to block the
412 effect of PMA, suggesting that IGf-1R is an upstrearn
413 regulator of PKCÔ phosphotylation in response to BMOV
414 and flot PMA.
DISCUSSION
BMOV bas been shown to exert glucoregulatory effects
in many rodent models of diabetes (10—13, 47); however,
the precise mechanism through which this response is
mediated remains targely unclear. We bave shown previously
that BMOV activates PKB (3), a central player involved in
carbohydrate rnetabolism (5). In the study presented here,
we demonstrate that BMOV-enhanced phosphorytation of
PKB in HepG2 ceils is associated with an increased level of
tyrosine phosphorylation of the total cellular proteins, W,t3,
BMOV
•‘t- .PKçTYtI
I
, ,
;
FIGURE 9: AG1024 decreased the level ofBMOV- but flot PMA
induced tyrosine phosphorylation of PKCô at tyrosine 311. Con
fluent, senim-starved HepG2 cells were pretreated with or without
10 ttM AG 1024 or AG 1478 (B) for 30 min followed by stimulation
with 1 mM BMOV or 100 nM PMA for 15 min. The cells were
lysed, and equal amounts of total protein from the clarified lysates
were subjected to immunoprecipitation (IP) with total PKC6
antibodies followed by immunoblotting with antiphosphotyrosine
antibodies (PY99) (A) or were immunoblotted using phospho
specific (Tyr 311) PKCÔ antïbodies (B and C). A representative
immunoblot from three independent experiments is shown.
IGF-IR/3, IRS-l, and p85 subunit of PI3K. We have also
provided evidence that the PTK activity of the IGf-1R/3 is
responsible for BMOV-induced activation of the PKB
pathways. This conclusion is based on the use of highly
selective inhibitors of IGF-IR, EGfR, and PDGFR-PTKs
which showed that only the inhibition of IGF-IR-PTK by
AG 1024 blocked BMOV-induced PKE phosphoiylation. Our
results showing that BMOV treatrnent increased the level
of total tyrosyl phosphoiylation as well as Tyr 1131, 1135,
and 1136 phosphoiylation ofIGf-IR!3 which was specifically
inhibited by AG1024 suggested that the PTK activity oflGf
1R/3 was indeed being stimulated in response to BMOV. In
addition, the data showing that antisense-induced reduction
of IGf- 1 Rfl decreased the Ievel of BMOV-stirnulated PKB
phosphorylation provided ftirther proof for the participation
ofIGF-1R in mediating the effect ofBMOV. A rote ofIGF
1RJ3 in angiotensin II and F1202 (48, 49) induced ERKI/2
phosphorylation and in angiotensin II and purinergic receptor
P2Y12-induced P13-KJPKB signaling pathway bas been
reported previously (28, 50). Transactivation ofother growth
factor receptor PTKs bas also been suggested to play a
critical intermediaiy role in response to agonists coupled to
G-protein receptors (GPCR) (reviewed in ref 51). However,
the data presented here are the first to demonstrate that
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Biochemistiy
BMOV, a non-GPCR agent, also signais through IGf-1R-
PTK transactivation to activate PKB.
IR and IGF-1R exhibit a high degree of homology and
share several common signaling features (reviewed in ref
52), and despite having a higher 1C50 for IGf-IR-PTK,
AG1024 can aiso inhibit IR-PTK activity at high concentra
tions (29). furthermore, our resuits showing that BMOV
treatment increased the levei of tyrosine phosphorylation of
IR3 might support the idea ofa rote for IR-PTK in BMOV
induced responses. However, our observations that in CHO
1018 cells the extent of the insuiin response was significantiy
decreased while the BMOV effect was intact suggested an
IR-PTK-independent rnechanisrn of BMOV action. Earlier
studies using inorganic vanadium compounds have also
documented the iack of a rote of IR-PTK in inducing the
vanadium response (17, 53). In addition, several investigators
have aiso reported that the insulin-like effects of vanadium
were flot associated with an increase in the ievel of tyrosine
phosphoryiation of 1Rj3 in many systems (2, 17—20). Thus,
despite the fact that some studies have demonstrated an
increase in the level of IR tyrosine phosphorylation in vivo
in response to vanadium treatment in diabetic animal models
(10, 54), our data support the notion that IGF-1R-PTK
activation by BMOV may serve as an altemate mechanism
to mediate the insuhn-iike effect of this compound.
PKCÔ is a serine/threonine kinase that plays a key role in
many physiological responses such as growth regulation (55),
tissue remodeling (56), migration (57), and transformation
(45). In response to insuhn, PKCÔ and PKCO, two novel
PKC isoforrns, have been shown to convey an insulin signal
toward glucose transport (58, 59), glycogen synthesis (60),
and ceti proliferation (61). In contrast, several sttidies have
reported that PKCÔ may downregulate insulin signaling in
response to high glucose concentrations (62) and other stimuli
(63). Therefore, it appears that novei PKC isoforms may both
mediate stimulatoiy effects ofinsulin on glucose metabohsrn
and inhibit the intracellular insulin signaling pathway. Our
data showing that PKB phosphoiylation was blocked by
chelerythrine and rottierin and flot by G06976 or R031-
8220 suggested a role for PKCÔ in BMOV action. Since
tyrosine phosphoiylation ofPKCÔ has been shown to activate
its catalytic activity (43, 44), the resuits showing that both
total tyrosine phosphorylation and phosphorylation of Tyr
311 in PKCÔ were enhanced by BMOV provide additional
support for the involvement of this isoform of PKC in
mediating the BMOV response in HepG2 ceils. Interestingly,
hke its effect on PKB phosphorylation, rottlerin pretreatment
biocked the PKCÔ tyrosine phosphoiyiation induced by
BMOV. Rottlerin has been extensively used as a selective
inhibitor of PKCÔ; however, recent reports have suggested
that k may have additional, non-PKCÔ-dependent responses
such as depletion ofthe intracellular ATP ievei (22, 42, 64).
However, our data showing that rottlerin was unable to alter
the ATP concentration in HepG2 cells suggested that rottlerin
was exerting its effect via an ATP-independent mechanism
in these cells.
Furthermore, our resuits showing that in celis chronically
treated with PMA, the attenuated response ofBMOV on PKB
phosphorylation was associated with a decreased levet of
expression of PKC5 provided additional evidence of a rote
for PKCÔ in BMOV action. To the best of our knowledge,
these data are the first to demonstrate the involvement of
Bis(maltolato)oxovanadium(IV)-Induced PKB Phosphorylation I
PKC in vanadium-mediated PKB activation. This is consis
tent with previous reports where an involvement of PKCs
in mediating PKB activation was documented (37, 66). In
contrast, however, a negative regulatoiy rote of PKCÔ in
PKB activation bas also been suggested (67, 68). Because
PKC expression and its action have been reported to be
tissue-specific (69), it is possible that PKCÔ may elicit
different responses depending on ccli type. The attenuation
of BMOV-induced PKCÔ phosphorylation by AG1024
observed in our studies indicates that IGf-1R may be an
upstream mediator of this event. A requirement for PKCÔ
in IGF-1R-induced signaling bas also been described (45,
70, 71). However, the precise mechanism and intermediary
steps responsible for PKCÔ-mediated PKB activation in
response to BMOV remain to be explored. Moreover,
additional studies using genetic approaches to silence or
knock down PKCÔ by siRNA andlor oligonucleotides will
be needed to provide unequivocal evidence of a rote for
PKCÔ in vanadium-induced responses on PKB in HepG2
cells.
In summary, our studies have provided experimental
evidence of a rote for IGf-1R-PTK in BMOV-induced
activation of the PKB signaling pathway in HepG2 celts.
We have also demonstrated that PKCÔ activation plays an
intermediary role in transducing IGf-IR signaling leading
to PKB phosphorylation in response to BMOV. These data
provide novel insights into the cellular mechanism of the
insulinornimetic and glucoregulatory action of BMOV.
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H2O24nduced Phosphorylation ofERK1/2 and PKB Requires
Tyrosine Kinase Activity oflnsulin Receptor and c-Src
MOHAMAD Z. MEHDI, NIHAR R. PANDEY. SANJAY K. PANDEY. and
ASNOK K. SRIVASTAVA
ABSTRACT
Hydrogen peroxide (H20,) mimics many physiological responses of insulin, and increased 11202 generatiOn via
the Nox-4 subunit of NAD(P)H oxidase vas recently demonstrated to serve as a critical early step in the in
sulin signaling pathway. Exogenously added H202 lias also been shown to activate several key components of
the insulin signaling cascade. 11202-induced signaling responses have been found to be associated with the ac
tivation of receptor and nonreceptor protein tyrosine kinases (PTK), including the insulin receptor (IR)-f3
subunit. Therefore, in the present studies on Chinese hamster ovary ceils overexpressing wild-type IR-PTK
(CHO-IR) or a PTK-inactive form of IR (CHO-1018), we investigated whether IR-PTK plays a role in 11,0,-
induced signaling events. Treatment of CHO-IR celis with H,0, increased the phosphorylation of extracellu
lar signal-regulated kinases I and 2 (ERK1/2), protein kinase B (PKB), and glycogen synthase kinase-313 whfle
enhancing tyrosine phosphorylation of the IR-13 subunit and the p85 subunit of phosphatidylinositol 3-kinase
(PI3K). Compared with CHO-IR celis, the stimulatory effect of H,02 on ERK1/2 and PKB vas partially re
duced in CHO-1018 celis. However, pharmacological inhibition of Src family PTK by 4-amino-5-(4-
chlorophenyl)-7-(tert-butyl)pyrazolo[3,4-djpyrimidine (PP-2) almost completely blocked H,O,-stimulated
phosphorylation of the p85 subunit of PI3K, ERK1/2, and PKB. Moreover, H202, but flot insulin, induced Tyr
41$ phosphorylation of Src, which was also suppressed by PP-2. Taken together these data suggest that both
IR-PTK and Src family PTKs contribute to H20,-induced signaling in CHO-IR celis albeit IR-PTK lias a less
dominant role in this process. Antioxid. Redox Signal. 7, 1014—1020.
INTRODUCTION
REACTIVE OXYGEN SPECIES have been suggested to serveas mediators ofthe action ofseveral growth factors, cy
tokines, and insulin (5, 13, 20—22, 32). Insulin is the major
hormone involved in glucose homeostasis, and its effect is
initiated by binding to its receptor on ceil membranes. The in
sulin receptor (IR) is a heterodimeric (ce2, 2) protein, and in
sulin binding to the IR-cc subunit results in conformational
changes, leading to en]ianced intrinsic protein tyrosine kinase
(PTK) activity of the 3 subunit by multisite tyrosine phos
phorylation. Once activated, IR-PTK can phosphorylate sev
eral cytosolic IR substrates such as IRSs and Shc, which
serve as docking sites for Src homology 2 domain-containing
signaling molecules (37), triggering the activation oftwo key
signaling pathways. In one pathway. the association ofIRS-1
with Grb-2-SOS complex resuits in activation ofthe Ras, Raf,
MEK and extracelÏular signal-regulated kinase (ERK) path
way (36, 38). Activated ERK1/2 phosphorylates and activates
a downstream ribosomal protein kinase, p9Orsk. Both ERK1/2
and p90rk can be transiocated to the nucleus where they phos
phorylate transcription factors, and contribute the mitogenic
and growth-promoting effects ofinsulin (36, 37). The second
pathway that radiates from the IRS complex upon insulin
stimulation involves phosphatidylinositol 3-kinase (PI3K) ac
tivation (36, 38). PI3K phosphorylates phosphatidylinositol
Laboratory of Ccli Signaling, Research Centre, Centre hospitalier de l’Université de Montréat (CHUM)—Hôtel-Dieu and Department ofMed
icine, Université de Montréal, Montréal. Quebec. Canada.
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(PI) lipids at position 3 0f the inositol ring, and generates 3-
phosphorylated forms of PI, such as phosphatidylinositol
3,4,5-trisphosphate (30), which are implicated in the activa
tion of phospholipid-dependent kinase and related serine/
threonine protein kinases. These activated kinases in tum are
responsible for the phosphorylation and stimulation of sev
eral downstream signaling protein kinases, such as protein ki
nase B (PKB) (also known as Akt), glycogen synthase kinase
3 (GSK-3), p7OsSk (11), and protein kinase C- (PKC) (10).
Activation of these protein serine/threonine kinases lias been
demonstrated to mediate the metabolic effects of insulin at
the level of glucose transport, glucose transporter (GLUT-4)
translocation, glycogen and protein synthesis (36).
Recent studies have demonstrated that insulin stimulation
of celis generates a hydrogen peroxide (F{202) burst that en
hances the tyrosine phosphorylation ofIR and IRS-1 (22). An
important role for the NAD(P)H oxidase catalytic subunit ho
mologue Nox-4 in enhancing H»2 production in response to
insulin has been suggested recently (23). In addition, exoge
nously added F1202 lias been shown to mimic many pliysio
logical effects of insulin, including glucose transport (15),
glycogen synthesis (17), lipogenesis (24), lipolysis (19), and
phosphoenolpyruvate carboxykinase gene expression (33).
112O2 has also been found to increase tyrosine phosphoryla
tion ofthe IR-F3 subunit (15, 16) and activation ofthe ERKI/2
and PI3KIPKB signaling pathways in several cdl types (3, 4,
6, 8, 18, 31, 34, 35). A potential role for epidermal growth
factor (EGF) receptor transactivation (12, 2$, 39) and the src
family ofPTK in H202-induced signaling lias been postulated
(1, 2, 12). However, despite the ability of I12O2 to enhance
IR-PTK activity and IR-3 subunit phosphorylation, the possi
ble involvement of IR-PTK in H202-induced responses bas
not been characterized. Therefore, in the present studies, we
investigated the possible requirement of IR-PTK in H202-in-
duced phosphorylation ofthe ERK1/2 and PKB pathways.
Materiats
MATERIALS AND METHODS
Insulin was obtained from Eh Lilly Co. (Indianapolis, ÏN,
U.S.A.), F1202 from Sigma Chemical Co. (St. Louis, MO,
U.S.A.), and IRS-1 and p85 antibodies from Upstate Biotech
nology (Lake Placid, NY, U.S.A.). Phospho-specific and total
antibodies, against ERK1/2 and GSK-3p, antiphosphotyro
sine antibody (PY99), and IR antibody were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Plios
pho-specific and total PKB antibodies were procured from
New England BioLabs (Beverly, MA, U.S.A.), and phospho
specific c-Src antibody from Biosource (Camarillo, CA,
U.S.A.). Protein A Sepharose beads and enhanced chemilu
minescence (ECL) detection kits were from Amersham Phar
macia Biotech (Baie d’Urfé, Quebec, Canada).
Cett culture
Chinese hamster ovary (CHO) ceils overexpressing either
wild-type human IR (CHO-IR) or the PTK mutant form
(CHO-1018), a gift from Dr. Morris f. White (Joslin Diabetes
Center, Boston, MA, U.S.A.), were maintajned in Ham’s F-12
medium containing 10% fetal bovine serum. They were grown
to confluence in 100-mm plates and incubated in serum-free
F-12 medium for 16 h prior to the experiment (26).
Cett lysis and invnunoblotting
Celis subjected to various experimental treatments were
washed twice with ice-cold phosphate-buffered saline and
lysed in buffer A [25 mM Tris-HCI, pH 7.5, 25 mM NaCI, 1
mM sodium orthovanadate, 10 mM sodium fluoride, 10 mM
sodium pyrophosphate, 20 mM okadaic acid, 0.5 mM ethyl
ene-bis(oxyethylenenitrilo)tetraacetic acid, I mM plienyl
methylsulfonyl fluoride, 10 .tg/m1 aprotinin, and 1% Triton
X-100]. The lysates were clarified by centrifugation to re
move insoluble material. The clarified lysates, norrnalized to
contain equal amounts ofprotein, were subjected to 12% so
dium dodecyl sulfate—polyacrylamide gel electropboresis
(SUS-PAGE) under reducing conditions, transferred to
polyvinylidene difluoride (PVDF) membranes, and incubated
with respective primary antibodies, followed by incubation
with a liorseradisli peroxidase-conjugated second antibody.
The antigen—antibody complex was visualized with an ECL
detection kit. The immunoblots were quantified by densito
metric scanning with NIH ImageJ software (27).
Immunoprecipitation
The clarified cdl lysates, normalized to contain equal
amounts of protein (500 gg), were immunoprecipitated
overnight with 1 ig ofPY99 antibody at 4°C, followed by in
cubation with protein A Sepharose for an additional 2 h. 1m-
munoprecipitated phosphotyrosine proteins were collected by
centrifugation, and washed twice with buffer A and once with
phosphate-buffered saline. The phosphotyrosine protein im
munoprecipitates were subjected to 7.5% SUS-PAGE under
reducing conditions, transfened to PVDF membranes, and
incubated with respective primary antibodies. Proteins were
detected by a horseradish peroxidase-conjugated second anti
body and visualized with an ECL detection kit (27).
PI3K assay
The clarified ceIl lysates were subjected to immunopre
cipitation with 2 ig ofp8SŒ antibody for 2 h at 4°C, followed
by incubation with protein A Sepharose for an additional 2 h.
The immunoprecipitates were waslied before PI3K assay, as
described earlier (26). The phosphorylated Iipid products
were extracted and separated by ascending thin-layer chro
matography (26). Radioactivity in the spots corresponding to
PI 3-phosphate was quantified by Phosphorlmager (Molecu
lar Dynamics, Sunnyvale, CA, U.S.A.).
RESULTS
Effect ofHO on ERKJ/2, PKB, and GSK-313
phosphorytation in CHO-IR cetÏs
We first evaluated whether II2O2 alters the activation of
ERK1/2, PKB, and its downstream targets in CHO-IR cells.
As increased phosphorylation in specific serine/threonine
residues of these molecules is associated with their activa-
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tion, their activity was measured by using phospho-specific
antibodies. As shown in Fig. lA, treatment of IR-overex
pressing celis for 5 min with escalating concentrations of
H,02 induced ERKI/2, PKB, and GSK-3Ç3 phosphorylation.
H»2 increased ERKJ/2 phosphorylation at concentrations as
low as 10 .tit!with maximal effect at 100 1iAl, whereas higher
concentrations (500 jiJvi to 1 iM) were required to elicit ro
bust PKB phosphorylation. Next, we assessed the time de
pendence of the H»2 response. As seen in Fig. lB, 1 mlvi
F1202 rapidly enhanced the phosphorylation ofERKI/2, PKB,
and GSK-33. The increase occurred within 5 min and then
declined slowly to almost basal levels within 60 min of H»,
treatment.
A CHO-ifi
p-PKB
PKB —— —
p-GSK-3 .—.-;;;;-.,:;-
GSK-3p
B
H202 (mm):
p-ERK1/2
p-PKB
do-m
0 5 10 30 60
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—
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FIG. 1. H,O,-induced ERK1/2, PKB, and GSK-3f3 phos
phorylation is time- and dose-dependent in CHO-IR cetls.
Confluent, semm-starved CHO-IR ceils were incubated with
different concentrations of H,O, for 5 min (A) or with 1 mit-i
H», for the indicated time periods (B). The celis were lysed,
and the lysates were subjected to immunoblotting using phos
pho-specific (Tyr-204)-ERK 1/2 antibodies (upper immunoblot
in A and 3), phospho-specific (Ser-473)-PKB antibodies (mid
die immunobiot in A and B), and phospho-specific (Ser-9)-
GSK-313 antibodies (lower immunobiot in A and B). The re
suits are representative ofthree independent experirnents.
H20,(mM): b b o—
p-ERK1J2
[
______________
p-PKB
FIG. 2. H,O,-induced ERK1/2 and PKB phosphorriation
is partially dependent on IR-PTK activity in CHO celis.
Confluent, serurn-starved CHO-IR and CHO-1018 celis were
mcubated in the absence or presence of 0.1 nl.ï insuhn (lus)
(A) or with different concentrations of H,O, (B) for 5 min. The
celis were Iysed, and the lysates were subjected to immunoblot
ting using phospho-specific (Tyr-204)-ERK 1/2 antibodies
(upper immunoblot in A and 3) and phospho-specific (Ser
473)-PKB antibodies (lower immunoblot in A and B). The re
suits are representatiue of three independent experiments.
Effect ofH2O2 on ERK]/2 and PKB
phosphorylation in IR-PTK-deficient ce Ils
To examine the role of IR-PTK in H202-induced ef
fects on ERK1/2 and PKB phosphorylation, we studied
CHO-1018 celis that overexpress an inactive form of IR
PTK. The inactive form of IR was generated by the muta
tion oflysine 101$ to alanine in the ATP-binding domain of
the IR-p subunit. This mutation resuits in the loss of ATP
binding activitv and, thus, PTK function (7). As illustrated in
Fig. 2, both insulin and H,02 enhanced the phosphoryla
tion of ERK1/2 and PKB in CHO-IR ceils overexpressing a
normal IR. However. in CHO-1018 celis, the insulin-induced
phosphorylation of both ERKI/2 and PKB was almost
completely attenuated, whereas the H,02-evoked increase
tvas partially blocked in this celi type. These data suggested
that, compared with insulin, H,02-induced phosphoryla
tion ofERKl/2 and PKB is exerted in part through IR-PTK
activity.
A CHO-IR dO-1 01$
Ins (nM): 0 0.1 0 0.1
p-ERK1/2
_ _ _
____________
p-PKB
_ _
B CHO-IR Cl-10-lOIS
11202 (p.M):
p-ERK1/2 “—
ERK1/2 I
______
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Effect ofH2O2 on IR, IRS-], andp85 tyrosine
phosphorytation
As the insulin effects on ERK1/2 and PKB are mediated
through the enhanced tyrosine phosphorylation of IR and
IRS-l, we next explored if; simiiarly to insulin, H202
creases the tyrosine phosphorylation of IR and IRS-1. As
shown in Fig. 3, bath insulin aiid H202 augmented tyrosine
phosphorylation of the IR- subunit, but tyrosine phosphory
lation of the IR-t3 subunit induced by F1202 was significantiy
lower than that observed with insulin. Furthermore, whereas
insulin enhanced the tyrosine phosphorylation of IRS-1, a
similar effect ofH,02 on IRS-i tyrosine phosphorylation was
flot detected in CHO-IR celis (fig. 3). In contrast, bath in
suhn and H202 treatment resulted in enhanced tyrosine phos
phorylation ofthe p85 subunit ofPl3K.
Requireinent of c-Src in H202-induced ERK]/2 and
FKB phosphotytation
The resuits with CHO-1018 celis indicated that the R202
effect on ERK1/2 and PKB phosphorylation required addi
tional signais besides JR-PTK. As potential involvement of
the Src family of PTKs in H202-induced signahng has been
proposed in other ccii types, we investigated if, in CR0
ceils also, Src-PTK was responsibie for triggering the
phosphoryiation ofvarious signaling components. We utihzed
PP-2 [4-arnino-5-(4-chloraphenyl)-7-(tert-butyl)pyrazolo[3,4d]
pyrimidine], a selective inhibitorofSrc-PTK, and PP-3 (4-amino-
7-phenylpyrazoi [3 ,4-d]pyrimidine), an inactive analogue of
PP-2, ta examine the contribution of Src in H20,-induced in
creased phosphorylation events. As depicted in Fig. 4, treat
ment of celis with PP-2 aimost completely suppressed H202-
stimulated phosphorylation of bath ERK1I2 and PKB. As
1_P: PY99
:
0
FIG. 3. H202-induced tyrosine phosphorylation of IR and
p85, but flot IRS-l, in CHO-IR celis. Confluent, serum
starved CHO-IR ceils were incubated with i 00 nM insulin (las)
or with 1 mM H202 for 5 min. The ceils were lysed, and equal
amounts of total protein from the clarified lysates were
subjected ta immunoprecipitation (IP) with an antiphospha
tyrosine (PY99) antibody. The immunoprecipitates were
immunoblotted with the indicated antibodies. A representative
immunoblot (13) fram three independent experiments is
shown.
Oi O9
C .Ç?;b 1
L ‘
FIG. 4. H,O,-induced ERK1/2 and PKB phosphorylation
is totally dependent on Src-PTK activity in CHO-IR ceils.
Confluent, serurn-starved CHO-IR cells were pretreated with
or without 10 1iM PP-2 or its inactive analogue PP-3 for 30
mm, foliowed by incubation with I mM H202 or 100 nM insulin
tIns) for 5 min. The celis were lysed ami the iysates were sub
jected ta immunoblotting using phospho-specific (Tyr-204)-
ERK1/2 antibodies (upper immunoblot), phospho-specific
(Ser-473)-PKB antibodies (middle immunobiot), and phospho
specific (Tyr-4i8)-Src antibadies (lower immunablot). The re
sults are representative ofthree independent experiments.
PP-2 isa patent and specific inhibitor ofc-Src activity, and its
ability ta suppress H202-induced responses suggested a raie af
Src in this process, we directly assessed if H202 would en
hance Src activity in CHO-tR ceils. This was achieved by
evaluating the increase in Tyr-4i 8 phosphoryiation in the acti
vation ioop of c-Src. As shown in Fig. 4, H202 treatment en
hanced the Tyr-4i 8 phosphorylation of Src, which was aimost
compietely blocked in PP-2-pretreated ceHs.
Effect oJPP-2 on IR andp85 tyrosine
phosphoiyÏation and ofwortrnannin on ERK]/2
and PKB phosphoiytation induced by 11202
Ta determine if c-Src is an upstream mediator of IR and
p85 tyrosine phosphoryiation, we evaluated the effect afPP-2
on H202-induced phosphorylation ofthese signaling campa
nents. As iiiustrated in Fig. SA, PP-2 treatment failed ta black
tyrosine phosphorylation of the IR- subunit, whereas it
completely attenuated the tyrosine phosphoryiation of the
p85 reguiatary subunit of PI3K. Next, we examined if p85
phospharyiation by H202 was associated with an increase in
the PI3K activity ofCHO-IR celis. As seen in Fig. 53, R202
treatment enhanced PI3K activity, which was sensitive ta in
hibition by wartmannin, a specific PI3K inhibitor. Further
more, bath ERKI/2 and PKB phosphoryiation induced by
H202 were almost completely attenuated by wortmannin pre
treatment afcells (Fig. 5C).
DISCUSSION
In this study, we have shown that exogenousiy added H202
enhanced the phasphorylation ofERK1/2 and PKB signaling
pathways in CHO-IR ceiis. The increased phospharylatian of
p-ERKI/2
p-PKB
p-Src
IRlB: W
lB: IRS-1
lB: p6
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FIG. 5. H20,-induced p85 phosphorylation and ERK1/2
and PKB phosphorylation are dependent on Src-PTK ami
PI3K, respectively. Confluent, serum-starved CHO-IR celis
were pretreated with 10 pli PP-2 or its inactive analogue PP-3
(A) or 100 nii’Iwortmannin (W) (B and C) for 30 mm, followed
by incubation with 1 mJvf F1,09 for 5 min. In A, the celis were
lysed, and equal amounts of total protein from the clarified
lysates were subjected to immunoprecipitation (IP) with an
tiphosphotyrosine (PY99) antibody. The immunoprecipitates
were iinmunoblotted (lB) with IR antibodies (upper im
munoblot) and p85 antibodies (lower immunoblot). In 3, the
cells were lysed, and the ceil lysates were subjected to immuno
precipitation using p85a antibodies. PI3K activity was mea
sured in p85a immunoprecipitates with PI as substrate
and [-y-32PjAIP as phosphoryl group donor. The position of PI
3-phosphate (PI3P) is indicated. In C, the ceils were lysed and
the lysates were subjected to immunoblotting using phospho
specific (Tyr-204)-ERKI /2 antibodies (upper immunoblot) and
phospho-specific (Ser-473)-PKB antibodies (lower im
munoblot). DM80, dimethyl sulfoxide. The resuits are repre
sentative of three independent experiments.
ERK1/2 and PKB was associated with heightened tyrosine
phosphorylation ofthe IR-13 subunit and p85 subunit ofPI3K.
We have also provided evidence that PTK activity of the IR-
subunit is partially responsible for H702-induced activation
of the ERKI/2 and PKB pathways. Ihis contention is based
on the results with the CHO cells that overexpress a PTK-in
active form of IR. Althougli earlier studies have demonstrated
a stimulatory effect of F1202 on tyrosine phosphorylation of
the IR-3 subunit in adipocytes, no attempts have been made
to determine the contribution of IR-PTK in H20,-induced
signaling events. Thus, to the best of our knowledge, this
work provides the first evidence in support of the involve
ment of IR-PTK in H20,-induced phosphorylation of
ERKI/2 and PKB.
H,02 lias recently emerged as an important redox molecule
for the action ofseveral growth factors, cytokines, and insulin
(5, 13, 20—22, 32). Some ofthe effects ofH2O2 on signaling
events have been shown to be mediated by transactivation of
EGf receptor PTK and the Src family of PTKs in several cdl
types (1,2, 12, 28, 39). In CHO-IR celis, H9O2also enhanced
Src activity, as judged by the increased phosphorylation of
Tyr-418 in the activation loop ofSrc. The participation ofSrc
in H702-induced signaling in CHO cells xvas evaluated by
using PP-2, a highly specific inhibitor of Src PTK activity.
PP-2 almost completely attenuated the H20,-induced in
crease ofphosphorylation ofERK1/2, PKB, and the p85 sub
unit of PI3K. This is in contrast to the partial inhibition
elicited in IRPTK-deficient cells where the H202-induced ef
fect was blocked by only 20—30% (Fig. 2). An important role
of Src PTK in insulin-induced activation of PKOE was dem
onstrated recently in primary cultures of skeletal myotubes
(29). In these studies, insulin stimulated Src PTK activity,
which was blocked by PP-2 (29). Moreover, PP-2 also inhib
ited insulin-induced IR-f3 tyrosine phosphorylation, as weIl
as glucose uptake in these myotubes. In the case of CHO-IR
celts, however, neither insulin- nor H20,-induced IR- sub
unit phosphorylation was blocked by PP-2. Furthermore,
PP-2 was ineffective in inhibiting the increased phosphoryla
tion ofERK1/2 and PKB induced by insulin (data not shown),
whereas it completely blocked the H202-evoked effect in
these cells (Fig. 4), which suggested that Src-PTK-dependent
pathways in CHO-IR cells mediate the F1207 response and not
that of insulin. furthermore, in contrast to insulin, H209
treatment did flot enhance IRS-1 tyrosine phosphorylation,
but increased tyrosine phosphorylation of the p85 subunit of
PI3K, which was sensitive to inhibition by PP-2. Src family
PTK-catalyzed Tyr-688 phosphorylation of p85 was recently
shown to activate P13K in COS cells (9). The fact that H202
induced PI3K activation in these cells, and wortmannin, a
specific inhibitor ofPI3K, blocked H202-evoked activation of
ERK1/2 and PK.B in these cells, suggests that PI3K may be
an upstream intermediate in H202-induced signaling events.
Recent studies have shown that insulin-induced generation
of H,07 via NAD(P)H oxidase activation serves as a trigger
to initiate insulin signahng (23). In these experiments, abla
tion ofNox-4, one ofthe subunits ofNAD(P)H oxidase com
plex, resulted in diminished 3909 production, associated with
decreased tyrosine phosphorylation ofIR and IRS-1 (23). The
data indicated that endogenously generated H,09 in response
to insulin is able to enhance IRS-l phosphorylation in 313-L 1
adipocytes (23), whereas the results with CHO-IR cells dem
— —
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onstrated that exogenous H202 fails to modify IRS-1 phos
phorylation (fig. 3). Thus, it appears that the intracellular up
stream targets of endogenously generated and exogenously
added H»2 may be different.
The precise mechanism by which F1202 induces tyrosine
phosphorylation ofsubstrate proteins remains obscure; how
ever, its ability ta inhibit the activities of many protein tyro
sine phosphatases (PTPases), such as PTPIB (18), and SF1?-
2 (25), has been suggested as a potential mechanism. PTPase
inhibition by H202 is accomplished by oxidatian of catalyti
cally essential cysteine residue in the active site of PTPase
(14); this inhibition shifts the equilibrium ofthe phosphory
lation—dephosphorylation cycle, resulting in increased tyro
syl phosphorylation of substrate proteins, such as Src, the
IR-13 subunit, and the p85 subunit of PI3K. These tyrosyl
phosphorylated proteins promote the assembly of signaling
molecules responsible for activating various components of
the mitogen-activated protein kinase and PI3K signaling
pathways.
In summary, our studies have demonstrated that H202-in-
duced activation of ERKY/2 and PKB is associated with en
hanced tyrosine phosphorylation ofthe 1R-3 subunit, the p85
subunit of PI3K, and c-Src in CHO-IR celis. We have also
provided evidence of the involvement of bath IR-PTK- and
Src-PTK-dependent upstream mechanisms as mediators of
the H202 response.
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CHO, Chinese hamster ovary; CHO-IR, Chinese hamster
ovary celis overexpressing insulin receptor; ECL, enhanced
chemiluminescence; EGE, epidermal growth factor; ERK, ex
tracellular signal-regulated kinases; G SK, glycogen synthase
kinase; H202, hydrogen peroxide; IR, insulin receptor; IRS,
insulin receptor substrate; PAGE, polyacrylamide gel elec
trophoresis; PI, phosphatidylinositol; PI3K, phosphatidylinos
itol 3-kinase; PKB, protein kinase B; PKC, protein kinase C;
PP-2, 4-amino-5-(4-chlorophenyl)-7-(tert-butyl)pyrazolo[3 ,4-
d]pyrimidine; PP-3, 4-amino-7-phenylpyrazol[3,4-cllpyrimi-
dine; PTK, protein tyrosine kinase; PTPases, protein tyrosine
phosphatases; PVDF, polyvinylidene difluoride; PY99, an
tiphosphotyrosine antibody; SDS, sodium dodecyl sulfate.
REFERENCES
I. Abe J and Berk BC. fyn and JAK2 mediate Ras activation
by reactive oxygen species. J Biot Chem 274: 21003—
21010, 1999.
2. Abe J, Okuda M, Huang Q, Yoshizumi M, and Berk BC.
Reactive oxygen species activate p90 ribosomal S6 kinase
via Fyn and Ras. JBiol Chem 275: 1739—174$, 2000.
3. Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Tanaka
M, Shiojima 1, Hiroi Y, and Yazald Y. Oxidative stress acti
vates extracellular signal-regulated kinases through Src
and Ras in cultured cardiac myocytes of neonatai rats. J
Clin Invest 100: 1813—1 821, 1997.
4. Baas AS and Berk BC: Differential activation ofmitogen
activated protein kinases by H202 and
°2 in vascular
smooth muscle celis. Circ Res 77: 29—36, 1995.
5. BaeYS, Kang SW Seo MS, Raines IC, Tekie E, Chock PB,
and Rhee 5G. Epidermal growth factor (EGf)-induced
generation of hydrogen peroxide. Raie in EGF receptor
mediated tyrosine phosphoiylation. J Biol Chem 272:
217—221, 1997.
6. Blanc A, Pandey NR, and Srivastava AK. Distinct raies of
Ca2*, calmodulin, and protein kinase C in H202-induced
activation of ERK1/2, p38 MAPK, and protein kinase 3
signaling in vascular smooth muscle cells. Antioxid Redox
Signal 6: 353—366, 2004.
7. Chou CK, Duil TJ, Russeil DS, Gherzi R, Lebwohl D, Ui!
rich A, and Rosen 0M. Human insulin receptors mutated
at the ATP-binding site lack protein tyrosine kinase activ
ity and fail ta mediate postreceptor effects of insuhn. J
Biol Chem 262: 1842—1 847, 1987.
8. Clerk A, fuiler SJ, Michael A, and Sugden PH. Stimula
tion of “stress-regulated” mitogen-activated protein ki
nases (stress-activated protein kinases/c-Jun N-terminal
kinases and p38-mitogen-activated protein kinases) in per
fiased rat hearts by oxidative and other stresses. J Biol
Chem 273: 7228—7234, 1998.
9. Cuevas BD, Lu Y, Mao M, Zhang J, LaPushin R, Simi
novitch K, and Miils GB. Tyrosine phosphorylation of p85
relieves its inhibitory activity on phosphatidyhnositoi 3-
kinase. JBiol Chein 276: 27455—27461, 2001.
10. Dong LQ, Zhang RB, Langiais P, He H, Ciark M, Zhu L,
and Liu f. Primary structure, tissue distribution, and ex
pression ofmouse phosphoinositide-dependent protein ki
nase-i, a protein kinase that phosphorylates and activates
protein kinase Czeta. JBiol Chem 274: 8117—8122, 1999.
ii. Downward J. Mechanisms and consequences of activation
ofprotein kinase B/Akt. Coi-r Opin CeliBiol 10: 262—267,
1998.
12. Frank GD, Mifune M, Inagami T, Ohba M, Sasaki T, Hi
gashiyarna S, Dempsey ?J, and Eguchi S. Distinct mecha
nisms of receptor and nonreceptor tyrosine kinase activa
tion by reactive oxygen species in vascular smooth muscle
ceils: roie of metailoprotease and protein kinase C-delta.
Mol CelÏBiot23: 1581—1589, 2003.
13. Griendling KK, Minieri CA, Oiierenshaw JD, andAlexan
der RW. Angiotensin II stimulates NADH and NADPH ox
idase activity in cultured vascuiar smooth muscle cells.
CircRes74: 1141—i 148, 1994.
14. Guan KL and Dixon JE. Evidence for protein-tyrosine
phosphatase catalysis proceeding via a cysteine-phosphate
intermediate.JBiol Chem 266: 17026—17030, 1991.
15. Hayes GR and Lockwood DH. Raie of insulin receptor
phasphorylation in the insulinomimetic effects of hydro
gen peroxide. Froc NarlAcad Sci USA 84: 8115—8119,
1987.
1020 MEHDI ET AL.
16. Koshio O, Akanurna Y, and Kasuga M. Hydrogen peroxide
stimulates tyrosine phosphorylation ofthe insulin receptor
and its tyrosine kinase activity in intact celis. Biochem J
250: 95—101, 1988.
17. Lawrence JC Jr and Lamer J. Activation ofglycogen syn
thase in rat adipocytes by insulin and glucose involves in
creased glucose transport and phosphorylation. J Bio!
Chem 253: 2104—2113, 1978
18. Lee SR, Kwon KS, Kim SR, and Rhee 8G. Reversible in-
activation of protein-tyrosine phosphatase ] B in A43 1
ceils stimulated with epidermal growth factor. JBiot Chem
273: 15366—15372, 1998.
19. Little SA and de Haen C. Effects cf hydrogen peroxide on
basal and hormone-stirnu]ated lipolysis in perifiised rat fat
ceils in relation to the mechanism of action of insulin. J
Biot Ctiem 255: 10888—10895. 1980.
20. Lo YY and Cruz TE Involvement of reactive oxygen
species in cytokine and growth factor induction of c-fos
expression in chondrocytes. J Biol Chem 270: 11727—
11730, 1995.
21. Lo YY, Wang JM, and Cruz TE Reactive axygen species
mediate cytakine activation of c-Jun NH2-terminal ki
nases. JBïol Chem 271: 15703—15707, 1996.
22. Mahadev K. Wu X, Zi]bering A, Zhu L, Lawrence JT, and
Goldstein BJ. Hydragen peraxide generated during cellu
lar insulin stimulation is integral ta activation cf the distal
insulin signaling cascade in 3T3-L1 adipocytes 1. J Bio!
Chem 276: 48662—48669, 2001.
23. Mahadev K, Motoshima H, Wu X, Ruddy JM, Arnold ES,
Cheng G, Lambeth JD, and Goldstein BJ. The NAD(P)H
oxidase hornclog Ncx4 modulates insulin-stimulated gen
eration cf H202 and plays an integral role in insulin signal
transduction. Mol Ceil Biol 24: 1844—1854, 2004.
24. May JM and de Haen C. The insulin-like effect cf hydre
gen peroxide an pathways cf lipid synthesis in rat
adipccytes. JBiol Chem 254: 9017—9021, 1979.
25. Meng IC, Fukada T, and Tanks NK. Reversible oxidatian
and inactivation cf pratein tyrasine phasphatases in vivo.
Mot Ccli 9: 387—399, 2002.
26. Pandey SK, Anand-Srivastava MB, and Srivastava AK.
Vanadyl sulfate-stimulated glycagen synthesis is assaci
ated with activation cf phosphatidylinositol 3-kinase and is
independent cf insulin receptar tyrasine phasphorylation.
Biochemist;y 37: 7006—7014, 1998.
27. Pandey SK, Theberge Jf, Bemier M, and Srivastava AK.
Phasphatidylinositat 3-kinase requirement in activation of
the ras/C-raf-1/MEK/ERK and p70(s6k) signaling cascade
by the insulincmimetic agent vanadyl sulfate. Biochem
istiy38: 14667—14675, 1999.
28. Rao GN. Hydragen peroxide induces complex formation
cf SHC-Grb2-SOS with receptor tyrosine kinase and acti
vates Ras and extracellular signal-regulated protein ki
nases group cf mitogen-activated prctein kinases. Onco
gene 13: 713—719, 1996.
29. Rosenzweig T, Aga-Mizrachi S, Bak A, and Sampscn SR.
Src tyrosine kinase regulates insulin-induced activation of
protein kinase C (PKC) delta in skeletal muscle. Ceti Sig
na! 16: 1299—1308, 2004.
30. Shepherd PR, Witliers DJ, and Siddle K. Phcsphcinositide
3-kinase: the key switch mechanism in insulin signalling.
Biochem J333 (Pt 3): 471—490, 1998.
31. Srivastava AK and Pandey SK. Stimulation ofmitogen
activated protein kinases ERK-1 and ERK-2 by H207 in
vascular smocth muscle ce]ls. In: Tue Hypertrophied
Heart, edited by Takeda N, Naganc M, and Dhall NS.
Baston, MA: Kiuwer Academic Pubtishers, 2000, p?.
197—206.
32. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, and finkel T.
Requirement for genemation cf 117O7 for platelet-derived
grawth factor signal transduction. Science 270: 296—299,
1995.
33. Suthemland C, Tebbey PW and Granner DX. Oxidative and
chemical stress mimic insulin by selectively inhibiting Oie
expression cf phosphoencipyruvate carbaxykinase in he
patoma celis. Diabetes 46: 17—22, 1997.
34. Ushic-fukai M, Alexander RVÇ Akers M, and Griendiing
KK. p38 mitogen-activated prctein kinase is a critical
compcnent cf the redox-sensitive signaling pathways ac
tivated by angictensin 11. Role in vascular smccth mus
cle ceil hypertrcphy. J Bio! Cheni 273: 15022—15029,
1998.
35. Ushic-Fukai M, Alexander RVvÇ Akers M, Yin Q, Fujic ‘Y
Walsh K, and Griendiing KK. Reactive oxygen species
mediate the activation cf Aktlpmctein kinase B by an
giotensin Il in vascular smccth muscle ceils. J Biot Chem
274: 22699—22704. 1999.
36. White ME lES prcteins and the ccmmon path ta diabetes.
Am JPhysioi Endocrino! Metab 283: E413—E422, 2002.
37. White Mf. Insulin signaling in health and disease. Science
302: 1710—1711,2003.
38. White Mf and Kahn CE. The insulin signaling system. J
Bio! Chem 269: l—4, 1994.
39. Zhcugang S and Schnellmann RG. H202-induced tmansac
Ovation of EGF receptcr requires Src and mediates
ERKI/2, but net Akt, activaticn in renal ceils. Am Jfhys
io! Renal Physiot 286: F$58—F865, 2004.
Address reprint requests to:
Ashok K. Srivastava, Ph.D.
Research Centre, CHUM—Hôtel-Dieu
3850 St. Urbain Street, Room 7-135
Montreal (Quebec) H2W 1T7
Canada
E-niait:
Received for publication Octcber 28, 2004; accepted febmary
2, 2005.
ç
(J
